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Abstract
In this thesis I have determined the effects of seizures on AMPA receptors and examined
the effects of AMPA receptor modulation, by medium chain triglycerides and derivatives,
on seizures. AMPA receptors play a central role in synaptic transmission in the brain and
are critical for the generation of seizure activity.
Recent work has indicated that prolonged seizures alter AMPA receptor transmission. Here I
determined whether these changes occur in an acute in vitro seizure model, to aid exploration
of the underlying mechanisms of these alterations. I demonstrated that, as observed in vivo,
seizure activity changes the kinetics of AMPA receptor-mediated currents by increasing the
proportion of GluA2-lacking, calcium permeable AMPA receptors. I next showed that this
subunit switch is dependent on the activation of NMDA receptors and calcineurin.
In a separate set of experiments I determined the effects of a range of novel AMPA receptor
antagonists on synaptic transmission and seizure activity. Decanoic acid, a key component
of the medium chain triglyceride ketogenic diet used in refractory epilepsy, has recently
been shown to act as a non-competitive AMPA receptor antagonist. Here I showed that a
range of structurally related compounds which also act as AMPA receptor antagonists are
effective in in vitro models of seizure-like activity. I have further explored the mechanisms
underlying decanoic acid’s action. Decanoic acid is synergistic with the AMPA receptor
antagonist, perampanel, and is not use-dependent. Moreover, I have shown that decanoic
acid has an action at voltage-gated sodium channels to decrease the intrinsic excitability of
neurons. Decanoic acid reduces the persistent sodium current, without altering the transient
sodium current. Surprisingly, decanoic acid has minimal effect on in vivo status epilepticus
(prolonged seizure activity) possibly because of rapid and extensive metabolism by the liver.
Lastly, I undertook preliminary experiments in human neurons. Decanoic acid effectively
reduces induced seizure-like activity in slices from surgically-resected human neocortical
tissue. It inhibits AMPA receptor-mediated currents but does not alter intrinsic excitability,
as in rat CA1, possibly due to regional differences in neuronal properties.
My findings indicate that seizure activity rapidly changes the AMPA receptors expressed
in the synapse and identify a range of compounds that target AMPA receptors, which are
effective against seizure activity.
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Chapter 1
Introduction
1.1 Epilepsy
Historically, epilepsy has been described as a spectrum of disorders caused by hyper-excitable
networks in the brain. The physiologist Fritsch (1838-1927) and psychiatrist Hitzig (1838-
1907) were the first to match the mechanism of epilepsy with hyper-excitability; in their
paper entitled ’On the Electric Excitability of the Cerebrum’ they presented experiments
in which they provoked seizures by electric stimulation in the brain cortex of dogs (Fritsch,
1870; Magiorkinis et al., 2014).
Currently around two-thirds, of the 1% of the population with epilepsy, achieve complete
seizure control with currently available AEDs. Temporal lobe epilepsy (TLE), the most
common form of epilepsy, is defined by spontaneous recurrent seizures originating in the
temporal lobe and is often accompanied by cognitive deficits (ILAE case report, 2004).
Seizures may trigger neuronal cell death through excitotoxicity leading to hippocampal
sclerosis (Meldrum, 1993), although whether sclerosis is the consequence or the cause of
pathological activity is debatable (but see Uysal et al., 2003; Kobayashi et al., 2002). In
this section I will describe some of the most clearly defined cellular and network changes
that occur during epileptogenesis.
1.1.1 Epileptogenesis
Epileptogenesis is the gradual progression of the brain from a normal into an epileptic
state following an initial insult such as brain trauma, stroke, tumour, infection and status
16
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epilepticus (SE). During the latent period following a triggering insult to the brain there
may not be spontaneous seizures. However, structural and functional changes occur, which
increase the propensity for spontaneous seizures by altering the physiology of neuronal
networks. There are changes at both the network and neuronal level after an initial insult;
Neuronal death occurs via the necrotic and apoptotic pathways, rearrangement of circuits
causes the formation of aberrant connections, and in some areas (e.g. dentate gyrus) there is
increased neurogenesis (Bengzon et al., 1997; Parent et al., 1998). Surviving neurons often
compensate for reduced connections through an increase in intrinsic excitability and axonal
sprouting. New or dispersed granule cells are observed outside the usual dense layers, the
extent of which is related to cell loss in the polymorph layer of the dentate gyrus (Houser,
1990).
1.1.2 Hippocampal networks in epilepsy
The hippocampus is a highly connected brain region with many properties that allow the
generation of epileptic events. Due to intrinsically burst-generating cells and recurrent
excitatory connections, the CA3 region relies upon inhibition for regulating network ex-
citability (Colom and Saggau, 1994). Synaptic connections are readily strengthened or
weakened with repetitive activation, and the possible presence of gap junctions increases
the ability of hippocampal neurons to synchronise their firing.
Interictal and ictal activity can be initiated within the same neuronal network. Interictal
activity is distinct from ictal events as it may have an anti-ictal effect (de Curtis et al.,
2012), although there is often an increase in interictal activity prior to the transition to
seizures. Synaptic mechanisms and key receptor contributions may vary during different
stages of an epileptic event. Glutamatergic transmission through α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors is required for the spread of pre-ictal
activity, which has a distinct initiation site, is high amplitude and spreads more quickly than
interictal activity, at least in vitro (Huberfeld et al., 2011). The hyperpolarising actions
of γ-aminobutyric acid (GABA)A receptors are important for restraining excitation during
interictal and pre-ictal stages of seizure development. During an ictal event however, GABA
may become depolarising from intracellular chloride loading and the corresponding shift in
driving force of the GABAA receptor mediated currents (Sepkuty et al., 2002).
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The dentate gyrus has been considered a gateway which controls the spread of seizures
through the hippocampal network, via entry from the entorhinal cortex (Behr et al., 1998).
From this entry point signals propagate to CA3, which is particularly important in syn-
chronisation and in interictal discharge generation. Finally signals propagate to CA1,
an area which can also directly receive perforant path input, and back out through the
entorhinal cortex in a re-entrant loop. This loop may promote feed-forward propagation
(Lu et al., 2016), which leaves the hippocampal network prone to runaway excitation. For
more about basic hippocampal circuitry, see section 1.6.
Some evidence suggests that the hippocampus reverts to a morphologically younger de-
velopmental stage during epileptogenesis. Cajal-Retzius cells, which usually disappear
during development, have been found in sclerosed hippocampi (Blumcke et al., 1996b).
Increased dentate gyrus neurogenesis has also been reported particularly in tissue that was
obtained from young patients (Blumcke et al., 2001).
1.1.3 Receptors changes in epilepsy
There are also alterations in both receptors and ion channels which change network ex-
citability; for example there is a loss of the potassium channel KV4.2 (Francis et al.,
1997) and hyperpolarisation-activated cyclic nucleotide-gated 1 (HCN1; Shah et al., 2004)
channels, but an up regulation of calcium channels such as CaV3.2 (Khosravani et al., 2005).
Some of these changes have a clear pro-epileptic effect, whereas other are compensatory
attempts to reduce excitation. Further, it is sometimes difficult to establish the functional
consequences of epilepsy-induced alterations, for example with changes in HCN-mediated
currents.
Many anti-epileptic drugs (AEDs) target synaptic receptors, which suggests that reducing
transmission across the synapse may be a particularly effective way of controlling seizure
activity (see Fig 1.1). Epileptiform activity can cause an up-regulation of the NR2B subunit
of N -methyl-d-aspartate (NMDA) receptors; and NMDA receptors containing this subunit
have been implicated in neuronal death by activating a range of apoptotic intracellular
cascades (Hardingham et al., 2002). In response to epileptiform activity, there are changes
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in the localisation of GABA receptors expression and subunit composition. This may occur
to minimise damage.
Similarly, AMPA receptor activation is important for the spread of seizures through neuronal
networks; changes in receptor expression and localisation is seen after seizures (see section 1.4).
Also, variations in post-transcriptional processing, including alternative splicing and pre-
mRNA editing of AMPA receptors have been seen during epileptogenesis. Expression of
calcium permeable (CP)-AMPA receptors could contribute to the damage caused by Ca2+
overloading and a larger single-channel conductance (Liu and Zukin, 2007).
Receptor changes are not unique to neurons. Astrocytes also show alterations in glutamate
transporters and receptors, as well as inwardly rectifying potassium channels (Kir channels)
and aquaporins (Binder and Steinhuser, 2006).
1.1.4 Cell loss in epilepsy
Cell death in response to seizures follows specific patterns depending on the seizure foci, or
the model used in vivo. Status epilepticus is an extreme form of epilepsy, characterised by
prolonged seizures, resulting in considerable cell loss (Meldrum, 1993). In the hippocampus,
the CA1 pyramidal cell layer and dentate hilar cells are particularly at risk of cell loss. This
pattern of cell loss can be matched in rodent models of epilepsy such as perforant path
stimulation (PPS model) and to a lesser extent, the kindling model (Parent et al., 1998).
Neuronal death may occur by necrosis or apoptosis depending on the trigger, the time
point after seizures and the cell type (Sloviter et al., 1996). Apoptosis from excitotoxicity
is prominent in cells that are not used to a high calcium load such as CA1 pyramidal
neurons. As well as increased calcium infllux, the formation of reactive oxygen species
(ROS) such as superoxide (O−2 ) by NADPH oxidase and xanthine oxidase (Kovac et al.,
2014; Williams et al., 2015). Cell loss is partially compensated for by increased neurogenesis
in the hippocampus, but many of the new neurons here form connections which may promote
seizure propagation (Blumcke et al., 1996a). Glial cells respond to seizures by reactive mi-
crogliosis and then astroglial death. This disrupts the blood-brain barrier and is involved
in formation of aberrant synaptic connections (Binder and Steinhuser, 2006).
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Neuronal death can cause drug refractory epilepsy, as well as cognitive decline, memory
loss and behavioural changes. If the cells targeted by AEDs are lost then the controlling
effect is lost (Sisodiya, 2003).
1.2 Epilepsy treatments
The first-line of treatment for seizure control is always pharmacological. If multiple AEDs
are tried without success, other treatments such as surgery or dietary change can prove
effective for seizure prevention. However, epilepsy is not a static disorder. Patients can
become refractory to treatments which have controlled seizures for many years previously.
In this case, using an AED with a different molecular target can be effective or a non-
pharmacological treatment option can be attempted (see Fig 1.1).
1.2.1 Antiseizure drugs
Many people achieve adequate seizure control from currently available AEDs. Common
targets for AEDs are voltage-gated (VG) ion channels and synaptic receptors (Meldrum
and Rogawski, 2007). Most AEDs have multiple mechanisms of action, and such drugs have
also been reported to target synaptic receptors in addition to their action on VG sodium
channels (Fig 1.1). Even though the drugs may be effective against seizures, it is common
for AEDs to have significant side-effects that limit use, which may lead to non compliance
in drug taking.
These AEDs are seizure blocking but not disease modifying, as they only provide symptomatic
treatment and have not been demonstrated to alter the course of epilepsy. A number of
factors affect the efficacy of AEDs including compliance and drug resistance. The cause of
drug resistance is likely to be multifactorial; changes at the blood-brain barrier could reduce
the concentration of drug reaching the brain and acquired changes at the target membrane
could block effectiveness (Loscher et al., 2013). Animal studies suggest that treatment from
the initial trigger causing epilepsy may prevent epileptogenesis (Walker et al., 2002).
Pre-clinical studies in which AMPA receptors are blocked have generally looked promising
as epilepsy treatments. However, as AMPA receptors play a critical role in the mechanism
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Figure 1.1: Schematic of common neuronal targets of current anti-epileptic drugs.
AEDs target synaptic proteins to (a) reduce excitatory transmission and (b) increase
inhibitory transmission. A large class of drugs also target voltage-gated (VG) sodium
channels which block the intrinsic excitability of neurons. Red boxes contain examples
of drugs acting at these specific targets, for controlling seizures. Reused with permission
from Bialer and White (2010).
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of learning and memory, concerns have been raised about their clinical use. More recently,
interest has been regenerated at targeting AMPA receptors in epilepsy (Rogawski, 2013).
Perampanel is a newly approved AED which targets all subtypes of AMPA receptor. It acts
as a selective negative allosteric AMPA receptor antagonist, which has slow kinetics, a high
affinity and is concentration-dependent. Perampanel inhibits AMPA receptor-induced Ca2+
influx from the GluA2-lacking AMPA receptors, in cell cultures of cortical cells (Hanada
et al., 2011).
Although not a prescribed treatment, post-seizure administration of AMPA receptor an-
tagonists results in attenuation of AMPA receptor potentiation and phosphorylation in
animal studies (Rakhade et al., 2008). This treatment was also found to prevent long term
increases in seizure susceptibility and seizure-induced neuronal injury.
1.2.2 Invasive treatments for epilepsy
For those whose seizures can not be managed by AEDs alone, there are invasive treatments
which can allow seizure control. Resection of the region generating seizures, or cutting
connections from the onset zone to other brain areas can prevent seizures, but are only
possible in focal epilepsy and carry the normal risks associated with brain surgery. Before
surgery, patients undergo seizure monitoring, electroencephalogram (EEG), magnetic resonance
imaging (MRI), and positron emission tomography (PET) examination to gain vital in-
formation about the location and size of the seizure focus. These tests determine if surgery
is a possible option.
Neuromodulation therapy involves implanting a stimulating electrode to target specific
areas, such as the epileptic foci. Deep brain stimulation and transcranial direct current
stimulation are examples of neuromodulation. The hippocampus and thalamus are often
targets for this (Morace et al., 2016). Although it is unclear how neurostimulation works,
one hypothesis is that applying current to a certain structure will induce local inhibition to
inhibit overexcitable tissue, or projections between hyperconnected networks.
Transcranial magnetic stimulation uses strong current stimulation at low frequency targeting
the epileptic zone. It has long lasting effects and significantly reduces seizure frequency in a
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randomised controlled study in humans (Sun et al., 2012). Electrical stimulation promotes
plasticity, which could lead to the longer term benefits in epilepsy.
1.2.3 The ketogenic diet
Controlled dietary interventions represent another method of seizure control, which is par-
ticularly effective in children whose seizures cannot be controlled by medication alone.
During the 1920s the effects of starvation, by induction of the ketogenic diet, and altered
cerebral oxygen were of interest in seizure control (Lennox and Cobb, 1928). The ketogenic
diet is a strict high-fat, low-carbohydrate diet commonly used in refractory epilepsy. It is a
successful epilepsy treatment in 30% of patients after 12 months (Li et al., 2016), but there
are difficulties relying on seizure control through this diet due to high attrition rates (Payne
et al., 2011), as it is inflexible and difficult to tolerate. Adverse gastro-intestinal related
effects are common, such as diarrhoea, vomiting, bloating, and cramps (Liu, 2008).
Several variations of the ketogenic diet exist, with the medium chain triglyceride (MCT)
ketogenic diet allowing more flexibility, as some calorific intake from carbohydrates is
allowed. In this diet a high percentage of daily calories are obtained from MCT oil, which
is derived from coconut oil and contains 81% octanoic acid and 16% decanoic acid, both of
which reach the brain at a clinically relevant concentration (Haidukewych et al., 1982).
1.2.3.1 Metabolic effects
The mechanism by which the ketogenic diet allows seizure control is not completely understood
yet. Initially the fasting period of the ketogenic diet was thought to bring cessation from
seizures by forcing the main method of metabolism to change. The primary source of energy
for neurons is switched from glucose to ketone bodies, which are produced during the course
of the diet (Lutas and Yellen, 2013). Later, ketone bodies were thought to be an active
molecule in seizure control. Several other mechanisms exist that may be responsible for
the antiepileptic action of the ketogenic diet, including disruption of glutamatergic synaptic
transmission, inhibition of glycolysis, and activation of ATP-sensitive potassium channels
(Lutas and Yellen, 2013).
Fatty acids are broken down by β-oxidation in the mitochondria (see Fig.1.2). This reaction
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increases expression and activity of mitochondrial uncoupling proteins in the hippocampus
of juvenile mice subjected to a high-fat ketogenic diet. The process also produces acetyl-CoA
and co-enzymes that reduce ROS formation by the respiratory chain. This may constitute
a neuroprotective mechanism aimed at reducing oxidative stress (Sullivan et al., 2004).
In studies in which mitochondrial function is impaired, the ketogenic diet improves mi-
tochondria respiratory chain function (Greco et al., 2015). Specifically, MCTs are used by
the liver to produce β-hydroxybutyrate and acetoacetate, which are ketone bodies and can
be used as an energy source. The MCT decanoic acid increases seizure threshold when
administered alone in mice (Wlaz et al., 2015).
1.2.3.2 Synaptic targets
Recently it has been shown that decanoic acid acts via synaptic AMPA receptors as a
non-competitive antagonist (Chang et al., 2016). Decanoic acid, a ten carbon, straight-
chain fatty acid is present at higher concentrations in those on the ketogenic diet and
is able to cross the blood-brain barrier (Haidukewych et al., 1982). A binding site has
been proposed on the AMPA receptor from amino acid modelling, which is different to
that of perampanel (see also section 1.4.4). In acute hippocampal slices, decanoic acid
application can completely block epileptiform discharges in seizure models (Chang et al.,
2013). Decanoic acid acts on all subunits of AMPA receptors, but favours GluA2 (Chang
et al., 2016).
Reducing glutamatergic transmission onto excitatory pyramidal cells would logically reduce
transmission of over-active signals. This same mechanism at inhibitory interneurons could
disinhibit the circuits, although if GABAergic transmission during seizures becomes de-
polarising then a general toning down of synaptic transmission would be advantageous (see
Cossart et al., 2005 for review).
Polyunsaturated fatty acids found in the typical ketogenic diet act at the A-type potassium
channel and on the transient sodium current, to reduce intrinsic excitability (Tigerholm
et al., 2012). It is would be surprising for this, or any one of the mechanisms described
above, to be the only anti-seizure mechanism that the ketogenic diet works via, as many
patients achieve seizure freedom on the ketogenic diet even after failed attempts with con-
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Figure 1.2: Schematic of fatty acid metabolism.
Medium chain triglycerides (such as decanoic acid) can move across the cell membrane and
into the mitochondria without an carrier protein. Fatty acids are converted to acetyl-CoA
in hepatocytes by β-oxidation. Acetyl-CoA is converted into ketone bodies, or used as
a substrate in the Krebs cycle, where glucose is produced. Medium chain triglycerides,
ketone bodies and glucose are all able to cross from blood capillaries through the blood-
brain barrier (BBB) into the CNS. Glucose is converted to pyruvate by glycolysis inside the
neuron. Pyruvate and ketone bodies can be converted back to acetyl-CoA, which can enter
Krebs cycle, in a process that produces the energy substrate ATP via the electron transport
chain (ETC), as well as glutamate. Krebs cycle co-produces Flavin adenine dinucleotide+H2
(FADH2) and Nicotinamide adenine dinucleotide+H (NADH). These redox cofactors can
salvage ROS. Figure is based on Gano et al. (2014).
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ventional AEDs. The benefit of the diet is likely to be a general facilitative effect of
multiple mechanisms of action. The difficulty complying with the specific requirements
for the ketogenic diet restrict its benefit for controlling seizures in the general population
with epilepsy. By determining the targets through which molecules in the ketogenic diet act
to control hyperexcitable networks, a new treatment might be found that would be based
on the ketogenic diet but allow dietary flexibility.
26
Chapter 1. Introduction
1.3 The ionotropic glutamate receptors: AMPA receptors
As the main excitatory receptor in the brain, AMPA receptors are an obvious target for the
control of seizures. The family of ionotropic glutamatergic receptors encompasses AMPA
receptors along with NMDA receptors and kainate receptors. These are encoded by 18 genes,
producing 18 individual subunits (Traynelis et al., 2010). AMPA receptors are expressed
throughout the brain, on all known neuronal cell types as well as in glia.
1.3.1 General structure of AMPA receptors
AMPA receptors are tetramers, formed by the pairing up of two dimers of subunits. They
can assemble with identical subunits (homomers) or as a combination of different subunits
(heteromers) from the four AMPA receptor subunits (GluA1-4; Gan et al., 2014). The
subunit configuration determines receptor kinetics, modulation and localisation via post
translational modifications and interactions with other modulators. If a subunit combination
is successfully formed, then the completed receptor is assembled with auxiliary subunits in
the endoplasmic reticulum (ER) and exported to the target membrane.
At the synapse, following binding of glutamate or an agonist the AMPA receptors rapidly
activates and allows Na+ , K+ and, depending on the channel selectivity, Ca2+ to pass before
inactivating from the agonist unbinding or desensitising. From resting membrane potential
(RMP) Na+ entry depolarises the cell membrane from resting membrane potential; AMPA
receptor-mediated currents reverse at 0mV.
All AMPA receptor subunits comprise 3 transmembrane domains (TMD) and 1 re-entrant
loop, with an intracellular C-terminal, an extracellular N-terminal and ligand binding
domain (LBD). Crystallisation of homomeric AMPA receptors, without the fluid C terminal,
was achieved by Sobolevsky et al. (2009), with the addition of heteromeric receptor crys-
tallisation more recently by Herguedas et al. (2016). The TMD forms the channel pore, and
contains the Q/R RNA edit site, which is described below. An alternative splicing site on
the LBD of AMPA receptor subunits results in flip/flop variants of each subunit. The flop
variant has faster desensitisation kinetics and is more common in mature healthy neurons
(Mosbacher et al., 1994). However, in the GluA1 homomer, both isoforms desensitise at
equal rates (Quirk et al., 2004). The GluA1 subunit also contains a long carboxy (C) tail
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with a PDZ binding motif that defines which scaffold and trafficking proteins it is able
to interact with. This C-terminal domain contains many phosphorylation sites, as well as
ubiquitination, nitrosylation, sumoylation and intracellular protein binding sites.
In the hippocampus, most principal cells express surface AMPA receptors containing both
GluA1 and GluA2 subunits (Lu et al., 2009). Inclusion of the GluA2 subunit dramatically
alters permeability of Ca2+ and Zn2+ through the pore, mediated by a post-transcriptional
modification site (Q/R) on GluA2 mRNA (Sommer et al., 1991). After editing neutral
glutamine (Q) to charged arginine (R), positively charged calcium ions are repelled by
the positively charged pore lining. Therefore there is almost complete block of calcium
permeability when the GluA2 subunit is present in the receptor. 99.99% of pre-mRNA
receptors have this post-transcriptional modification by adenosine deaminase acting on
RNA (ADAR2), which is protective against calcium-induced cell death. ADAR2 deficiency
produces lethal seizures in mice (Peng et al., 2006). Another RNA edit site, the R-to-G site,
is not fully edited when expressed functionally. This is also edited by ADAR2 and changes
the kinetics of desensitisation (Hume et al., 1991).
Calcium permeable (GluA2-lacking) channels incur use- and voltage-dependent channel
block from endogenous intracellular polyamines. Polyamines block the pore more strongly
when the neuron is depolarised, so the channel is less able to pass outward current than
inward current. The strong inward rectification of CP-AMPA receptors allows them to
be easily distinguished from calcium impermeable (CI) subtypes by their current-voltage
(I-V ) relationship (Cull-Candy et al., 2006). Further, CP-AMPA receptors have markedly
increased single-channel conductance (Swanson et al., 1997) and desensitisation rates (Hume
et al., 1991).
1.3.2 Auxiliary subunits regulate AMPA receptors
Auxiliary subunits such as transmembrane AMPA receptor regulatory proteins (TARPs)
increase the diversity of AMPA receptor properties by allowing specific protein interactions
both within the cell and in the extracellular matrix (Schwenk et al., 2014). These subunits
interact with synaptic proteins to dynamically regulate surface expression, calcium per-
meability, accumulation, localisation into and out of the synapse, pharmacology and kinetic
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properties of the channel (Cuadra et al., 2004; Menuz et al., 2007; Bats et al., 2013;
Studniarczyk et al., 2013).
TARPs are grouped into type I and atypical type II families. Stargazin (γ-2), a typical TARP
and the most studied auxiliary subunit, slows channel deactivation and desensitisation
(Tomita et al., 2007b), and greatly increases single-channel conductance (Soto et al., 2007).
Both stargazin and γ-8 dramatically increase the magnitude of glutamate evoked currents
from GluA1 cRNA injected oocytes (Chen et al., 2003). Furthermore, stargazin’s presence
markedly attenuates the block of CP-AMPA receptors by intracellular polyamines (Soto
et al., 2007), while enhancing their sensitivity to extracellular philanthotoxin-433 (Jackson
et al., 2011) and increasing their permeability to Ca2+ (Kott et al., 2009). Native AMPA
receptors contain one to four TARPs, but there is little interaction between TARPs (Kato
et al., 2007). A different set of auxiliary AMPA receptor subunits, the cornichons, do not
additively increase conductance when expressed alongside TARPs, but may displace AMPA
receptor binding to γ-8 (Kato et al., 2010).
TARPs are differentially expressed throughout the brain. In the hippocampus, mature
synapses require GluA1 and γ-8 (Rouach et al., 2005) and genetic deletion of γ-8 selectively
abolishes sustained depolarisations when bathed in AMPA. Other TARPs are likely to
be important for anchoring AMPA receptors to PSD-95, and fo reducing receptor desen-
sitisation in response to synaptic glutamate. PSD-95 concentration at the synapse directly
determines the number of synaptic AMPA receptors expressed, via their mutual interaction
with TARPs.
For CP-AMPA receptors, interaction with an auxiliary subunit can double the average
single-channel conductance, slow desensitisation and deactivation, and enhance calcium
permeability without affecting open probability (Tomita et al., 2007a; Kott et al., 2009;
Soto et al., 2014). Auxiliary subunits are also able to attenuate intracellular polyamine
block across all voltages, reverting from inward rectification to a linear I-V relationship
(Soto et al., 2007). The conductance of isolated CP-AMPA receptors is already double that
of GluA2-containing AMPA receptors (Swanson et al., 1997), so modulation of CP-AMPA
receptors by auxiliary subunits can substantially increase excitatory synaptic transmission.
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AMPA receptors also interact with cornichons (Schwenk et al., 2009), CKAMP44, and
GSG1L (Schwenk et al., 2014; McGee et al., 2015) which is found in dendritic spines of CA1
pyramidal cells and co-localises with GluA2- or GluA4-containing AMPA receptors.
1.3.3 Post translational modifications of AMPA receptors
The location and biophysical characteristics of AMPA receptors can be modulated by protein
interactions at the PDZ tail of the C terminal. Throughout the intracellular domain, there
are sites for phosphorylation by protein kinase A (PKA), protein kinase C (PKC), and
the SRC family tyrosine kinase STEP61(Lu and Roche, 2012; Hayashi and Huganir, 2004).
Proteins can be diversified by tagging with other small molecules at defined sites. Palmi-
toylation of GluA2 at C610 increases the stability of CI-AMPA receptors (Yang et al., 2009).
This adaptation shows subunit specific effects, and proteins can also be ubiquitinated, gly-
cosylation, nitrosylated and sumoylated.
Phosphorylation patterns are dynamically regulated, and can affect the AMPA receptor-
mediated currents differently depending on the sites phosphorylated. At GluA1, calcium
entry activates CaMKII to phosphorylate S831, which increases single-channel conductance
in CI-AMPA receptors only (Derkach et al., 1999). CaMKII also acts at S567 in loop 1 to
negatively regulate synaptic delivery (Lu et al., 2010). Further, phosphorylation of T840 on
GluA1 by PKC may be important in LTD, for reducing the number of AMPA receptors
present at the synapse (Delgado et al., 2007).
Altering the phosphorylation pattern on GluA2 subunits has a more complex effect. This
subunit is not present in most CP-AMPA receptors, so phosphorylation will specifically
affect CI-AMPA receptors. The S880 position is phosphorylated by PKC, causing in-
ternalisation of GluA2-containing receptors by regulating interactions with intracellular
trafficking regulators (Chung et al., 2000). Conversely, phosphorylation at Thr912 leads
to activity-dependentreinsertion of internalised GluA2-containing AMPA receptors, via the
JNK1 pathway. Phosphorylation at tyrosine sites (including Tyr869, Tyr873, and Tyr876) also
regulates receptor trafficking indirectly by changing GluA2’s association with intracellular
proteins. New phosphorylation sites by kinases are still being characterised.
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Post-translational modifications are triggered by small molecule interactions at the PDZ
domain of the C terminus of AMPA receptors, which is different in GluA1 subunits (type
I) and GluA2 subunits (type II). This means the two subunits interact with separate
proteins; different PDZ domains cannot even both bind to the same version of the scaffolding
protein PSD95. 4.1N is required for GluA1 insertion into the membrane, and its action is
enhanced by phosphorylation or palmitoylation (Lin et al., 2009). SAP97 is also required for
trafficking; it interacts with myosin VI to form a trimeric complex with GluA1 to deliver it to
the membrane. Conversely, ablation of Arc/Arg3.1 selectively recruits CP-AMPA receptors
to the membrane for homeostatic scaling (Shepherd et al., 2006). A key modulator of AMPA
receptor expression is Protein interacting with C-kinase-1 (PICK1), which clusters AMPA
receptors and has a Ca2+ binding domain that could act as a trigger for AMPA receptor
internalisation. Ca2+ enhances PICK1 binding to GluA2 and vesicle fusion proteins, to
promote endocytosis of CI-AMPA receptors which have been phosphorylated by PKC at
S880 (Hanley, 2008). This instability of phosphorylated CI-AMPA receptors is in contrast
to the stabilisation of CP-AMPA receptor at perisynaptic sites by phosphorylation at S845
(He et al., 2009).
Small molecules can interact with mRNA to influence which subunits are translated, and act
on nascent proteins at the ER to regulate which will reach the membrane. MicroRNAs are
small non-coding RNA molecules which are a form of RNA silencing and post-transcriptional
regulation of gene expression. They block the transcription or degradation of a target gene.
miRNA124 blocks GluA2 expression by targeting the 3-UTR, leading to the formation of
CP-AMPA receptors (Dogini et al., 2013; Dutta et al., 2013). MicroRNAs are dynamically
regulated in disease states; for example, miRNA124 is upregulated in epilepsy.
1.3.4 Location and function of CP-AMPA receptors
Under physiological conditions, multiple brain regions have expression of CP-AMPA receptors.
For example, in the cerebellum CP-AMPA receptors are expressed in stellate and basket
cells, and are used to increase the fidelity of signal propagation along dendrites, since they
have a higher conductance and faster channel kinetics than CI-AMPA receptors or NMDA
receptors (Abrahamsson et al., 2012; Geiger et al., 1995).
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In hippocampal CA1 neurons, the majority of excitatory synapses onto pyramidal neurons
express heteromeric AMPA receptors containing GluA1-GluA2 subunits, with a smaller
contribution of GluA2-GluA3 heteromers and ∼8% GluA1 homomers (Wenthold et al.,
1996). CP-AMPA receptors are present on specific interneurons (e.g. OLM interneurons;
Lamsa et al., 2007) and glia (Schwenk et al., 2014). There is also age-dependent control
of AMPA receptor expression. Early in development, GluA2 lacking AMPA receptors are
also expressed at synapses in the neocortical principle cells and CA3 pyramidal neurons (Ho
et al., 2007).
CP-AMPA receptors are physiologically interesting as they promote signal transfer close
to resting membrane potential and are blocked by polyamines at near 0mV and positive
potentials. This contrasts with NMDA receptors which pass more conductance at similar
potentials. CP-AMPA receptors allow a unique form of LTP at O-LM interneuron synapses
described as ”anti-Hebbian”, as it is induced by presynaptic activity but prevented by
postsynaptic depolarisation (Lamsa et al., 2007).
The transient expression of CP-AMPA receptors at CA1 pyramidal neuron synapses during
LTP induction and stabilisation has been described (Plant et al., 2006). However, others
have also found CP-AMPA receptors are not necessary for initiation nor stabilisation of LTP
(Gray et al., 2007); the requirement may be dependenton the protocol of LTP induction
(Park et al., 2016). Silent synapses, the term given to synapses containing NMDA receptors
but without AMPA receptors, may have incorporation of CP-AMPA receptors before maturation
and the expression of CI-AMPA receptors (Morita et al., 2014). It has been suggested
that CP-AMPA receptors are dynamically regulated globally, and removed during sleep.
Increases in GluA1-containing AMPA receptor levels in are seen in synapses at both the
cortex and hippocampus during wakefulness, and decreases during sleep (Vyazovskiy et al.,
2008). Expression levels may also be dependentof the oestrogen cycle (Tada et al., 2015).
In pathological conditions, there have been many reports of CP-AMPA receptor expression
in cells where they are not usually found. Ischemic insults trigger the long-lasting down-
regulation of GluA2 mRNA and protein expression in CA1 pyramidal neurons, inducing
a switch to CP-AMPA receptor expression (Gorter et al., 1997; Dias et al., 2013). In
ischemia, the GluA2 subunit switch is PKC-dependent and involves dissociation of GluA2
32
Chapter 1. Introduction
from PICK1 (Terashima et al., 2004). PICK1 overexpression increases CP-AMPA receptors
at pyramidal neuron synapses, possibly by blocking recycling of GluA2 subunits, and blocks
LTP (Terashima et al., 2008). Phosphorylation of GluA2 at S880 by PKC is crucial for
determining the GluA2 binding partner; it therefore regulates its interaction with GRIP
(Glutamate receptor interacting protein)/ABP. GluA2 phosphorylation favours binding to
PICK1 and hinders interaction with GRIP1.
After SE or spinal cord injury, and in those with Amyotrophic Lateral Sclerosis (ALS)
and Alzheimers disease there is also evidence suggesting a decrease in GluA2 mRNA and
an increase in CP-AMPA receptor expression (Grooms et al., 2000). These changes in
expression are seen both on a local and on a global scale.
1.3.5 AMPA receptor trafficking and constitutive recycling
If the trigger causing an AMPA receptor subunit switch in pathological states were char-
acterised, then the effect of blocking the switch could be studied. However, the precise
mechanism of CP-AMPA receptor insertion and CI-AMPA receptor removal is not known.
AMPA receptors at the synapse are highly mobile, with a basal turnover rate of 16% surface
AMPA receptors endocytosed in 30 minutes (Ehlers, 2000). Trafficking occurs both in a
constitutive and in an activity-dependent way, with different mechanisms required for each.
AMPA receptors are removed from somatodendritic sites and replacements found from a
pool of receptors in the dendritic spine in a one for one manner, at a rate independent
to the activity level. This endocytosis requires clathrin, Arc, and binding of the GTPase
dynamin-3 to the PSD-enriched protein Homer (Hanley et al., 2002). The endosome either
fuses with a lysosome leading to degradation of the receptor, or transports it back to the
membrane surface.
As well as leaving directly from the postsynaptic density (PSD), AMPA receptors can leave
the synapse by lateral diffusion as has be observed in single-particle tracking experiments.
At the perisynapse, the GluA1 subunit moves freely in the membrane. In contrast, it loses
mobility at the synapse (Passafaro et al., 2001; Collingridge et al., 2004; Constals et al.,
2015). This is because the long C-tail on the GluA1 subunit has a PDZ binding motif which
defines the scaffold and trafficking proteins it interacts with, and this blocks its ability to
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be directly inserted into the PSD in the absence of activity. Conversely, GluA2 contains
a short C-tail, allowing it to be inserted directly into the PSD regardless of activity level.
It can directly interact with N-ethylmaleimide Sensitive Fusion protein (NSF; Song et al.,
1998) and PICK1 (Braithwaite et al., 2002) as is necessary for membrane fusion. GluA2-3
heteromeric CI-AMPA receptors replace (CP), GluA1-homomers at the synapse through
this pathway.
The edited GluA2 subunit is present as a dimer and retained in the ER, to ensure a large pool
is constantly available. Unedited subunits readily form tetramers and exit the ER, targeted
to nascent or pre-existing synapses. This limits the level of unedited GluA2 subunits in
AMPA receptors delivered to synaptic and extra synaptic sites. GluA2 binding to GRIP1
may be important for trafficking and targeting of CI-AMPA receptors (Setou et al., 2002).
GRIP and PICK1 are in dynamic equilibrium; after phosphorylation of GluA2 by PKC,
the GluA2-GRIP relationship is weakened but PICK1 is unaffected. This allows GluA2
to be inserted into the membrane, and internalised receptors can be captured by PICK1.
PICK1 over-expression increases AMPA receptor-EPSCs and the appearance of synaptic
CP-AMPA receptors in acute cultured hippocampal slices (Terashima et al., 2004).
Vesicles containing new or recycled AMPA receptors are trafficked to dendritic membranes
by kinesin and dyneins. They are then exocytosed by the vesicular SNARE family of proteins
and NSF (Araki et al., 2010).
1.3.6 Regulated trafficking of AMPA receptors
In response to activity, dynamin-dependent endocytosis and exocytosis of specific AMPA
receptor compositions is triggered. Endocytosis is decreased by synaptic blockade, and
increased by synaptic activity, via protein interactions and site directed phosphorylation.
An estimated 60-70% of the AMPA receptor population are intracellularly localised, ready
for delivery to the cell surface (Bredt and Nicoll, 2003). Further, it has been shown in culture
that many dendrites contain GluA1 and GluA2 mRNA, allowing rapid receptor production
when the activity level changes (Grooms et al., 2000).
Phosphorylated GluA1-containing AMPA receptors are transported to the membrane by
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Ca2+ -sensitive, actin-based motor proteins myosin-Va/Vb. Conversely, dephosphorylation
initiates the removal of receptors from the synapse. Dephosphorylation of GluA1 by calcineurin,
a Ca2+ -dependent serine/threonine phosphatase, leads to the internalisation and degradation
of CP-AMPA receptors. Reduced activity of calcineurin increases synaptic expression of CP-
AMPA receptors by stabilizing GluA1 phosphorylation (Kim and Ziff, 2014).
STEP61 is the tyrosine phosphatase present in CA1 pyramidal neurons, which dephos-
phorylates sites at AMPA receptor GluA2 subunits and at NMDA receptors. Dephos-
phorylation of GluA2 subunits causes internalisation of AMPA receptors (Zhang et al.,
2008), as well as acting on NMDA receptors.
1.3.6.1 Hebbian Plasticity
AMPA receptors are trafficked to alter the strength of the synapse in different forms of
plasticity. In classical Hebbian plasticity, NMDA receptor activation causes an influx of
Ca2+, which triggers dynamic AMPA receptor movement into or out of the membrane.
Multiple kinases and phosphatases are involved. Simply, activity-dependent activation of
PKA, CaMKII or SAP97 causes delivery of AMPA receptors to the perisynapse, and phos-
phorylation of synaptic AMPA receptors to increase their activity (Song and Huganir, 2002;
Fox et al., 2007; Howard et al., 2010); whereas GluA1 dephosphorylation by calcineurin and
PP1 signals for receptor internalisation (especially CI-AMPA receptors) and LTD. GluA1
phosphorylation increases the number (Hayashi et al., 2000) and clustering (Xie et al., 1997)
of AMPA receptors, or decreases the rise time and decay time constant of synaptic potentials
(Ambros-Ingerson et al., 1993). By contrast, phosphorylation of the GluA2 subunit generally
leads to internalisation and its dephosphorylation is important in synaptic retention. As
discussed above, CP-AMPA receptors may be necessary for stabilisation of LTP (Park et al.,
2016), possibly via CaMKI (Guire et al., 2008).
A PKA and CaMKII independent, but PKC and NMDA receptor-dependent form of CP-
AMPA receptor mediated LTP has recently been described (Kim et al., 2015b). This form
of LTP can be induced when the post synaptic membrane is hyperpolarised in the CA1
of mice lacking GluA2 (Wiltgen et al., 2010). Decreased phosphorylation of IP3 receptors
causes decreased Ca2+ release from the ER, activating less calcineurin. This stabilises phos-
35
Chapter 1. Introduction
phorylation of GluA1 subunits at S845, keeping them at the synapse to increase the number
of CP-AMPA receptors. In addition, a CP-AMPA receptor and protein synthesis-dependent,
but NMDA receptor-independent form of plasticity was also seen at CA1 synapses with this
conditional knock-out (KO) mouse (Asrar et al., 2009). Calcium entry through the CP-
AMPA receptor may be sufficient to induce some forms of LTP when NMDA receptors are
blocked or not activated. Polyamine-dependent facilitation allows for selectively enhancing
synaptic gain at CP-AMPA receptor expressing synapses following use-dependant relief of
polyamine block during high-frequency stimulation (Rozov and Burnashev, 1999).
LTP at dentate gyrus granule cells and fast-spiking interneurons requires coincident activation
of CP-AMPA receptors and group I mGluR, causing a strong intracellular Ca2+ elevation
(Hainmuller et al., 2014) for PKC activation. The GluA1-S845 site is necessary for maintaining
a perisynaptic pool of CP-AMPA receptors, and these could be recruited to participate in
synaptic transmission upon Group 1 mGluR activation (He et al., 2009). This induction
is NMDA receptor independent and similar to that seen in other interneurons (eg. O-LM
interneurons). The pathway of synaptic strengthening has been studied in vivo (Clem and
Barth, 2006). Whisker stimulation causes potentiation in a synapse specific manner via
CP-AMPA receptor expression. This was seen only in cortical layer 4-2/3 neurons, so it
may be the case that only certain synapses increase CP-AMPA receptor expression during
potentiation, or that the expression is restricted only to active synapses.
In cerebellar stellate cells high frequency activity replaces the synapse population of CP-
AMPA receptors with CI-AMPA receptors (Liu and Cull-Candy, 2000). This process
involves PICK1 and NSF interaction with GluA2 (Gardner et al., 2005) and is a self
regulating mechanism involving the subunit contribution of AMPA receptors, without affecting
the number of receptors.
Conversely, in LTD the role of CP-AMPA receptors is unclear. Calcineurin dephosphorylates
S845 and promotes AMPA receptor removal from synapses and endocytosis. CP-AMPA
receptors are recruited to synapses by anchored PKA during LTD induction but are then
rapidly removed by anchored calcineurin. Blocking CP-AMPA receptor activity, recruitment,
or removal interferes with NMDA receptor signalling for LTD. Removal of GluA2-containing
AMPA receptors is enough to induce some forms of LTD, but additional contributions from
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CP-AMPA receptors are required for robust LTD expression. A-kinase anchor proteins
(AKAPs) and calcineurin mediate removal of both versions of AMPA receptor (Sanderson
et al., 2016).
1.3.6.2 Homeostatic plasticity
Homeostatic plasticity is a process to tune synapses within an optimal activity band,
required to restabilise networks and maintain a constant output over time. Bidirectional
changes in mini EPSC amplitude measure the scaling up of both synaptic CI- and CP-AMPA
receptor numbers in conditions of low activity, and down in conditions of high activity (Wang
et al., 2012; Turrigiano et al., 1998).
Over a longer time scale and at a more global level than LTP, initiation of homeostatic
plasticity is thought to require CP-AMPA receptors. The loss of activity through L-type
Ca2+ channels, AMPA receptors or by reduced firing, leads to increases in vesicle pool size
and the addition of postsynaptic CP-AMPA receptors to the existing population of CI-
AMPA receptors (Ju et al., 2004; Thiagarajan et al., 2005). Stimulated AMPA receptor
endocytosis requires the GluA2 subunit, and reducing GluA2 levels with shRNA blocks
synaptic scaling. Hou et al. (2008) used cultured neurons to look at site specific changes.
CP-AMPA receptors are required for the early induction of homeostatic plasticity only, and
PI3K activity was required as it initiates protein synthesis processes. CP-AMPA receptor
inclusion may be in input specific scaling only, not global homeostatic plasticity (Hou et al.,
2008). Molecular mechanisms are also dependent on the induction method and which
synapse is involved.
Synaptic up-scaling of CP-AMPA receptors can be triggered by intracellular and glial-
released molecules, for example retinoic acid and the cytokine TNFα (Poon and Chen,
2008; Ogoshi et al., 2005). Arc/arg3.1 is an immediate-early gene regulated by neuronal
activity, which mediates both global regulation and local homeostatic plasticity at individual
synapses. Usually, Arc/arg3.1 is involved in CP-AMPA receptor upscaling (Beique et al.,
2011); at distal dendrites mRNA accumulates at sites of synaptic activity and is locally
translated (Steward et al., 1998). Arc/arg3.1 is co-ordinately induced in populations of
neurons implicated in learning, such as hippocampal place cells in vivo.
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Homeostatic plasticity can be distinguished from LTP/LTD by the activation of group 1
mGluRs. LTD is caused by activation of mGluR1 by agonist binding, whereas activity-
dependent Homer1a expression switches mGluR1 from agonist-dependent to independent
action. This causes widespread AMPA receptor down-regulation during homeostatic plasticity
(Hu et al., 2012), via mechanism linked to the reduction of tyrosine phosphorylation at
GluA2.
1.3.6.3 Metaplasticity
Metaplasticity is a higher order regulatory process, described as the plasticity of synaptic
plasticity. It sets the threshold and direction of plasticity to keep synapses in a dy-
namically functional range and prevents the saturation of receptors (Abraham and Bear,
1996). Networks are primed over hours and days by situations such as environmental
enrichment or stress; this affects subsequent induction and persistence of plasticity.
The adaptation of plasticity features changes on both sides of the synapse. Presynaptic
increases in vesicle turnover are present as well as increases in homomeric GluA1 expression.
CP-AMPA receptor recruitment confers a meta-plastic state that promotes LTD, which lasts
for days and has a function in processes such as in memory consolidation or in response to
prolonged inactivity of synapses as may arise with sensory impairment, stroke, and other
forms of neural damage (Thiagarajan et al., 2005).
The mechanisms involved in metaplasticity may be important for synaptic changes observed
in epilepsy. An induction protocol which caused depression of LTP in control slices failed
to affect LTP amplitude in acute slices after febrile seizures, indicating a failure of meta-
plasticity mechanism (Zhang and Luo, 2011). Conversely, after a kindling protocol stimulation
was less able to induce LTP in the CA1 than in control slices (Schubert et al., 2005).
The expression functional plasticity (FP) has been coined to describe those changes in
stimulus-response relationships or in spontaneous patterns that are experimentally induced
by electrical stimulation and lasting at least on the order of one hour (Wagenaar et al.,
2006). However, this may depend of how strong the induction protocol is. This could be a
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good time window in which to study seizure-induced changes.
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1.4 AMPA receptors in epilepsy
As the most common fast excitatory receptors in the brain, AMPA receptors are important in
epileptic synchronisation and the spread of epileptiform activity across networks. Increased
excitability is temporally associated with a rapid increase in expression of AMPA receptor
subunits GluA1 and GluA2 after seizures (Rakhade et al., 2008); this may indicate an
increase in both CP- and CI-AMPA receptors.
Whilst mutations in AMPA receptors have not been identified as a cause for genetic epilepsies,
the observation that mutations in TARPs do cause seizures is consistent with the view that
AMPA receptors play a fundamental role in the disorder (Barad et al., 2012). Within
the seizure onset area, the distribution of polyamines is differentially altered compared to
propagation areas in tissue from MTLE patients (Laschet et al., 1999). Since polyamines
are involved in the control of NMDA receptors and CP-AMPA receptors, this is likely to
affect neuronal excitability within the network.
1.4.1 Subunit expression is changed post-status epilepticus
Pathophysiological networks states can allow expression of CP-AMPA receptors at synapses
in which they are not usually seen, as discussed in section 1.3.4. When there is a switch in
the subunit composition of AMPA receptors, this can be monitored at the level of mRNA
and proteins. Changes at the AMPA receptor have an effect on synaptic function in models
in vitro, in vivo, and in studies on humans with epilepsy (Loddenkemper et al., 2014).
Specifically, Grooms et al. (2000) and Hu et al. (2012) found a marked decrease in both
GluA1 and GluA2 expression 12-16 hours after SE. In different regions of the hippocampus
both total mRNA content and protein levels were altered; this indicates that the changes
were not limited to surface expression of the receptor. There could, however, still be a
change in synaptic expression without change in mRNA levels (Cull-Candy et al., 2006).
The general rule of GluA2 prevailing over other AMPA receptor subunits in normal adult
pyramidal neurons changes 3 days post-SE. GluA2/3 receptors still predominate until 7 days
after SE, when more CP-AMPA receptors are expressed (Hu et al., 2012). It has also been
demonstrated that expression of GluA1 is elevated in the human epileptic hippocampus,
and this positively correlates with axonal sprouting (Ying et al., 1998).
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A study by Rajasekaran et al. (2012) found increased rectification of AMPA receptors after
10 minutes (modelling refractory-SE) and 60 minutes (modelling late-SE) of status, when
recording evoked EPSCs from CA1 pyramidal neurons in pilocarpine injected adult rats.
GluA2 internalisation and changes in internal Ca2+ levels were seen using immunocyto-
chemistry and live cell imaging in hippocampal cultures in the 0-Mg2+ model of epileptiform
activity (Rajasekaran et al., 2012).
Additionally, inhibition of Q/R editing by ADAR2 in GluA2 results in increased excitability
of hippocampal neurons with associated spontaneous seizures (Krestel et al., 2004).
1.4.2 Age-dependency of AMPA receptor composition
There is age-dependence both in the AMPA receptor composition of healthy neurons, and in
their response to epileptic insults. In the immature brain during peak synaptogenesis, CP-
AMPA receptors are expressed at relatively high levels compared to adults (Kumar et al.,
2002; Pandey et al., 2015). The highest risk of seizure occurs in the very young and in the
very old, although immature brains are more resistant to seizure-induced neuronal damage.
There are age-specific differences in structure, physiology and metabolism to allow effective
development of networks in the brain, epileptic neurons reverting back to an immature state
may be proepileptic.
Immature brains have reduced overall expression of AMPA receptors, and respond to kainic
acid by increasing GluA2 expression. The reduced calcium permeability of these AMPA
receptors is protective against excitotoxicity. Further, seizures in immature rats lead to
transient increases in GluA1 phosphorylation with increased AMPA receptor-mediated currents,
and blocking this phosphorylation decreased the susceptibility of mice to PTZ and hypoxia-
induced seizures (Rakhade et al., 2012).
1.4.3 Toxicity due to CP-AMPA receptors
A change in the subunit configuration could enhance the toxicity of endogenous glutamate
following neurological insult. Glutamate induces cell death by increasing [Ca2+]i in neurons
via NMDA receptors and CP-AMPA receptors, thereby leading to a rise in the generation
of free radicals and activation of proteases, phospholipases and endonucleases. Post seizure,
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NMDA receptor-induced apoptosis requires calcium entry through CP-AMPA receptors for
transcriptional activation of the specific cell death programs (Friedman, 2006). Hippocampal
pyramidal neurons do not express high levels of Ca2+ -binding proteins or fast, local
calcium extrusion pumps, as they do not experience a high calcium load under physiological
conditions. Therefore, acute loss of the GluA2 subunit would be expected to confer enhanced
toxicity to endogenous glutamate and vulnerability to neuronal insults. Furthermore, CP-
AMPA receptors are permeable to Zn2+, which causes toxicity as it inhibits cellular energy
production when it accumulates intracellularly, leading to cell death (Dineley et al., 2003).
The c-Jun N-terminal kinase (JNK) signalling pathway, a subfamily of mitogen-activated
protein kinase (MAPK), is activated by CP-AMPA receptors in a Ca2+ concentration-
dependent manner (Vieira et al., 2010). MAPK signalling pathways are one of the major
signalling systems that transduce extracellular signals into cells. Activation of this pathway,
in response to Ca2+ increase or ROS activation, is important after an excitotoxic stimuli for
inducing apoptosis (Cui et al., 2007).
Another way in which CP-AMPA receptors can be toxic to the cell is by their higher
conductance level through each channel. This increases the risk of excitotoxicity. Ca2+ influx
mediates a rapid increase in CaMKII, PKA, and PKC activity in hippocampal neurons which
may lead to enhanced phosphorylation of both GluA1 and GluA2 subunits, and therefore
increased conductance. As CA1 pyramidal neuron dendrites have a high input resistance
compared to interneurons, the fidelity of signal transfer from dendrites to the soma is higher.
The increased conduction creates an opportunity for summation of postsynaptic potentials
(Spruston, 2008).
GluA2 is internalised upon phosphorylation of S880 by PKCγ. This process is facilitated by
its interaction with the PICK1-PKCγ protein complex. Rakhade et al. (2012) demonstrated
in a recent report that S880 phosphorylation of GluA2, following hypoxia-induced seizures
in neonatal rat, was associated with enhanced functional expression of CP-AMPA receptors
(Rakhade et al., 2012). Accelerated endocytosis of the GluA2 subunit may be mediated by
seizure-induced expression of the immediate early gene, Arc. Arc expression is induced in
both the dentate granule cells (DGCs) and CA1 neurons as early as 30 minutes following
pilocarpine-induced SE. In an earlier report, Teber et al. (2004) demonstrated that even
sub-convulsive doses of pilocarpine-induced a rapid expression of Arc in rat forebrain (Teber
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et al., 2004).
S831 phosphorylation of the GluA1 subunit increases the open probability of AMPA receptors,
creating a feedforward loop that leads to membrane insertion of extrasynaptic CP-AMPA
receptors. These receptors are trafficked laterally to the synaptic membrane, further strengthening
this excitatory connection (Huie et al., 2015).
A different target which has been implicated in the expression of CP-AMPA receptors
is Poly (ADP-ribose) polymerase 1 (PARP-1). PARP-1 alters protein expression at the
nucleus by polyADP-ribosylation and is hyperexpressed in CA1 after SE (Kim et al., 2014).
This reversible post-translational modification is a signal for intracellular stress which can
induce apoptosis (Basello and Scovassi, 2015). PARP-1 activation has been associated with
increased CP-AMPA receptor expression in CA1 but not CA3 pyramidal neurons (Gerace
et al., 2014).
RE1-Silencing Transcription factor (REST/ NRSF) is a transcriptional regulator, involved
in the switch of AMPA receptor phenotype and in the highly selective neuronal death seen
in global ischemia. It suppresses gene expression in those neurons that are destined to die.
After SE there is a transcriptional repression of GluA2 by upregulation of REST; acute
knockdown of REST prevents GluA2 suppression and rescues CA1 neurons (Noh et al.,
2012).
Mice with a knock out (KO) of the TARP γ-8 display typical kainate-induced seizures;
however the associated neuronal cell death is attenuated in the hippocampus of these mice
(Tomita et al., 2007a). γ-8 KO mice also show dramatic loss of AMPA receptor proteins and
extrasynaptic AMPA receptors, with only a modest decrease in synaptic AMPA receptors.
Stargazer mice, which lack γ-2, get their name from a characteristic upward gaze, caused
by absence seizures (Adotevi and Leitch, 2016).
Pharmacological block of AMPA receptors with NBQX does not prevent the reduction
in GluA2, suggesting that its mechanism of neuroprotection is by directly blocking modified
AMPA receptor channels. NBQX is likely to remain in the system long enough to act on the
new post-SE CP-AMPA receptors. However, overall block of AMPA receptor transmission
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could act on AMPA receptors found on inhibitory interneurons, which would increase ex-
citability.
1.4.4 Action of AEDs at the AMPA receptor
There is substantial interest in using AMPA receptor antagonists to control seizures but
at present only one, the non-competitive antagonist perampanel, is clinically approved
(Fig. 1.3). Perampanel can be given as an adjunction for refractory epilepsy, and has
a high potency (IC50 of 0.093 µM), compared to another non-competitive antagonist at
AMPA receptors, GYKI-52466 (GYKI; IC50 of 12.5 µM). Perampanel is moderately well
tolerated but side effects of dizziness, fatigue, irritability, nausea, and weight gain have been
commonly reported. NBQX shows anti-seizure but not antiepileptogenic effects in animal
studies (Twele et al., 2015). GYKI also shows anti-convulsant effects in both slice seizure
models and in vivo (Doczi et al., 1999; Yamaguchi et al., 1993). Decanoic acid, a major
component of the MCT ketogenic diet acts on AMPA receptors in a non-competitive way,
as discussed in section 1.2.3.2. It binds to all subunits, with a slight preference to GluA2/3
receptors (Chang et al., 2016).
Conversely, targeting other ionotropic glutamate receptors has little effect. In most in vitro
seizure models, NMDA receptor antagonists alone fail to substantially suppress or eliminate
epileptiform activity. Some AEDs acting at AMPA receptors have action at kainate too.
However, these receptors contribute less to synaptic transmission than AMPA receptors
(Frerking et al., 1998).
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Figure 1.3: Binding sites of AEDs acting at the AMPA receptor
Crystallised structure of the AMPA receptor (left) was achieved by Sobolevsky et al. (2009).
Schematic (right) showing AMPA receptor domains and the binding site of competitive
antagonists, with the proposed binding sites of decanoic acid and perampanel. Adapted
with permission from Rogawski (2016).
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1.5 Sodium channels
A common target of AEDs are VG ion channels, which transmit synaptic potentials and
action potentials along the dendrites and axons. Mutations within these channels are a
cause of many genetic forms of epilepsy.
Voltage-gated sodium channels (VGSCs) are present in all excitable tissue, and a requirement
for the fast-rising phase of action potentials. Neuronal sodium channels comprise one
α-subunit, which may be associated with either one or two β-subunits. In mammalian
cells, nine α-subunit isoforms (NaV1.1-NaV1.9) are expressed, from which NaV1.1, NaV1.2,
NaV1.3 and NaV1.6 are predominantly expressed in the CNS. The α-subunit contains four
homologous domains containing six transmembrane segments each (S1-S6) as well as a pore-
forming loop (Marban et al., 1998).
Much of our knowledge about sodium channels matches the m gates that underlie activation,
and the h gate that mediates inactivation, as postulated by Hodgkin and Huxley (Hodgkin
and Huxley, 1952). The Na+ channel transitions through various conformational states
in the process of opening, by cooperative action of the four S4 segments serving as the
activation sensors. The voltage sensitivity comes from a positively charged S4 segment
in each domain of the α-subunit (Yarov-Yarovoy et al., 2012), which moves in response
to membrane depolarisation. Segments S5 and S6 form the channel pore and the ex-
tracellular loops between S5 and S6 are important for establishing the ion-selectivity of
the channel, allowing sodium but not potassium or calcium ions to pass through (Payandeh
et al., 2011). During maintained depolarisation, the channel shuts. The cytoplasmic loop
between domains DIII-IV acts as a gate responsible for the fast inactivation of open sodium
channels.
Sodium channel mediated currents have been studied in detail using neurotoxins. Tetrodotoxin
(TTX) blocks Na+ channels potently (at nM concentrations) in neuronal and skeletal muscle
isoforms, but much higher concentrations (∼ 5-10µM) are required to block cardiac channels
(Zimmer et al., 2014). The different states of sodium channel activation and inactivation can
be measured by recording current responses to changes in the membrane voltage. The same
channel can alter its gating to produce both transient (INaT) and persistent (INaP) currents.
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INaP boosts distal synaptic potentials to allow them to reach the soma, and is important
for behaviours such as autonomous pacemakers and fast spiking. These are not the only
currents produced by the sodium channel. NaV1.6 interacts with an auxiliary subunit, which
is required for resurgent currents, when the channel moves from an open, inactive state to
closed state. The axon initial segment and nodal membranes in many neurons express a
high density of NaV1.6 channels (Burbidge et al., 2002).
1.5.1 Sodium channels in epilepsy
Mutations in subunits of the sodium channel can cause epilepsy (O’Brien and Meisler, 2013).
Mutations in the SCN1A gene, coding for α1 of NaV1.1 have been associated with various
types of epilepsy. 1200 different mutations in the SCN1A gene have been identified in studies
using either knockin animal models or induced pluripotent stem cell (iPSC)-derived neurons
from humans with the mutations. The β-subunit SCN1B was the first molecular link to be
established in Generalised epilepsy with febrile seizures plus (GEFS+). Since this, its been
shown that in GEFS+ most mutations appear in the S4 voltage sensor region of SCN1A.
A variety of functional defects, often missense mutations, have been found, including an
increase in INaP (Uebachs et al., 2010; Agrawal et al., 2003).
In Dravet syndrome, one-third of children have mutations in SCN1A, the majority being
frame-shift or missense, especially at the pore region (S5-S6). The type of mutation can map
onto severity of the disease symptoms; nonsense mutations cause a more severe phenotype.
The more debilitating mutations are de novo. Single amino acid mutations at different
locations throughout the channel are likely to give rise to multiple distinct functional deficits,
contributing to the varied clinical manifestation and severity of SCN1A epilepsy disorders.
Single gene mutation diseases are good targets for gene therapy and modification studies,
using new techniques such as clustered, regularly interspaced, short palindromic repeat
(CRISPR) technology.
Anti-convulsants block voltage sensitive sodium channels to stop seizures (Ragsdale and
Avoli, 1998; Mantegazza et al., 2010; Goldfarb, 2011; Colombo et al., 2013). Many AEDs
act in an use- and voltage-dependent manner, which allows them to selectively prevent
high frequency firing, with much less influence on normal action potentials and activity.
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However, most drugs targeting sodium channels act on transient (sub- and supra-threshold)
and persistent currents together. Phosphorylation of sodium channels changes kinetics of
the channel and could alter effect of AEDs. For example, the effect of topiramate on INaT
is reduced when the sodium channel is phosphorylated (Curia et al., 2007).
During epileptiform activity there is a reduction in the driving force for VG Na+ channels.
The significant shift in sodium reversal potential (+25mV from +55mV; Raimondo et al.,
2015) reduces the driving force and alters action potential kinetics. This could reduce the
ability of neighbouring VG Na+ channels to recruit each other during the course of action
potential generation. Interestingly, chronic epileptic-like activity can lead to upregulation
of INaP (Chen et al., 2011), potentially constituting a positive feedback mechanism for
triggering further seizures. It would be beneficial to find a way to just target persistent
currents in epilepsy.
One day after induction of SE there was a 50% loss of the NaV1.1-positive interneurons
(Qiao et al., 2013). NaV1.6 immunoreactivity in the dendritic region of CA1, and CA3 was
persistently reduced at all time-points during epileptogenesis (Blumenfeld et al., 2009). In
layer 5 of the entorhinal cortex, the INaP was larger at a time point coinciding with the onset
of spontaneous recurrent seizures (Agrawal et al., 2003). Although glia are non-excitable
cells which rarely express sodium channels, some astrocytes expressed NaV1.1 and NaV1.6
at 3 weeks after SE.
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1.6 Circuits of the hippocampus
The hippocampus is where seizures initiate in mesial TLE, and is a well defined brain
region important in epilepsy research. It is located in the medial temporal lobe and, along
with the entorhinal cortex, subiculum, presubiculum, parasubiculum and the dentate gyrus,
constitutes the hippocampal formation (Spiers, 2012). The hippocampus is required for the
formation of new memories and for spatial navigation. Synapses in the hippocampus are
highly plastic, and neuronal networks here can be synchronised to generate oscillations with
varying frequencies and behavioural correlates. For instance the coupling of gamma and
theta oscillations, produced by different neurons in the hippocampus, are vital to memory
formation (Butler and Paulsen, 2015). These brain functions arise from networks in which
individual neurons continuously receive synaptic inputs that are shaped by their intrinsic
membrane properties.
The hippocampal formation mainly receives inputs from the entorhinal cortex, which goes
via the perforant path to the dentate gyrus, CA3 and CA1. From the dentate gyrus,
mossy fibres send axons to CA3, from which Schaffer collaterals send outputs to CA1. CA1
pyramidal neurons send projections to the subiculum or out to the entorhinal cortex, via the
angular bundle (Andersen, 2007). The principal cells of the hippocampus are aligned in a
densely packed single cell layer. These excitatory pyramidal neurons, which are multipolar as
they form apical and basal dendrites extending in both directions from the cell body and have
strictly laminated inputs. The dentate gyrus is full of densely packed, small granule cells
(Andersen, 2007). The subgranular zone of the hippocampus is an area of adult neurogenesis
proliferation, influenced by environmental factors and disturbed in epilepsy. The dentate
hilar area usually contains a low density of neurons, but dentate granule cells disperse here
in chronic epilepsy.
Throughout the hippocampus, there is a heterogeneous GABAergic interneuron population.
These inhibitory neurons control excitation, and regulate the temporal precision of spiking.
Interneurons can be distinguished electrophysiologically from principal neurons as they
often have high rates of spontaneous activity and fire in relation to theta rhythm (Freund
and Buzsaki, 1996). Interneurons can be categorised based on their subcellular targets on
principle neurons; for example, somatostatin interneurons usually target the dendrites and
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parvalbumin interneurons target the cell body of the same cells. Further, glial cells can be
electrophysiologically distinguished from principle neurons as they are electrically passive.
Glial cells influence synaptic transmission via release of gliotransmitters (glutamate, ATP,
adenosine and cytokines) and regulation of the extracellular environment (such as by K+
buffering). This regulation likely alters the survivability and functioning of newly formed
connections (Ota et al., 2013).
One of the most common forms of epilepsy, temporal lobe epilepsy is characterised by
seizures originating in the hippocampus. Animal research of this brain region important
because in rodents, the hippocampus also readily generates epileptiform activity and has
been instrumental in advancing our understanding of ictogenesis.
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1.7 Models of temporal lobe epilepsy
1.7.1 Human resected tissue slices
Brain tissue removed in surgery for refractory epilepsy can be sliced and stored for several
hours in artificial cerebrospinal fluid (aCSF). There is no control over the tissue received
from surgical patients, so results can be very variable. Factors such as age of the patient,
type of epilepsy, duration of seizures and current AED treatment profile would influence the
network activity, and would ideally be controlled as is in animal studies.
Comparisons between rat and human neurons shows differences at the cellular and network
level which should be taken into account when interpreting animals studies with relevance
to humans. Human pyramidal neurons differ in their subcellular architecture and could
have information processing capabilities distinct from rodent and macaque neurons (Mohan
et al., 2015). Specifically, astrocytes and pyramidal neurons in the human temporal cortex
are 23 times larger than rodents, and processes are 10 times more complex (Oberheim
et al., 2009). There are neuron types in human which are not classified in rodents, as well
as more diverse interneurons. Also, the absolute numbers and density of neurons, spines,
and synapses are highly species-specific (DeFelipe et al., 2002); there are at least twice the
number of synapses per pyramidal neuron in humans as in mice.
Histopathological studies comparing a number of clinical factors with neuronal architecture
found no significant correlation between total dendrite length nor number of branch points
when compared to the number of seizures, disease severity, or age of the patient (Mohan
et al., 2015). However, there may be a more subtle change to neuron shape, or only certain
neuronal types affected which would not have been apparent from this study.
1.7.2 Acute slices
In vitro models of epileptogenesis are useful to study the mechanism of molecular changes
without the many confounding factors present in animal models. It can be useful to
compare effects in multiple in vitro models, as inducers acting on specific receptors can
cause specific outcomes. However, long range connections are cut in the production of
acute slices and further the solutions used to store slices are artificial, which could dialyse
important modulatory factors.
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1.7.2.1 0-Mg2+
Epileptiform activity generated in aCSF with Mg2+ removed consists of bursts of action
potentials riding on paroxysmal depolarising shifts. This leads to the development of
synchronous, electrographic discharges (Mangan and Kapur, 2004). Bursting causes changes
in the properties of GABAA receptor similar to animals after 1h SE, including diminished
mIPSC amplitude and decreased surface expression of GABAA receptor subunit γ-2.
NMDA receptors are involved in the generation of epileptiform events, as these are blocked
by d-AP5. Adding in a near-physiological concentration of Mg2+ (1mM) also completely
and reversibly blocks recurrence of epileptiform activity. Activation of AMPA receptors is
important for maintaining epileptiform activity; in addition, pathological discharges in this
model depend on gap junction coupling of neurons and astrocytes. Since excessive activation
of NMDA receptors in 0-Mg2+ aCSF could cause model specific changes in AMPA receptors,
it is important to verify the findings using other epilepsy models.
1.7.2.2 PTZ
Application of pentylenetetrazol (PTZ) and increasing K+ concentration from 2.5mM to
6mM induces ictal and interictal activity in EC-hippocampal slices. PTZ is a GABAA
receptor antagonist, acting at the picrotoxin binding site (Huang et al., 2001). Activity is
generated from the EC and the CA3, which is then sent onto CA1 and other areas. PTZ
can also be used to develop both acute and chronic animal models of epilepsy, especially in
pre-clinical drug studies.
1.7.3 In vivo models
In vivo models are used in the study of basic mechanisms of epilepsy in intact networks.
They are also indispensable to test confounders which may impact the clinical outcome
when using a particular drug, including bioavailabilty. Acute seizures are initiated by
injection of chemoconvulsants, such as PTZ, or by electrical stimulation in the maximal
electrical shock (MES) test. This models give useful information on seizure threshold and
are good as a simple initial screen of anti-seizure potential. Chronic seizures are induced
by chemical or electrical kindling, where multiple subthreshold doses eventually causes
seizures after network changes within the animals brain. Further, induced SE leads to
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spontaneous seizures after injection of kainate or pilocarpine, or perforant path stimulation
(PPS). Chronic models of epilepsy are used to compare seizure frequency and severity in
differently treated groups of animals. They must be recorded continuously by video/EEG
monitoring during this period for seizure monitoring (Loscher, 2011), and ex vivo brain
tissue can be used for single cell electrophysiology and histochemistry. Finally, there are
genetic models of epilepsy produced either from animals with a random mutation causing
spontaneous seizures, or by genetic manipulation (e.g. stargazer mouse).
1.7.3.1 Perforant Path Stimulation
PPS is a post-SE model of epilepsy, induced by constant supra-threshold current pulses to
the perforant path. Initially seizure activity depends entirely on ongoing stimulation; but
then seizures becomes self-sustaining and no longer depend on the external stimuli. This
second phase is refractory to treatment with standard anticonvulsants and may involve
molecular alterations at GABA receptors, or long-term potentiation of excitatory synapses.
Animals stimulated in such a way develop temporal lobe epilepsy with spontaneous seizures
after a latent period of up to 3 weeks. Many AEDs are able to suppress seizures in PPS,
so this model has pharmacological validity. However, as there is variability between TLE
patients and epilepsy is not a static disorder, response rates to AEDs can change over time.
The neuropathological changes seen following PPS, such as patterns of sclerosis, match
many patients with TLE. This contrasts with kainate- or pilocarpine-induced SE, which
leads to more widespread damage to the brain (Loscher, 2011). Since PPS stimulation
does not rely on exogenous application of a chemical agent, it has high validity. However,
PPS is a technically difficult, expensive, and time-consuming model. This is a particularly
important consideration when looking at chronic effects of treatments, as continuous seizure
monitoring is required.
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Thesis Aims
1. Explore whether excessive network activity causes a shift towards GluA2-lacking
AMPA receptor expression on CA1 pyramidal neurons
2. Measure if this shift is blocked in the presence of NMDA receptor inhibitors
3. Determine if specific CP-AMPA receptor inhibitors block epileptiform activity in a
similar way to general AMPA receptor inhibitors
4. Investigate whether AMPA receptor inhibition by decanoic acid can explain the success
of the ketogenic diet
5. Explore if other neuronal targets of decanoic acid reduce network excitability
6. Determine if recordings from human neocortical neurons can be compared to results
obtained in rats
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Materials and Methods
2.1 Animals
Wild type Sprague Dawley (SD) male rats were imported from Charles River, group housed
and left to acclimatise for 1 week before use in experiments.
2.2 Acute rat hippocampal slices
P21-P26 SD rats were sacrificed by isofluorane anaesthesia (Henry Schein, UK) followed by
cervical dislocation, in accordance with UK Animals (Scientific Procedures) Act 1986. The
whole brain was quickly removed for dissection and placed in oxygenated ice-cold slicing
solution containing (in mM): 87 NaCl, 12.5 NaHCO3, 75 sucrose, 25 glucose, 2.5 KCl,
1.25 NaH2PO4, 7 MgCl2, 0.5 CaCl2, bubbled with 95% O2/5% CO2 to maintain pH at 7.4
(Osm:316mOsm).
For EC-hippocampus combined horizontal slices the cerebellum and forebrain were removed,
and hemispheres were separated by cutting through the midbrain to expose the hippocampus
(Fig. 2.1a). Each hemisphere was cut dorsally parallel to a prominent blood vessel (the
”magic cut”; Fig. 2.1b; Bischofberger et al., 2006), glued to the platform and then immersed
in oxygenated ice-cold sucrose solution in the slicing chamber of a vibrotome (Leica VT1200S,
Milton Keynes UK). Slices (350µM thick) were obtained at a speed of 0.10-0.12mm/s and
cutting frequency of 0.85.
Slices were allowed to recover at 35°C for 15 minutes before being transferred to a submerged
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chamber (see Fig. 2.2) at room temperature for at least 30 minutes recovery in oxygenated
aCSF containing (in mM): 125 NaCl, 2.5 KCl, 1 MgCl2, 20 NaHCO3, 1.25 NaH2PO4,
25 glucose, and 2 CaCl2 (osmolarity 296 mOsm). Slices were then either transferred to a
different incubation solution for at least one hour or left for a further 30 minutes before
recording.
2.3 Ex vivo induction of epileptiform activity
At least one hour prior to recording, slices were transferred to an oxygenated interface
chamber in a water-bath at 34°C (Fig. 2.2) containing either 0-Mg2+ aCSF (solution as
above, with MgCl2 excluded, KCl increased to 5mM, and 5mM Na-pyruvate), PTZ-aCSF
(solution as above, with 2mM PTZ, KCl increased to 6mM, and 5mM Na-pyruvate) or
control aCSF. Epileptiform discharges, recorded as population spikes consisting of positive
field potentials, were recorded from stratum radiatum and appeared 5-30 minutes after
incubation in the modified aCSF.
Interface style chambers (Fig. 2.2b) provide a humidified carbogenated atmosphere, which
may provide a more ”physiological-like” environment when compared to the submerged
chambers. Slice viability and neuronal health based on the electrophysiological recordings
obtained were improved by incubation in an interface chamber. Slices stored in the interface
chamber stayed viable for up to eight hours after slicing. These chambers promote the
induction of interictal and ictal activity in slice models of seizures, possibly due to the
ability of the system to cope with increased metabolic demands (Hajos and Paulsen, 2009).
Epileptiform activity could be generated by application of PTZ or 0-Mg2+ aCSF at room
temperature, but was stronger and more consistent when induced at 34°C.
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Figure 2.1: Brain dissection schematic for EC-hippocampal horizontal slices.
a) Dotted lines show cutting plane to remove forebrain and cerebellum (in blue) for
horizontal hippocampal slices (an outline of the hippocampus is shown in the middle).
b) Third cut to the whole brain is parallel to the rhinal artery. This provides a stable base
to glue the brain and horizontal hippocampal slices at the correct orientation. (a) adapted
from: Amaral DG, Witter MP. Hippocampal formation. In: Paxinos G, editor. The Rat
Nervous System. Second. London, Academic Press; 1995. pp. 443-493.
Figure 2.2: Submerged and interface chambers.
a) Submerged chamber. Slices were stored on nylon mesh, fully submerged in aCSF with
carbogen gas (95% O2 5% CO2 ) bubbled in the chamber to oxygenate slices. b) Gas-
fluid interface chamber. Slices being incubated at 35°C were held in an interface chamber
to increase viability. Slices were stored on nylon mesh, partially submerged in aCSF in a
chamber filled with aCSF with carbogenated gas (95% O2 5% CO2 ) bubbling through.
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Compound Conc. Provider Reference
4-AP 5mM Sigma Royeck et al. (2008)
4-BCCA 1mM TCI Chemicals Chang et al. (2015)
4-EOA 1mM Chemos GmbH Chang et al. (2015)
4-MNA 1mM Alfa Aesar Chang et al. (2015)
CdCl2 300µM Sigma Yue et al. (2005)
Decanoic acid 10-1000µM Sigma Chang et al. (2016)
d-AP5 50µM Tocris Zamanillo et al. (1999)
FK506 10mM Tocris Eckel et al. (2014)
GYKI-52466 50µM Sigma Donevan and Rogawski (1993)
LY-294002 20µM Echelon Chang et al. (2014)
Na-pyruvate 5mM Sigma Kovac et al. (2012)
NASPM 70µM Alomone Loweth et al. (2014)
NBQX 10µM Alomone Sanderson et al. (2012)
PTX 50µM Sigma Opazo et al. (2010)
PTZ 2mM Sigma Chang et al. (2014)
QX-314 Br 50µM Alomone Chen et al. (2011)
Spermine 100µM Sigma Zamanillo et al. (1999)
TC-2153 1µM Sigma Xu et al. (2014)
TEA-Cl 20mM Sigma Yue et al. (2005)
TTX 1µM Alomone Royeck et al. (2008)
Table 2.1: Compounds used in project, with standard concentration used.
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2.4 Single cell electrophysiology
During single cell recording, hippocampal slices were placed on a double-sided, dual perfusion
chamber and held in place with a handmade harp, consisting of a platinum wire bent into
a horseshoe shape with single nylon threads from tights glued across. Slices were con-
tinuously perfused with oxygenated aCSF. Patch electrodes were prepared from filamented
thick-walled borosilicate glass (World Precision Instruments, UK) pulled on a horizontal
microelectrode puller (model P-97, Sutter Instruments, UK) using a two-stage pull protocol.
Whole-cell patch clamp recordings were made from the soma of CA1 pyramidal neurons,
which were identified visually by their shape and physiological properties (Hamill et al.,
1991). Neurons were visualised with an upright microscope (Olympus BX51WI) using a
40x water immersion objective, with a charge-coupled device (CCD) camera for viewing
through a video monitor. A differential interference contrast (DIC) microscope was used
to clearly visualise cells in deeper layers of the tissue, where the neurons are healthiest.
Recordings were performed using an Multiclamp 700B amplifier (Molecular Devices, UK).
The headstage was mounted on a PatchStar motorised micromanipulator (Scientifica, UK).
Whole-cell patch clamp configuration was achieved by patching in voltage clamp. Positive
pressure was applied to the patch pipette to prevent clogging at the tip as it was lowered
into the slice. The current transient elicited by a 5mV hyperpolarising voltage step was
continually monitored during seal formation. When approaching a cell, an expanding dimple
in the cell membrane was observed and the current transient decreased. After positive
pressure was released, the seal became GW in resistance with the aid of negative pressure
applied through the pipette tip, and changing the pipette potential from 0mV to -70mV.
Pipette capacitance was corrected and then short, gentle ramps of negative pressure were
applied to rupture the membrane and achieve whole-cell electrical access.
Ten minutes after access was established, series resistance compensation was applied between
55 and 80%, following whole-cell capacitance measurement. This is necessary to compensate
resistance at the pipette tip, and is required to minimise errors in command voltage and
to improve the accuracy of current kinetics. Access resistance was continually monitored
by measuring the size of capacitance transients in response to a 5mV hyperpolarising step.
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Recordings in which access resistance changed more than 20% were rejected. Cell input
resistance was measured from steady-state currents in response to various depolarising steps.
The currents were low-pass filtered at 5kHz and digitised at 20kHz using a PCI-6221 card
A/D converter (National Instruments, UK) and recorded using LabVIEW software (National
Instruments, UK). In all experiments, the recording chamber was maintained at 32°C using
an inline heating system coupled with an automatic temperature controller (Scientifica,
UK).
2.4.1 Voltage clamp
Voltage clamp was used to study the current-voltage (I-V ) relationship of pharmacologically
isolated VG ion channels or synaptic currents evoked by extracellular tissue stimulation.
2.4.1.1 Extracellular neuronal stimulation
Evoked EPSCs (eEPSCs) were obtained by stimulation of the Schaffer collaterals using a
concentric bipolar platinum-iridium electrode (125µm, FHC, Bowdoin, ME) approximately
100-300µm from the recorded cell. Constant current pulses (200µs; 0.1 Hz) were ad-
ministered to the slices using a constant current stimulus isolator (DS3, Digitmer, Hert-
fordshire, UK); the stimulus intensity was standardised at 1.5 times the minimum provoking
EPSC response.
2.4.1.2 AMPA receptor-mediated currents
In CA1 pyramidal neurons voltage clamp is spatially limited (Bar-Yehuda and Korngreen,
2008). The injected current required to maintain the holding potential is filtered along axons
and dendrites, and further currents originating from distal synapses are distorted kinetically
by the time they reach the soma. To improve space clamp issues, a caesium-based internal
solution, which blocks K+ leak channels was used, and series resistance was compensated
as described above. As the response from many synapses is measured, the more proximal
synapses with the greater clamp will be more influential in the response.
eEPSCs mediated by AMPA receptors were isolated by including 50µM PTX and 50µM d-
AP5 in the recording solution, to block GABAA and NMDA receptor currents respectively.
As GABAA receptor currents were blocked, a cut was made to separate CA3 from CA1
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to block spontaneous activity generated here from contaminating recordings during these
whole-cell voltage clamp recordings. Patch pipettes were filled with internal solution,
filtered through a 22nm pore, containing (in mM): 125 cesium-methylsulphonate (Cs-MSF),
10 HEPES, 10 Na-phosphocreatine, 8 NaCl, 0.33 Na3-GTP, 0.2 EGTA, 5 TEA-Cl, 4 ATP-
Mg (buffered to pH 7.3 with CsOH; 315 mOsm) and had a final resistance of 2.5-4.5 MW.
Liquid Junction Potential (LJP) is caused by the difference in mobility of ions through the
tip of the pipette. LJP of 13 mV was taken into account before each recording (calculated
in silico using LJP Calculator: JPCalcW). The internal solution contained spermine to
compensate for the loss of endogenous cellular polyamines by dialysis of the cell contents
and QX-314 Br (50µM) to block VG sodium channels and therefore abolish escape currents
due to unclamped spikes.
The I-V relationship of AMPA receptor-mediated EPSCs was obtained by measuring the
leak subtracted peak of 6-10 averaged eEPSCs at various holding potentials (-70 to +70 mV).
Points were fitted with a linear relationship at negative potentials and this was either ex-
trapolated into positive potentials, or positive potentials were fitted with a polynomial re-
lationship to match the curved relationship (fitting used is indicated in each figure legend).
As AMPA receptors are constitutively recycled from the synapse, all whole-cell recordings
were initiated within 20 minutes of removal from the incubating solution.
The level of CP-AMPA receptor expression influences I-V relationships due to polyamine-
dependent inward rectification. This can be measured using the Rectification Index (RI).
RI was defined as:
RI =
I+50mV
I−50mV
(2.1)
in all experiments (except in Fig. 3.4 and Fig. 3.6 where the holding potentials compared
were +40 mV/-40 mV and +40 mV/-60 mV respectively, due to different voltage steps
being recorded). RI is around 1 at a synapse containing only CI-AMPA receptors . In
synapses containing only CP-AMPA receptors, the RI can be expected to be <0.25, and 0.7
is an arbitary value used as a cut-off to guide when a combination of CP- and CI-AMPA
receptors are present at the synapse (Wang and Gao, 2010).
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Data were collected using LabVIEW and was analysed in LabVIEW, or using scripts written
in Python. Statistical analysis was performed using SPSS (IBM, Portsmouth, UK), Origin
9.0 (OriginPro 9; MA, USA), or Python (Python Software Foundation). Cells with a RI
calculated at >2 were discarded as outliers (n=1 cell). Each treatment group contained
recordings in neurons from at least 3 separate animals. Treatment group sizes were chosen
by performing a power calculation based on preliminary data (GPower 3.1). Mean eEPSCs
recorded from both treatment groups were used to calculate RIs, which were then compared.
2.4.1.3 Voltage-gated sodium channel currents
To study VGSC currents in voltage clamp, CA1 pyramidal neurons were patched using
an internal solution containing (in mM): 125 Cs-MSF, 10 HEPES, 10 Na-phosphocreatine,
8 NaCl, 0.33 Na3-GTP, 0.2 EGTA, 5 TEA-Cl, 4 ATP-Mg (buffered to pH 7.3 with CsOH; 315
mOsm). LJP of 11 mV was compensated for before all recordings. To isolate sodium channel
currents, 20mM TEA-Cl, 5mM 4AP and 0.3mM CdCl2 were included in the extracellular
recording solution to block VG potassium channels and calcium channels respectively.
To measure transient sodium currents, cells were held between -70 mV and +20 mV, at
10 mV steps. Three cycles of baseline currents were recorded, after which 300µM decanoic
acid was washed in for three more cycles, followed by wash-in of 1µM TTX, as TTX is
difficult to wash out of slices. Only one cell was recorded per slice for the same reason.
Currents were averaged over 2 or 3 cycles per cell and traces made in TTX were subtracted
for each holding voltage. During analysis of transient sodium currents, data was excluded
if there was evidence of imperfect voltage clamp (ie. the peak was not within the first
20ms of the current response). Currents were then normalised to cell capacitance (pF) to
control for changes in peak current and maximum conductance due to variations in cell size,
and pA/pF was plotted against holding potential. Transient sodium channel currents were
converted into conductances using Ohm’s law (eq. 2.2; Yue et al., 2005):
G(V ) =
I(V )
(V − VNa) (2.2)
where G(V ) is the conductance, I(V ) the peak current recorded at test potential V , and
VNa is the sodium reversal potential estimated using the Nernst equation (eq. 2.3; taken
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as +55 mV in my experiments).
E =
RT
zF
ln
[X]o
[X]i
(2.3)
The activation curve (conductance-voltage relationship) was derived from the I-V curves
obtained by plotting the peak current over voltage steps. Comparing conductance allowed
me to look at voltage-dependence with differences in driving force taken into account. G(V )
was then fitted with the following Boltzmann function:
G(V ) =
G(max)
1 + exp[(V50 − V )/k] (2.4)
where Gmax is the maximal Na
+ conductance, V50 is the membrane voltage (V ) at which
G(V ) is 50% of Gmax, and k is the slope of the G(V )/V relationship at V50.
To measure persistent sodium currents (INaP), the membrane potential was ramped from
-80 mV to +20 mV over 50 seconds (2mV/s). This slow ramp speed is required to see
persistent currents in CA1 pyramidal neurons (Park et al., 2013). Recordings were filtered
at 4kHz and acquired at 10kHz, as the protocol was longer for these experiments and the
time scale of the current of interest was slower than previous. Two recording cycles were
collected for the baseline before 300µM decanoic acid was washed in for two more cycles,
followed by wash-in of 1µM TTX. Currents were averaged over 2 or 3 cycles per cell and
TTX subtracted.
INaP traces were converted to conductance traces using eq. 2.2, and peak conductance was
compared between control and decanoic acid by fitting a Boltzmann function using eq. 2.4,
as in Royeck et al. (2008). Peak conductance was normalised to baseline and compared to
decanoic acid wash-in and TTX wash-in. Voltage of half-maximal activation (V50) and the
slope factor (k) of INaP were also compared.
2.4.2 Current clamp
Current clamp was used to record the number and shape of action potentials in response
to increasing current injections, and the size of voltage response to current injections in
the presence of TTX. Before recording, slices were incubated at room temperature in aCSF
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or for 50 minutes with the phosphoinositide 3-kinase (PI3K) inhibitor, LY-294002 (20µM),
added to the aCSF.
Whole-cell electrical access to CA1 pyramidal neurons was obtained in voltage clamp mode
as described above, before switching to current clamp mode without current injection. Using
whole-cell capacitance and access resistance estimates from voltage clamp mode, the bridge
was balanced, and cell was left for 10 minutes. CA1 pyramidal neurons had a resting
membrane potential of between -75 mV to -55 mV. Microelectrodes were filled with a K-
gluconate based internal solution, containing (in mM): 140 K-gluconate, 10 HEPES, 10
Na2-phosphocreatine, 8 NaCl, 0.33 Na3-GTP, 0.2 EGTA, 2 ATP-Mg; and they had a final
resistance of 2.5-4.5 MW. LJP was 8mV and was taken into account before all recordings.
PTX (50µM), d-AP5 (50µM) and NBQX (10µM) were included in the recording solution to
block GABAA receptors, NMDA receptors and AMPA receptors respectively. TTX (1µM)
was sometimes included in the recording solution to block VG sodium channel currents.
The sample frequency was initially set at 20kHz for counting the number of action potentials.
It was then increased to 50kHz for analysis of action potential shape, with a Bessel filter of
8kHz. Voltage traces in response to 6-8 incrementing current steps of 25pA or 40pA were
recorded using LabVIEW, with step size chosen in order to initiate action potentials on the
2nd-3rd step. Decanoic acid or BCCA were dissolved in dimethyl sulphoxide (DMSO) at
1000X stock, and volume matched decanoic acid or DMSO was washed into the recording
solution to achieve a final concentration of 300µM.
Action potentials were counted by voltage threshold detection using Clampfit, and parameters
were compared between treatment groups using a Python script. The change in number of
action potentials at each current step was compared using area under the curve (AUC).
2.4.2.1 Analysis of action potentials
Limit cycle plots of dV/dt were drawn for traces recorded at 50kHz, with a Bessel filter
of 8kHz. The differential of voltage over time was taken and plotted against voltage to
give a representation of the kinetics of the action potential. From this the RMP, Vrepolarise,
Vthreshold and Vpeak could be determined and compared in treatment groups.
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2.5 Extracellular recordings
Extracellular recordings were used to record network activity in response to extracellular
stimulation or application of exogenous chemicals causing epileptiform activity. EC-hippocampal
slices (350µM) were prepared because intact connections are required for PTZ-induced
epileptiform activity, and recordings were made from the stratum radiatum of CA1. Recording
electrodes were pulled from thick-walled borosilicate glass as previously described, filled with
aCSF and had a resistance of 1MW. Electrode position determined the polarity and shape
of population response (Fig. 2.3).
2.5.1 Epileptiform activity
Slices were placed in a dual-perfusion recording chamber, which allows perfusion on both
sides of the slice, and were continuously perfused with PTZ-aCSF. Fatty acid derivatives
were dissolved in DMSO at 1000X stock, then were added to the recording solution to
achieve a final concentration of 1mM. The compounds tested were 4-methylnonanoic acid
(MNA), 4-ethyloctanoic acid (EOA), trans-4-butylcyclohexane carboxylic acid (BCCA), 4-
n-pentylphenylethanoic acid (PPEA) and 2-(4-pentylcyclohexyl) ethanoic acid (2PEA). All
compounds were over 95% purity. Decanoic acid was dissolved in DMSO at 2000X stock,
and GYKI was prepared at 1000X stock in distilled water. Field potentials were recorded
for a stable 10 minute baseline before compound application. After 40 minutes recording
with the compound in solution, drug washout was recorded using PTZ-aCSF for 30 minutes.
Spontaneous epileptiform discharges were recorded, digitised at 10kHz (4kHz filter, gain of
100), and analysed using WinEDR (Strathclyde Electrophysiology Software). An automated
event detection program was used (WinEDR) and verified manually. The number of epileptiform
events were binned into 5 minute intervals, normalised to baseline and averaged.
2.5.2 Synergy between decanoic acid and perampanel
After a stable 10 minute baseline field potential recording in PTZ-aCSF, perampanel was
added to the bathing solution at the required concentration from a 50mM stock solution
dissolved in DMSO. Decanoic acid was washed in at appropriate concentrations from a
600mM stock dissolved in DMSO. 100nm perampanel was the highest concentration that
does not itself reduce epileptiform activity.
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Figure 2.3: Position of stimulating electrodes and recording electrode in stratum radiatum
of CA1, and the field response.
a) Two independent Schaffer collateral pathways were stimulated by electrodes placed
on either side of a recording electrode in the CA1 st. radiatum. b) Dependence of the
fEPSP shape, size and polarity on the recording electrode position. Recording a synaptic
input (orange) from the electrode placed in st. radiatum (blue) during Schaffer collateral
stimulation produces a negative-going fEPSP response (blue trace), whereas recording from
the electrode placed in st. pyramidale (red) during Schaffer collateral stimulation produces
a positive-going fEPSP response (red trace). Adapted with permission from Einevoll et al.
(2013).
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Epileptiform discharges were counted in one minute bins. The number of epileptiform
discharges in each bin after seven minutes decanoic acid wash-in were averaged, and normalised
to a perampanel-containing baseline. Hill functions were plotted for each slice and the con-
centration of decanoic acid that reduced epileptiform discharges by 50% was read off at
normalised epileptiform discharges of 0.5.
2.5.3 Use-dependence
For use-dependence studies, field EPSPs (fEPSPs) were recorded in response to stimulation
of two independent Schaffer collateral pathways. Two concentric bipolar platinum-iridium
electrodes (125µm, FHC, Bowdoin, ME) were placed in the stratum radiatum at different
depths either side of a recording electrode, which was also placed in the radiatum layer
of CA1 (Fig. 2.3). AMPA receptor-mediated responses were pharmacologically isolated
by including PTX (50µM) and d-AP5 (50µM) in the recording solution to block GABAA
receptor and NMDA receptor-mediated currents, respectively.
To confirm that the stimulation pathways activated independent populations of synapses,
a paired pulse (PP) protocol (pulse width 1ms; pulse interval 100ms) was first executed in
each pathway. During successive activation of independent pathways there was not expected
to be any PP potentiation. The evoked current amplitude from each pathway did not differ
from each other by >10%. After pathway independence was confirmed, a stable (<20%
change in the fEPSP amplitude over 15 minutes) baseline period was recorded. Constant
current pulses (1ms; 0.025 Hz) were administered to the slice using a constant current
stimulus isolator (DS3, Digitmer, UK). Subthreshold (e.g. half-maximal) stimulation was
used to avoid saturation of the fEPSP response. If a population spike was seen in response
to stimulation, then the recording electrode was moved to get a more appropriate response.
After a baseline period, stimulation of one pathway was stopped and decanoic acid (in
DMSO) was added to the recording solution, to achieve a final concentration of 300µM.
After 30 minutes, stimulation of the second pathway was resumed and fEPSP slopes in
both pathways were compared. Recordings were collected using LabVIEW and exported
as ASCII files for analysis in Python. During analysis, fEPSP responses were binned into
groups of 2 consecutive recordings and the average was taken to reduce variation. Responses
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were normalised to baseline.
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2.6 Human surgically resected tissue
Informed written patient consent to use resected tissue for basic research was obtained
prior to the surgery. Tissue was collected directly from the surgery theatre at the National
Hospital for Neurology and Neurosurgery and immediately immersed in ice cold sucrose or
choline-based aCSF containing (in mM): 110 CholineCl, 26 NaHCO3, 7 MgCl2, 2.5 KCl,
1.25 NaH2PO4, 0.5 CaCl2, 10 glucose, 11.6 Na-ascorbate, 3.1 Na-pyruvate. The time from
tissue removal to slicing procedure was approximately 15 minutes. The meninges were
removed from the sample and areas damaged by removal were cut away. Then a suitable
angle for cutting was chosen and the brain was glued to the tissue holder with a 2cm3
agar block glued behind for support. Slices (350µM or 450 µM) were stored at 34°C for
15 minutes and then left in oxygenated aCSF in a submerged holding chamber at room
temperature for at least 1 hour before use. Preparation and slicing of the human tissue
samples was carried out by Dr Tom Jensen, Dr Ivan Pavlov or myself.
Neocortical pyramidal cells in layer 2-3 were targeted with the stimulating electrode placed
in a region of cell fibres nearby. Data was collected using the same protocols and compound
concentrations as in rodent experiments (described above).
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2.7 Computational models
2.7.1 Quantitative modelling of Schaffer collateral-CA1 synapse
This model used a linear current-voltage relationship to simulate a synapse with 100%
GluA2-containing AMPA receptors. Conversely, data from a kinetic model of kainate
receptors (Bowie et al., 1998) built into a point process in NEURON (Carnevale and Hines,
2006) was used to simulate a synapse containing 100% GluA2-containing AMPA receptors.
Data were collected using a Python script modelling activation of a synapse containing only
AMPA receptors, tested at different holding potentials. The ratio of CP- to CI-AMPA
receptors was varied to determine the proportion of CP-AMPA receptors required to detect
using rectification index (<0.7 was chosen as the threshold to indicate synaptic CP-AMPA
receptor presence).
2.7.2 Peak-scaled non stationary fluctuation analysis
Noise analysis of synaptic currents can be used to estimate the kinetics and conductance of a
receptor (Benke et al., 2001). For this, evoked AMPA receptor-mediated currents from CA1
pyramidal cells were recorded in whole-cell configuration at a holding potential of -60 mV
in response to external stimulation of Schaffer collateral fibres. >20 eEPSCs were collected
at 20kHz for noise analysis as there was much variability between response amplitude and
decay.
Recorded files were exported from LabVIEW as ASCII files and converted to CSV format.
A Python script subtracted the average baseline, taken immediately before trigger of the ex-
tracellular stimuli, and then EPSCs were aligned by peak. The time points of interest were
from peak of response to 6x tdecay. Responses were normalised by scaling the average to each
peak (Traynelis et al., 1993), however the peak amplitudes were fairly consistent between
cycles as external stimulation likely activated all AMPA receptors from the stimulated fibres,
onto the recorded cell. Mean current was binned into 50 groups based on current decay,
and for each bin the variance was determined. Variance (σ2) was plotted against mean
peak scaled current (I ). Single-channel current (i) was estimated by fitting the theoretical
relationship for the peak scaled variance:
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σ2 = σ2s +
(
iI¯ −
(
I¯2
N
))
(2.5)
to different fractions (50% and 100%) of the measured current-variance relationship. In
this equation, N is the average number of channels open at the peak of the EPSC, as
opposed to the number of channels in the postsynaptic membrane. When peak-scaling is
used, the relationship is fitted to a modified equation, in which information on N is lost.
The single-channel conductance (γ) can be calculated by:
γ = i/V (2.6)
where V is the driving force (holding potential minus assumed reversal potential of 0mV).
A holding potential of -60mV was used throughout the NSFA experiments. Therefore, the
equation:
γ = i/− 0.06 (2.7)
was used to estimate single-channel conductance.
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Figure 2.4: Estimation of single-channel conductance by peak scaled non-stationary
fluctuation analysis
a) Example normalised AMPA receptor-mediated current (black line) with single sweep
overlaid (red dotted line), and variance (top trace). b) Variance vs. mean current from
40 sweeps at -60 mV. Estimated of i from eq. 2.5 is based on the initial gradient of the
relationship.
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2.8 Rodent model of epilepsy
2.8.1 Electrically-induced Status Epilepticus model
2.8.1.1 Animals
Male Sprague-Dawley rats (280-320g, Charles River, UK) were used throughout. Animals
were housed individually with access to food and water ad labium and maintained on a
12:12 hour light/dark cycle. All animal procedures had local ethical approval and followed
the UK Home Office Animal (Scientific Procedures) Act, 1986.
2.8.1.2 Electrode preparation
Bipolar Teflon-coated stimulating electrodes were prepared from two intracranial electrodes
wound tightly around each other by hand to prevent coating being removed from the
remainder of the wire. Tips were kept ∼0.7mm apart to avoid short-circuiting. A scalpel
blade was used to remove<0.5mm insulation to leave a conductive tip exposed. The unipolar
Teflon-coated recording electrode was produced by removing <0.5mm insulation at the tip
of the electrode. The reference electrode was produced from a 4cm silver wire soldered to
a stainless steel gold plated socket contact. All electrodes used were from Plastics One Inc,
Bilaney Consultants UK Ltd., UK.
2.8.1.3 Electrode implantation surgery
Rats were given 1 week to accommodate after arrival, then were weighted and checked for
signs of ill health before the procedure. Rats were anaesthetised (5% isofluorane in 2L/min
O2) in an anaesthetic chamber, then their head area shaved with an electric shaver (Wella,
UK) and cleaned with iodine (Videne, MidMeds Ltd., UK). The analgesic buprenorphine
was administered (0.2mg/kg sc-40 minutes onset, 12 hour analgesia, Temgesic, Scherig-
Plough, UK) and gel drops were given to protect the eyeballs (Viscot Tears). The animal
was then secured centrally in a stereotaxic frame (David Kopf Instruments, USA) with ear
bars, incisor teeth bar and a nose bar to keep secure. The animal was placed on a heat
mat with its tail tucked under to maintain optimum body temperature and enhance post-
op recovery. Isofluorane delivery was reduced to 2-3% in 2L/min O2 and monitored. Once
there was no response to ear and toe pinch and breathing was satisfactory, skin was removed
from the top of head (∼1cm2) and subcutaneous tissue cleared to reduce infection.
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A stereotaxic drill (Model 1471, David Kopf Instruments, USA) attached to the stereotaxic
frame was used to drill single burr holes through the skull for the bipolar stimulating
electrode (right angular bundle, 4.4mm lat. and 8.1mm caud.) and recording electrode
(right dentate gyrus, 2.5mm lat. and 4mm caud.), where coordinates were determined
compared to Bregma; from Paxinos and Watson’s rodent brain atlas (Paxinos et al., 1985).
Three additional burr holes were drilled for screws to hold the dental fixture in place.
The reference electrode was wound around the front screw and 1cm tucked subcutaneously.
Bipolar stimulating electrodes were placed in the angular bundle to target the perforant
path projection from layer II/ III of entorhinal cortex (Stringer and Colbert, 1994). The
recording electrode was placed in the dentate granule cell layer to pick up field potentials.
Correct positioning of the electrodes was tested by recording the response to single test
pulses. The recording electrode position was adjusted in the ventral plane until a maximal
granule cell population spike amplitude was seen in response to a 3.5mA, 150µs single
pulse stimulation (stimulating electrode lowered 3.5mm into the brain). Test pulses to the
Perforant Path (PP) were initiated via a Neurolog system (Digitimer Ltd, Welwyn Garden
City, UK) and stimulus isolator (Digitimer, UK) and the extracellular recordings from the
dentate gyrus were amplified and bandpass-filtered (0.1-50 Hz) then digitised and recorded
at 100 Hz using a CED micro 1401 and Spike 2 software (both CED, Cambridge, United
Kingdom). A positive-going field potential with >2mV population spike was recorded when
electrodes were in the correct position. The electrodes were mounted into a six-channel
plastic pedestal (Plastics One, UK) and secured with dental cement (Kemdent, Swindon,
UK). To improve recovery rates 2ml 0.9% w/v NaCl was administered subcutaneously and
rats were monitored regularly.
2.8.1.4 Induction of self-sustaining status epilepticus
7-10 days after the initial surgery, rats that did not display >10% body weight loss were
used to induce self-sustaining status epilepticus (SSSE). The pedestal was attached to a
six-channel cable to a counterbalanced six-channel commutator (both Plastics One, UK) so
that the animals were freely moving throughout. Stimulation of the perforant path was done
using a Neurolog system and electrical signals were bandpass-filtered (0.1-500Hz), digitised
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0 No signs
1 Facial movements
2 Wet dog shakes
3 Fore paw clonus
4 Rearing and both front paw clonus
5 Rearing and falling, wild jumping
Table 2.2: Racine score: Behavioural classification of seizure severity based on Racine
(1972). Animals in SSSE all reached at least stage 4 severity.
at 1000Hz (CED micro 140; CED, Cambridge, UK) and recorded using Spike 2 software
(CED, Cambridge, UK). After a 10 minute baseline recording, continuous stimulation
consisting of trains of 50µs monopolar pulses at 20 Hz was applied for 2 hours. Stimulus
intensity was adjusted to get 75% maximum population spike amplitude. Stimulation
continued for 2 hours before electrically-induced SE was stopped and animals were monitored
for up to 3 hours for development of SSSE. During stimulation and the subsequent recording
period, the behaviour of awake freely moving rats was evaluated every 15 minutes. The
severity of seizures were classified according to the Racine scale (Table 2.2) and particular
behaviours such as blank gaze, chewing, focal clonus and wet dog shakes were noted down
(Racine, 1972). All animals included in analysis reached at least stage 4 seizure severity
during SSSE, which was considered induced if behavioural seizures or synchronous electrical
events persisted for half an hour or longer, after stimulation. Animals displaying no be-
havioural seizures during PPS were excluded from analysis. After 30 minutes SSSE, either
decanoic acid (400-600mg/kg, Sigma Aldrich) or a control vehicle DMSO (0.1ml) was
injected intraperitoneally. At the end of the experiment, diazepam administered intraperitoneally
(15mg/ kg) terminated seizure activity and 5ml 0.9% w/v NaCl subcutaneously (B. Braun,
Germany) was given to rehydrate animals.
Spike frequency and electroencephalography (EEG) power were analysed oﬄine using Spike
2 (CED Ltd.). EEG signals were band pass filtered in the gamma frequency range (20-70 Hz)
to reduce noise contamination from movement artefacts while maintaining the signal in the
frequency band associated with seizures in human and rat models (Lehmkuhle et al., 2009).
Spike rate, EEG power, and integrated gamma power were compared between treatment
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groups. EEG power was calculated as the ratio of root mean square (RMS) amplitude
during seizure or with treatment to baseline, which has been used before to quantify seizure
activity (Yang et al., 2003). Average waveforms of the unfiltered data were also compared
before and after treatment. Event detection threshold was set as 7* baseline noise.
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2.9 Statistics
Power calculations were performed online to determine sample size requirements, where
preliminary data was available (G*Power). Electrophysiological data contained cells from
at least 3 animals per experiment.
Non-parametric tests were only considered in experiments with n=6 or over (and n<15),
where the Shapiro-Wilk test for normality showed that at least one data set in the comparison
was not from a normal distribution (OriginPro). If normally distributed, the unpaired
Student’s t-test was used to compare two groups using different neurons/ slices/ animals,
whereas paired Student’s t-tests were used to compare the same group at different time
points (for example after drug application). If the data set was reused, then significance
level was Bonferroni corrected to account for multiple comparisons. When normality was
rejected, a Mann-Whitney rank-sum test was the non-parametric test for unpaired data,
whereas Wilcoxon signed-rank non-parametric test was used for paired datasets. Analysis of
variance (ANOVA) was used to compare >2 groups, with a Tukey HSD post-hoc comparison
of means to determine which specific groups differed from each other. A Dunnett’s test was
used to compare multiple treatments to a single control.
Data were presented as mean±SEM unless specified otherwise. The value, n, gives the
number of cells (single cell experiments), slices (extracellular recordings), or animals (in vivo
experiments) included. For all statistical tests, exact p-value was declared and significance
with respect to the control is indicated on the figures using the following symbols: *p <0.05,
**p <0.01, and ***p <0.001. All statistics were performed using SPSS (IBM, Portsmouth,
UK), Origin 9.0 (OriginPro 9; MA, USA), or Python (Python Software Foundation).
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AMPA receptor properties are
altered after in vitro SE
3.1 Summary
In this chapter I used in vitro models of prolonged seizure-like activity to determine changes
to the properties of AMPA receptors following seizures.
AMPA receptor-mediated currents exhibit more marked inward rectification at CA1 pyramidal
synapses following pilocarpine-induced seizures (Rajasekaran et al., 2012). Rectifying currents
are a feature of calcium-permeable (CP)-AMPA receptors, so this indicates that following
seizures there is a dynamic shift at these synapses from the normal expression of GluA2-
containing AMPA receptors to expression of the GluA2-lacking subtype. In addition to more
inwardly rectifying currents, CP-AMPA receptors have a higher single-channel conductance
and a greatly increased permeability to divalent cations (Ca2+ and Zn2+).
I aimed to reproduce these results in a slice model of seizures. Using whole-cell patch clamp
I measured functional changes at the synapse. Electrophysiological data showed evidence
for CP-AMPA receptor expression. This was supported by pharmacological analysis using
a specific CP-AMPA receptor blocker. Determination of single-channel conductance using
non-stationary fluctuation analysis, however, failed to support the insertion of higher conductance
receptors, possibly due to confounds of the method used in neurons in situ.
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Finally, I tested whether inhibiting only CP-AMPA receptors would be sufficient to block
epileptiform activity in a slice model of persistent seizure-like activity. 1-naphthyl acetyl
spermine (NASPM) had no effect on the frequency or amplitude of activity. This is probably
because a low proportion of AMPA receptors are calcium-permeable and this subtype are
also expressed at higher levels on seizure-controlling interneurons.
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3.2 Introduction
There has been renewed interest in the role of AMPA receptors in epilepsy in part due
to the recent approval of the AMPA receptor antagonist, perampanel, as an adjunctive
treatment. Our understanding of the mechanism of epilepsy includes a clear role for glu-
tamatergic activity cascading within networks of synaptically connected excitatory neurons.
There are contradictory findings regarding changes to AMPA receptors following seizures
when looking at hippocampal mRNA and protein expression. CA1 pyramidal neuron
synapses predominantly include GluA2-containing, CI-AMPA receptors in the healthy adult
hippocampus (Lu et al., 2009). However CP-AMPA receptors are present in the immature
brain (Rakhade et al., 2012; Talos et al., 2008), under certain pathological conditions, and
after plasticity-inducing stimuli (Plant et al., 2006). One particular study has used whole-
cell patch clamp and biotinylation to show that CP-AMPA receptors are present at CA1
pyramidal neuron synapses in slices from rats following pilocarpine-induced SE (Rajasekaran
et al., 2012). Live cell imaging of hippocampal cultures shows GluA2 internalisation after
0-Mg2+ induced epileptiform activity (Rajasekaran et al., 2012).
Considerable evidence has accumulated showing a down-regulation of GluA2 expression in
CA1 and CA3 of the hippocampus following kainate seizures (Friedman et al., 1994; Grooms
et al., 2000; Condorelli et al., 1994), hypoxia-induced seizures (Sanchez et al., 2001) and
lithium-pilocarpine status (Hu et al., 2012; Condorelli et al., 1994). This is not associated
with either up- nor down-regulation of total AMPA receptor expression, but is consistent
with increased CP-AMPA receptor expression. Down-regulation of GluA2 expression is
also associated with cell layer patterns of neurodegeneration. However, this may vary
according to the model used, the time window after seizures, or specific neuron types.
For example, Russo et al. (2013) found decreased overall AMPA expression after 3 hours of
lithium-pilocarpine seizures, but conversely found increased GluA2 protein. Seizures may
also induce a rapid increase in the phosphorylation of GluA1 and GluA2 (Rakhade et al.,
2012), or changes in RNA editing affecting the final AMPA receptor properties (Liu and
Zukin, 2007; Krestel et al., 2004).
Humans studies determined the subunit composition of AMPA receptors in tissue extracted
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during surgery for refractory epilepsy. Tissue from the neocortex has an increased GluA1 to
GluA2 subunit ratio in patients, mainly due to a massive increase in GluA1 (Loddenkemper
et al., 2014; Talos et al., 2008). In the hippocampus, there are reduced GluA2 levels in
hippocampal areas with the most pronounced cell loss, but increased GluA2 levels within
the dentate gyrus (Blumcke et al., 1996b).
The turnover rate of AMPA receptors is high, which allows a dynamic response to changes
in the network activity level and is important for synaptic plasticity. Receptors move into
and out of the synapse by lateral diffusion. Endocytosis and exocytosis of AMPA receptors
occurs at extrasynaptic sites by separate constitutive and regulated pathways (Anggono and
Huganir, 2012).
In this chapter I tested the following hypothesis:
 There is increased expression of CP-AMPA receptors in acute-hippocampal prolonged-
seizure models, as has been seen in cell culture models and ex vivo slices from chronically
epileptic animals
This will provide a basis for further investigation into the mechanism leading to a seizure-
induced shift in synaptic AMPA receptor subtype.
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3.3 Results
3.3.1 Theoretical relationship between proportion of CP-AMPA receptors
and rectification index
CP-AMPA receptors - either GluA2-lacking or those expressing GluA2 in the unedited
form - can be detected by their inwardly rectifying currents. They pass relatively small
currents at positive holding potentials compared to negative voltages. This rectification
is conferred by voltage-dependent block by endogenous or exogenous polyamines such as
spermine. Channels from GluA2-lacking AMPA receptors show faster kinetics and larger
single-channel conductance, and are uniquely sensitive to externally applied polyamine
toxins such as 1-naphthyl acetyl spermine (NASPM). A useful method to estimate the
contribution of CP-AMPA receptors to an EPSC is to measure the rectification index (see
Chapter 2). The rectification index is 1 when currents have a linear relationship with voltage.
It decreases towards zero when CP-AMPA receptors are contributing to the current, due to
the polyamine-mediated ion channel block. Some groups use 0.7 as the index value at which
CP-AMPA receptors begin to be detected (Wang and Gao, 2010), so I first compared the
contribution of CP-AMPA receptors required to reach this detection threshold.
For this, I used a CA1 pyramidal neuron model built in NEURON. At a single point
process, I expressed either CI- or CP-AMPA receptors (Fig. 3.1a). The CI-AMPA receptor
was modelled with a linear I-V relationship. The CP-AMPA receptor model was built in
NEURON by Mr Jonathan Cornford using parameters from a model kainate receptor with
100µM spermine in the pipette (Bowie et al., 1998). Fig. 3.1b shows theoretical I-V curves
with different proportions of CP- to CI-AMPA receptors present at the synapse. ∼40%
CP-AMPA receptor expression is required for the RI to reach 0.7, which is the threshold
often set for CP-AMPA receptor detection (Fig. 3.1c).
3.3.2 Comparison of epileptiform activity between in vitro models of
seizure activity
I optimised the protocol of inducing epileptiform activity in hippocampal slices. An in
vitro model in hippocampal slices was used as a compromise between simple hippocampal
culture models and highly physiological ex vivo slices which are time consuming to prepare.
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Figure 3.1: In silico models of the synapse show that CP-AMPA receptors must be present
in high proportion to be detected by rectification index
a) The expected linear I-V curve at a point process with no CP-AMPA receptors present,
and with a rectification index (RI) of 1 [top]. A strongly inwardly rectifying I-V curve when
all AMPA receptors are calcium permeable and RI is 0.1 [lower]. b) As the proportion of
CP-AMPA receptors included at the synapse increases, the amount of current rectification
increases. c) Comparing the proportion of CP-AMPA receptors contributing to the overall
current to the subsequent RI. Over 40% CP-AMPA receptors are required for RI to be below
0.7 and the mixed category given (dashed line marks 0.7 threshold).
83
Chapter 3. AMPA receptor properties are altered after in vitro SE
As I planned to probe the mechanism leading to insertion of CP-AMPA receptors, it was
important to use an appropriate model for their detection. In tissue from in vivo animal
models, there is a model-dependence as to whether the effect is seen.
In extracellular recordings made from the stratum radiatum, epileptiform activity could
be induced in both the 0-Mg2+ and 2 mM PTZ-aCSF slice models, in an interface chamber
(Fig. 3.2). This was developed and sustained at both room temperature and 34°C. Epileptiform
activity began sooner and was more pronounced after induction at 34°C, so this temperature
induction was used for all experiments. Activity was larger amplitude and contained more
ictal like bursts in 0-Mg2+ aCSF, but the pyramidal neurons were visually less healthy in this
model. When 5mM pyruvate was included in the incubation solution it improved neuron
health (Kovac et al., 2012) and did not alter network epileptiform activity. Recent findings
show that pyruvate acts as an antagonist to AMPA receptors at 60mM (Pedersen et al.,
2016), so this was not included in the solution during whole-cell patch clamp recordings.
After slicing, the slices recovered at room temperature for at least 40 minutes, before being
incubated in the activity generating solutions. Slices were incubated in the epileptogenic
solution for at least 60 minutes. At least one slice per animal was recorded from using an
extracellular electode, which confirmed that all slices produced epileptiform activity after 60
minutes of incubation. Under basal conditions roughly 15-25% surface AMPA receptors are
internalised every 30 minutes (Ehlers, 2000), although expression of CP-AMPA receptors
persisted for hours in a hippocampal culture model of ischemia (Blanco-Suarez and Hanley,
2014). Nonetheless, in my experiments I only included recordings in which whole-cell con-
figuration was achieved within 20 minutes of removal from the incubation medium (Fig. 3.3).
3.3.3 0-Mg2+ aCSF induces rectifying AMPA receptor-mediated currents
I looked for evidence of CP-AMPA receptor expression in slice models of epilepsy by
measuring the rectification index. Pyramidal neurons from the hippocampus CA1 were
voltage clamped at holding potentials between -80mV and +60mV, at 20mV intervals.
Neurons in the 0-Mg2+ treatment group had inwardly rectifying currents, and control
neurons had a linear I-V relationship, as reported previously and consistent with predominant
CI-AMPA receptor expression (Rozov et al., 2012; Mattison et al., 2014; Fig. 3.4a). The
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Figure 3.2: Representative extracellular recordings from stratum radiatum in CA1.
Epileptiform activity is present after 60 minutes incubation in 0-Mg2+ or PTZ-aCSF at
room temperature (RT), but is stronger and more sustained when generated at 34° C.
Figure 3.3: General experimental outline I employed, using in vitro slice models to
compare AMPA receptor-mediated EPSCs.
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rectification index was significantly lower in the 0-Mg2+ group than control (Fig. 3.4b-
c; [control]: 1.07 ± 0.24, n=7; [0-Mg2+]: 0.60 ± 0.14, n=11. p= 0.038; Mann-Whitney
U-test). In the 0-Mg2+ treated group, current reversal was shifted positively, although
lines were fitted as reversing through 0mV, as assumed based on theory. Cell health was
noticeably worse after incubation in 0-Mg2+ aCSF than control aCSF, and the addition of
pyruvate was required to improve recording quality (observation not shown). There were
no significant differences between treatments groups when comparing input resistance, cell
size or leak currents (Supplementary Table 8.1). The quality of voltage clamp of the cell
will depend on the health of cells patched, which could be a confounding factor. 0-Mg2+
treatment could reduce the clamp quality, but as there was no difference in input resistance,
measured at -60mV, between treatment groups this should not be a significant factor.
3.3.4 PTZ-aCSF induces rectifying AMPA receptor-mediated currents
I next looked for evidence of CP-AMPA receptor expression in the PTZ slice model of
seizures. Pyramidal neurons from the PTZ treatment group had inwardly rectifying currents,
compared to the expected linear I-V relationship measured in the control group (Fig. 3.5b-c;
[control]: 0.93 ± 0.16, n=10; [PTZ]: 0.57 ± 0.09, n=11. p = 0.029, unpaired t-test with
equal variance). AMPA receptor-mediated currents were sensitive to NBQX (Fig. 3.5a).
The RI in the PTZ model was similar to that in the 0-Mg2+ model.
Cell health was similar in the PTZ-aCSF treatment group to control, and cells could be
patched without including pyruvate in the incubation solution. There was no difference
in rectification index between cells incubated in pyruvate and those not in pyruvate (not
shown; [PTZ only]: 0.60 ± 0.13, n=8; [PTZ-pyruvate]: 0.58 ± 0.07, n=8. p=0.44, unpaired
t-test).
3.3.5 Pharmacological detection of CP-AMPA receptors using NASPM
The effect of epileptiform activity on rectification index was apparent in both in vitro slice
models of seizures. The cells were healthier in the PTZ model so I chose to continue using
this treatment to induce seizure-activity throughout.
Next, I pharmacologically inhibited CP-AMPA receptors using NASPM, a polyamine and
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Figure 3.4: AMPA receptor-mediated currents are inwardly rectifying in the 0-Mg2+ slice
model of seizures.
a) Example whole-cell voltage clamp recordings after incubation in control and 0-Mg2+
aCSF. b) Normalised I-V curve in each treatment group. Black solid line is an extrapolation
of a linear fit to the data in the control group at negative values. Purple dotted line is a
polynomial fit to the 0-Mg2+ group at positive holding potentials only. c) Summary of RI,
*p<0.05, Mann-Whitney U-test.
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Figure 3.5: AMPA receptor-mediated currents are inward rectifying in the PTZ slice
model of seizures.
a) Example whole-cell voltage clamp recordings in control and PTZ-aCSF the treatment
groups. Blocking AMPA receptors with NBQX (10µM) eliminated eEPSCs at -60mV.
b) Normalised I-V curve is linear in the control group, and rectified in the PTZ group.
Black solid line is a linear fit to the data in the control group, orange dotted line is fit to
the PTZ group at positive holding potentials only. c) Summary of RI, *p<0.05, t-test.
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specific CP-AMPA receptor blocker, to confirm the presence of CP-AMPA receptors at
CA1 pyramidal neuron synapses. Using more than one method for detection of CP-AMPA
receptor is important as there are secondary reasons which could cause the same results
on rectification index. For example, some CI-AMPA receptors have been shown to produce
rectified AMPA receptor currents and auxiliary subunit interactions can enhance the polyamine
block incurring inwardly rectifying currents. AMPA receptor-mediated currents at -60 mV
significantly reduced in amplitude in the PTZ treatment group upon wash in of 70µM
NASPM (Fig. 3.6a-b; n=11, currents reduced to 0.81 ± 0.06 [normalised]; p=0.05, paired
t-test), and not in control slices (n=4, to 0.97 ± 0.04 [normalised]; p=0.15, paired t-test).
This indicates that CP-AMPA receptors were present at the synapse, and were inhibited by
NASPM.
Surprisingly, there was run-down in some recordings so the current amplitude at +40 mV
was also reduced, and the RI decreased in the PTZ group after NASPM wash-in (Fig. 3.6c;
0.50 ± 0.09 to 0.39 ± 0.08; p=0.02, paired t-test), but did not in the control group
(0.61 ± 0.23 to 0.6 0± 0.20; p=0.31, paired t-test). The contradictory finding that current
amplitude decreased at positive potentials with the block of CP-AMPA receptors warrants
further investigation.
3.3.6 Variance analysis for estimation of conductance of synaptic AMPA
receptors
I next used analysis of variance to look for CP-AMPA receptors in the PTZ seizure model.
Non-stationary fluctuation analysis (NSFA) is a method used to look at synaptic currents
and to estimate the average number of channels open at the peak of the current (N),
to determine the average single-channel conductance of these channels (γ). CP-AMPA
receptors generally have a higher γ than GluA2-containing subtypes, although this can be
dramatically altered by the association with auxiliary subunits (Swanson et al., 1997; Shelley
et al., 2012).
The AMPA receptor-mediated current-variance relationship is parabolic, and fits to Equation 2.5
(see Chapter 2) where σ2 is the variance, I¯ is the mean current, and i is the weighted-mean
single-channel current. This shape can be explained as there is little variance at the peak
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Figure 3.6: Pharmacological inhibition of CP-AMPA receptors in CA1 pyramidal neurons.
a) Example AMPA receptor EPSCs before [black] and with NASPM [coloured] to inhibit
currents from CP-AMPA receptors. Top traces are control conditions, lower traces after
incubation in PTZ-aCSF. b) Peak current amplitude decreased with NASPM application
[normalised]. c) Rectification index also decreased with NASPM. *p<0.05, t-test.
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current response (as all channels are open) and at very end of the current decay (as few
channels remain open). Conversely, there is more variance during the current decay as the
number of channels open varies between cycles.
My data were collected using a large extracellular stimulation electrode activating hundreds
to thousands of fibres that synapse onto the patched pyramidal cell. The original method
of NSFA has to be adapted for multi-synaptic responses (Traynelis et al., 1993). This peak
scaling causes a loss of information about synaptic channel number (N) and peak open
probability of channels (Po). Multi-synaptic EPSCs have slower rise times and decays from
dendritic filtering. Further, there is increased noise from asynchronous neurotransmitter
release and overlap of different time constants of activation than mono-synaptic recordings.
Sometimes a double response was generated from the stimulation, these responses could not
be used for NSFA.
Single channel currents were not changed by the seizure model ([control]: 0.13 ± 0.05pA,
n=5, [PTZ]: 0.11 ± 0.07pA, n=5; p=0.80, unpaired t-test, Fig. 3.7b), and single-channel
conductance was 2.19 ± 0.09pS [control] vs 1.81 ± 0.01pS [PTZ], (Fig. 3.7b; p=0.36,
unpaired t-test). These values are low compared to dendritically recorded CA1 EPSCs,
and the PTZ group was expected to have a higher single-channel conductance (Smith et al.,
2000; Benke et al., 1998). Variance was low at the peak and tail of the current, and the
data points parabolic to fit Equation 2.5. However parabolas were skewed towards the peak
currents, which could indicate that channels continue to open for the first time after the
peak response. Another explanation is that kinetic properties of specific receptors can lead
to a skewed variance vs. mean current relationship (Hartveit and Veruki, 2006).
3.3.7 Blocking CP-AMPA receptors with NASPM is insufficient to inhibit
PTZ-induced epileptiform discharges
A simple way to monitor the excitability of a seizure network is to count the number of
epileptiform events (Fig. 3.8a). I recorded activity extracellularly in the stratum radiatum;
each event was composed of trains of spikes starting with a fast, large, negative spike and
followed by smaller amplitude spikes in a slower downward phase (Fig. 3.8b). The event
polarity depended on the cell layer the recording was taken from (Fig. 2.3).
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Figure 3.7: Estimation of single-channel conductance is lower in the seizure group than
control, using peak-scaled NSFA.
a) Variance vs. mean evoked EPSC amplitude in control (n=5) and PTZ (n=5) treated
groups. Variance and peak-scaled amplitude were averaged over treatment groups, shaded
area denotes SEM. Grey and black solid lines are linear fits to 50% points in control and
PTZ groups respectively. b) Single channel current (i) and single-channel conductance (γ)
are not significantly different between groups, at a holding voltage of -60mV. ns: p>0.05,
unpaired t-test.
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If CP-AMPA receptor expression is increased at pyramidal neuron synapses under pathological
conditions, then inhibiting these channels following seizures could have a functional impact.
A CP-AMPA receptor blocker attenuated calcium bursts in hippocampal cultures incubated
in 0-Mg2+ aCSF (Rajasekaran et al., 2012). Further, inhibiting CP-AMPA receptors protects
hippocampal neurons against ischemia-induced cell death in an animal model (Noh et al.,
2005). I recorded network activity in the slice model of seizures to test if CP-AMPA receptor
inhibitors block epileptiform activity. I counted the number of epileptiform discharges,
where each discharge contained poly-spikes (Fig. 3.8a-b). Specifically, blocking CP-AMPA
receptors did not change the frequency of epileptiform activity (Fig. 3.8c; Number of
epileptiform events per 5 minutes [normalised to baseline]: [control] = 1, [NASPM] =0.99±0.24,
n=4; p=0.244, paired t-test; [washout] = 1.12 ±0.24). Some slices showed ictal-like activity
followed by long silent periods, so the binned event count was highly variable.
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Figure 3.8: Inhibition of CP-AMPA receptors was not sufficient to inhibit epileptiform
activity in a slice model of seizures
a) Example extracellular recordings after 1 hour in PTZ-aCSF [top], after application of
a specific CP-AMPA receptor blocker [middle], and on wash out with PTZ-aCSF [lower].
b) Close up of trace in (a) [orange box] showing a single epileptiform event, notice the large
amplitude downward spike followed by smaller spikes phasically reducing. c) Normalised
number of epileptiform events at with a CP-AMPA receptors blocker and wash out.
[Control]= grey, average between -10 and 0 minutes, [NASPM] = orange, average between
25 and 35 minutes, [washout]= turquoise, average between 50 and 60 minutes.
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3.4 Discussion
This chapter replicates previous findings, using an acute slice model of prolonged seizure
activity, showing expression of CP-AMPA receptors after seizures. I showed rectification
of I-V curves in two in vitro models, which supports the presence of synaptic CP-AMPA
receptors. Pyramidal neurons incubated in either 0-Mg2+ or PTZ-aCSF have decreased
rectification indexes (Figs. 3.4- 3.5). There was a high variability in the rectification
index between neurons in each group, and many factors are likely to influence the level
of CP-AMPA receptor expression at the synapse. My theoretical calculations showed that
40% AMPA receptors may be required before the RI detects expression (Fig. 3.1). This
simple calculation may exaggerate the ratio as CP-AMPA receptors have a greater single-
channel conductance. If only over-active synapses express CP-AMPA receptors, then what
proportion of synapses on a CA1 pyramidal neuron would be affected by this change?
Further, there are CP-AMPA receptors which do not exhibit inward rectification (Bowie,
2012), and conversely some auxiliary subunits reduce the polyamine block of CP-AMPA
receptors while enhancing calcium permeability (Jackson et al., 2011; Coombs et al., 2012).
This lead to the requirement of multiple experiments to test the presence of these receptors.
AMPA receptors are highly dynamic at synapses, so it was important for the measurement
of CP-AMPA receptor presence to be within an appropriate time window after removal from
the incubating solution. All recordings for the I-V curves reached whole-cell configuration
within 20 minutes of removal from the activity induction solution (0-Mg2+ or PTZ-aCSF).
In Fig. 3.6, the specific CP-AMPA receptor blocker, NASPM, reduced AMPA receptor-
mediated currents at -60mV. It also reduced the RI, which does not fit with results that
should be obtained from the remaining CI-AMPA receptor currents. This may be from a
problem with the specificity of the NASPM used, or a charging effect from the application
of a high concentration of ionised polyamine to the recording solution affecting the driving
force of Na+ and K+ .
Next, the single-channel conductance was estimated by peak scaled NSFA. Single channel
conductance (γ) was not found to be significantly different in the PTZ treated group
compared to control, which did not match with the I-V results. The analysis of many EPSCs
was needed to account for variation in response shape from multi-synaptic activation. More
95
Chapter 3. AMPA receptor properties are altered after in vitro SE
precise estimates could be achieved by recording from single channels, although access the
CA1 synapses would not be possible with glass micro-pipettes. γ is altered by different mean
opening times, and the estimation of γ is also affected by access resistance (RA) so I ensured
there was a <10% change in RA throughout the recording (started 10.6MW and ended
11.9MW; with >60% RA compensation; Supplementary Table 8.1). The variance values were
dependent on bin size, so I kept this consistent throughout analysis. Further, the recordings
in Fig. 3.7 were made >40 minutes after removal from the induction solution; the ex-
perimental set-up was such that only the healthiest cells were kept to perform recordings for
NSFA after the I-V experiments. As synapses onto CA1 pyramidal neurons are susceptible
to stimulation-induced changes in synaptic strength, the stimulation frequency did not
exceed 0.1Hz and therefore the recordings took a long time to be completed. This selection
bias may have meant that those with the least CP-AMPA receptors were included in
NSFA experiments. These limitations did not allow reliable estimation of single-channel
conductance from currents recorded in rat CA1 pyramidal neurons. However, this shows
a proof of principle, although it may be that fewer recordings of I-V curves are necessary
before moving onto collecting the NSFA data. It would be beneficial to repeat the ex-
periments in cells immediately removed from PTZ-aCSF.
My results provide evidence for the expression of CP-AMPA receptors at CA1 pyramidal
cell synapses in a seizure model. GluA2-lacking AMPA receptors have markedly increased
permeability to divalent cations such as Ca2+ as well as greater single-channel conductance
and desensitisation rates. The increased single-channel conductance raises the risk of ex-
citotoxicity for the cell, which could be a mechanism to mark the cell for apoptosis. The
faster desensitisation rate reduces the time window for integration of synaptic inputs when
CP-AMPA receptors are prevalent (Abrahamsson et al., 2012). This may be a mechanism
to lower the probability for synaptic strengthening. Ca2+ entry into the cell is precisely
controlled. The timing and intensity of intracellular Ca2+ elevation controls the direction
of synaptic plasticity depending which intracellular proteins are activated: CaM kinase or
calcineurin. Calcium entry can trigger further Ca2+ release from intracellular stores by Ca2+
-induced Ca2+ release (CICR). Initiation of this cascade will have consequences further than
the activated synapse. Since calcium buffering is disrupted in epilepsy, CP-AMPA receptors
may promote the initiation of apoptosis. The level of calbindin-D28k, a neuronal calcium
binding protein, is halved in the hippocampus in a chronic in vivo model of epilepsy (Carter
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et al., 2008).
Due to the polyamine block around Vrev, the largest influx of Ca
2+ will occur when CP-
AMPA receptors are activated at potentials closest to RMP, or even hyperpolarised potentials.
Conversely, pyramidal neurons in epileptic tissue spike more frequently than pyramidal
neurons in normal tissue, so are at the depolarised potentials of the peak of action potentials
(around +40 mV; Sterratt et al., 2012) more often. Although they have a greater single-
channel conductance, activation of CP-AMPA receptors carries reduced current when de-
polarised compared to GluA2-containing AMPA receptors, so increased synaptic CP-AMPA
receptor expression may dampen the excitable network activity. Specific inhibition of CP-
AMPA receptors by NASPM did not alter the frequency of epileptiform discharges. There is
high expression of CP-AMPA receptors in interneurons in healthy tissue and epileptic tissue
has reduced inhibitory drive, so blocking AMPA receptors on interneurons may increase
epileptic network activity. It is unclear why my results contradict previous findings, but
CP-AMPA receptor blockers could be expected to improve neuronal death by reducing
apoptosis as a separate action to that on network activity.
These results do not shed light on whether CP-AMPA receptors are added to the existing
complement of surface AMPA receptors, or whether they replace CI-AMPA receptors that
are internalised via GluA2 endocytosis. Recent studies suggest that CP-AMPA receptors
do replace CI-AMPA receptors at hippocampal synapses, at least in cell culture models of
ischemia (Blanco-Suarez and Hanley, 2014). The mechanism for how CP-AMPA receptors
become expressed at the hippocampal CA1 synapses is also not understood. In the following
chapter, I look at some key pathways linked to the inclusion of CP-AMPA receptors at the
synapse and look at the effect of pharmacologically blocking these.
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4.1 Summary
In this chapter I investigated the mechanisms by which seizure-activity leads to increased
expression of CP-AMPA receptors. I initially looked at the requirement of Ca2+ entry
through the NMDA receptor for CP-AMPA receptor expression at CA1 pyramidal neuron
synapses. Many dynamically regulated processes in cells are dependent on changes in
calcium concentration and phosphorylation levels, as these signal a change in the network
activity levels. As predicted, inhibiting NMDA receptors blocked the synaptic expression of
CP-AMPA receptors in a slice model of seizures.
Then I looked at the requirement of a serine/threonine phosphatase and a tyrosine phosphatase
for surface expression of CP-AMPA receptors. Inhibition of the serine/threonine phosphatase,
calcineurin, but not the tyrosine phosphatase, STEP61, occluded the effect of seizure activity.
These results indicate that calcineurin activation via calcium entry through NMDA receptors
mediates the shift from CI- to CP-AMPA receptors.
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4.2 Introduction
The signalling pathway which leads to expression of CP-AMPA receptors at pyramidal
neurons following seizures is not understood but is important to understanding their role
in network changes and neuronal death following SE. The shift could be mediated by
any candidate molecules in overlapping pathways, by inhibiting exocytosis of CI-AMPA
receptors to the synapse or by promoting the production of AMPA receptors subunits with
enhanced calcium permeability.
NMDA receptors respond to changes in network excitation as activation allows local Ca2+
influx, which reads out the activity of the synapse. Therefore, during a seizure there would
be much greater Ca2+ influx through NMDA receptors. Ca2+ is buffered differently in
nanodomains and microdomains, so excessive Ca2+ entry will therefore initiate different
intracellular cascade proteins compared to physiological conditions, including activation of
kinases and phosphatases (Alford et al., 1993). AMPA receptor phosphorylation by kinases
can have a dramatic effect on surface expression on a fast time scale. This is ideal for dynamic
responses to stimuli such as in synaptic plasticity. Depending on the site, phosphorylation
can alter trafficking, stabilisation at the synapse and gating kinetics. Phosphorylation
regulates with which proteins the receptor can associate. Phosphatase activation can also
regulate AMPA receptor trafficking indirectly by altering the phosphorylation patterns of
mediator proteins which interact with AMPA receptors to regulate their trafficking.
Calcineurin (CaN), a Ca2+ /calmodulin-dependent protein phosphatase, is activated by
Ca2+ influx via NMDA receptors and is increased in the hippocampus following seizures
(Kurz 2001). CaN has been implicated in activity-dependent regulation of GABAergic
inhibition (Eckel et al., 2014) and AMPA receptors (Beattie et al., 2000). At the AMPA
receptor CaN dephosphorylates serine 845 on the GluA1 subunit, which reverses PKA-
induced increased channel open probability and internalises CP-AMPA receptors (Sanderson
et al., 2012). Conversely, phosphorylation at S845 by PKA may stabilise CP-AMPA receptors
at the perisynapse for activity-dependent trafficking (Derkach et al., 2007; Oh et al., 2006;
Banke et al., 2000). Therefore this provides a balance between GluA1 insertion by kinases
and removal by phosphatases in synapses.
99
Chapter 4. Investigation into the mechanism of expression of CP-AMPA receptors
Additionally, tyrosine phosphatases such as Striatal-enriched protein tyrosine phosphatase
61 (STEP61) are also activated by NMDA receptors (Paul et al., 2003). STEP61 specifically
dephosphorylates tyrosine sites on the GluA2 AMPA receptor subunit and on NMDA
receptor subunit GluN2B. GluA2 dephosphorylation at T869, T873, and T876 (3Tyr) causes
AMPA receptor internalisation (Hayashi and Huganir, 2004). Genetic ablation of STEP61
renders mice more resistant to pilocarpine-induced SE than WT (Briggs et al., 2011).
STEP61 is increased following prolonged activity in cultures incubated with GABAA receptor
inhibitor bicucculine. Further, acute induction of an electroconvulsive seizure increases
STEP61 and decreases tyrosine-phosphorylation in the hippocampus. However, chronic elec-
troconvulsive seizures has no effect on STEP61 levels (Jang et al., 2016). As STEP61 reduces
surface expression of AMPA receptors, STEP61 upregulation may cause internalisation of
extrasynaptic GluA2 to promote CP-AMPA receptor expression.
Altering the phosphorylation pattern on GluA2 subunits has a more complex effect than
GluA1 subunits. GluA2 is not present in most CP-AMPA receptors, so phosphorylation
will specifically affect CI-AMPA receptors. STEP61 dephosphorylates amino acids at GluA2
without acting at GluA1.
Finally, auxiliary protein interactions have a major role in AMPA receptor trafficking and
expression at synapses (Bats et al., 2013; Studniarczyk et al., 2013). They regulate AMPA
receptor kinetics and, in some cases, the drug sensitivity of the receptor C-terminal protein
interactions (Rouach et al., 2005). The most well categorised are TARPs; but more recently
other families of auxiliary subunits have been established including cornichons, CKAMP44,
GSG1L, synDIG1 (see section 1.3.2 for more information). Cornichons have a well defined
role in the export of specific proteins from the ER (Brockie et al., 2013). Genetic knockout of
γ2 or γ8 TARPs does not change which subtype reaches the synapse, but does influence the
number of receptors there. TARPs also contain 9 phosphorylation sites which can further
diversify the influence they have at AMPA receptors.
In this chapter I tested the following hypotheses:
 Expression of CP-AMPA receptors in pyramidal neurons following seizures is initiated
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by NMDA receptor-dependent activity
 Downstream from Ca2+ entry through NMDA receptors, the phosphorylation patterns
of AMPA receptors determines CP-AMPA receptor expression
 The phosphorylation patterns on AMPA receptor subunits can influence the amount
of CP-AMPA receptor expression.
I aimed to determine the mechanism of subunit switch using acute hippocampal slices
incubated in PTZ-aCSF. I included a specific blocker of the signalling molecule of interest in
the induction medium throughout the entire induction period (>1 hour), and looked at the
I-V relationship of isolated AMPA receptor-mediated currents in each condition to compare
the contribution of CP-AMPA receptors.
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4.3 Results
4.3.1 Inhibition of NMDA receptors blocks expression of CP-AMPA receptors
in a seizure model
NMDA receptors are one of the main mechanisms of Ca2+ entry into cells. They are known
as coincidence detectors as they require both a depolarised membrane potential, to remove
the extracellular Mg2+ block, and activation by glutamate before they pass current. Strong
neuronal depolarisations occur during epileptic activity, which can remove the Mg2+ block
and increase NMDA receptor-mediated currents (Coan and Collingridge, 1985). Calcium
entry through NMDA receptors is the initial step in intracellular signalling cascades having
many effects at the synapse, including receptor trafficking. The NMDA receptor is key for
a number of physiological processes, including different forms of plasticity.
NMDA receptor activity is not always necessary for burst generation. Spontaneous activity
can be generated in the presence of NMDA receptor antagonists in kainic acid, high potassium
or 4-AP models of epileptiform discharges (Neuman et al., 1988; Psarropoulou and Avoli,
1992). I first looked at the role of NMDA receptors in the PTZ slice model of seizures.
Fig. 4.1a shows that in the PTZ model, NMDA receptors are not required for the maintenance
nor the generation of epileptiform activity. The frequency of epileptiform discharges was
not altered after application of 50µM d-AP5 (Fig. 4.1b; [PTZ]: 32.9 ± 10.9 events/min,
[+d-AP5]: 27.4 ± 10.6 events/min; n=4, p=0.18, paired t-test). Further, the frequency
of epileptiform discharges was the same when initiated in PTZ-aCSF alone or in PTZ-
aCSF with 50µM d-AP5 (Fig. 4.1c; [PTZ]: 18.7 ± 1.8 events/min (n=50), [PTZ-d-AP5]:
19.4 ± 8.1 events/min (n=5); p=0.17, unpaired t-test). On the other hand, seizures alter
NMDA receptor properties and one of the effects is an up-regulation of the NR2B subunit
(Di Maio et al., 2011; Hardingham et al., 2002).
Activation of NMDA receptors is a trigger for receptor trafficking, as occurs in LTP and
LTD. The NMDA receptor antagonist d-AP5 completely blocks the endocytosis of AMPA
receptors in response to mild stimulation (Carroll et al., 1999). I found that after one hour
of incubation in d-AP5, AMPA receptor-mediated currents showed no inward rectification
in either the control aCSF nor the PTZ-aCSF group (Fig. 4.2a-b), indicating that d-AP5
blocked expression of CP-AMPA receptors. There was no difference in the RI between
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groups (Fig. 4.2c; 0.71 ± 0.02 [control, n=4] vs. 0.78 ± 0.13 [PTZ, n=7]; p=0.46, unpaired
t-test), indicating that d-AP5 blocks the seizure-induced change in rectification. This fits
with previous data showing that NMDA receptors are required to trigger some forms of
AMPA receptor trafficking.
Next, I looked at the pathway downstream of NMDA receptors. Ca2+ entry via NMDA
receptors regulates phosphorylation of AMPA receptors by kinases and phosphatases.
4.3.2 Inhibiting calcineurin reduces seizure-induced rectification of AMPA
receptor-mediated currents.
Calcineurin (protein phosphatase 2B; CaN) is a Ca2+ and calmodulin-dependent serine/threonine
protein phosphatase that is distributed widely throughout the brain and can regulate the
activity of several ligand-gated ion channels, including AMPA and GABAA receptors. CaN
works antagonistically with kinases in the cell by dephosphorylating proteins. CaN is
anchored to the synapse with PKA by AKAP150, and internalises AMPA receptors by
opposing phosphorylation of the GluA1 subunit by PKA at S825 (Beattie et al., 2000).
Dephosphorylation at S825 increases mobility from the synapse; FK506 is a CaN blocker
which strongly inhibits AMPA receptor endocytosis induced by either AMPA or NMDA
application (Beattie et al., 2000). Further if the interaction between AKAP150 and CaN
is disrupted then phosphorylation at GluA1 S825 is increased and AMPA receptors are in-
corporated both basally and during activity (Sanderson et al., 2012).
Basal and maximal activity of CaN is increased in SE in vitro, and is dependent on NMDA
receptor activation (Kurz et al., 2001). CaN becomes truncated 24 hours after SE, possibly
as it is activated irreversibly. Incubation with the AMPA receptor blocker GYKI-52466
(GYKI) for one hour also prevents seizure-induced increases in CaN activity after hypoxia-
induced seizures (Sanchez et al., 2005). CaN regulates changes in GABA receptor subunits
after seizures (Eckel et al., 2014). FK506 has been shown to have neuroprotective effects
in a hippocampal slice culture, after 24 hours in kainic acid (Lee et al., 2010). Similarly
FK506 has been shown to decrease the frequency of seizures, in a model of temporal lobe
epilepsy (Nishimura et al., 2006). However, it is likely to have confounding results in vitro
as it will act on both inhibitory and excitatory neurons.
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Figure 4.1: Epileptiform activity is both sustained and initiated in the presence of a
NMDA receptor antagonist.
a) Example extracellular recordings show that PTZ-induced epileptiform activity [left] is
sustained 30 minutes after application of d-AP5 [middle] and can be initiated after 1 hour
in PTZ-aCSF in the presence of d-AP5 [right]. b) Application of d-AP5 does not alter the
frequency of epileptiform discharges. c) Summary showing the frequency of epileptiform
discharges was not altered when activity is initiated in the presence of d-AP5. ns: p>0.05
(unpaired t-test).
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Figure 4.2: Inhibition of NMDA receptors blocks rectification of AMPA receptor-mediated
currents in a slice model of seizures
a) Example whole-cell voltage clamp recordings (+50 mV and -50 mV) from pyramidal
neurons incubated in d-AP5 with control [left] and PTZ-aCSF [right]. Example whole-cell
voltage clamp recordings in control and PTZ-aCSF the treatment groups. b) Normalised I-V
curve is linear in the control group, and in the PTZ group in the presence of NMDA receptor
inhibitors. Black solid line is a linear fit to the data in the control group. c) Summary of
RI and individual data values; ns: p>0.05, unpaired t-test.
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Blocking CaN enhances LTP, and conversely decreases the amplitude of LTD after low
frequency stimulation (Wang and Kelly, 1996). Inhibition of CaN by FK506 may increase
synaptic expression of CP-AMPA receptors by stabilising GluA1 phosphorylation, or it may
block the internalisation of CI-AMPA receptors and therefore block expression of CP-AMPA
receptors, so could prevent epilepsy-induced changes in AMPA receptor trafficking. CaN
also dephosphorylates dynamin, synaptojanin, and the adaptor protein AP180, which are
important in receptor endocytosis (Clayton et al., 2007).
Following one hour of incubation, FK506 did not inhibit epileptiform activity in PTZ-
aCSF, and did not induce activity in control-aCSF (Fig. 4.3a). Currents did not show much
inward rectification in either group (Fig. 4.3b-d), indicating there was little CP-AMPA
receptor expression. There was no difference in the RI between groups (Fig. 4.3d; [control]:
0.73 ± 0.05, n=9; [PTZ]: 0.67 ± 0.11; n=8; p=0.08, Mann-Whitney U-test), indicating that
FK506 blocks the seizure-induced change in rectification. As the RI is still lower than one,
its difficult to interpret CP-AMPA receptor expression with certainty.
4.3.3 Tyrosine phosphatase inhibition increases rectification in control
slices to match the seizure model
The other phosphorylation target I considered was STEP61, which works antagonistically
with kinases by non-specifically dephosphorylating tyrosine residues on GluA2 AMPA receptor
subunits and GluN2B NMDA receptor subunits, as well as other targets that are distinct
from those of CaN. There are two splice variants of STEP: STEP61 is an intrinsic membrane
protein, and STEP46 is cytosolic. STEP61 is highly expressed in striatal neurons, is expressed
in hippocampal neurons and is associated with the ER. Although the specific tyrosine
residues on GluA2 regulated by STEP61 are unknown, the GluA2 phosphorylation state
at 3Tyr all regulate AMPA receptor trafficking. Tyrosine phosphorylation of GluA2 at
T876 is by SRC family protein tyrosine kinases and is required for AMPA- and NMDA-
induced internalisation of AMPA receptors as in LTD. Inhibiting this kinase blocks inter-
nalisation (Ahmadian et al., 2004; Hayashi and Huganir, 2004; Fox et al., 2007). Tyrosine
phosphorylation of GluA2 regulates GluA2 binding to GRIP/ABP, but not to PICK1. This
binding is also regulated by Ser880 phosphorylation by PKC, which allows multiple methods
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Figure 4.3: Inhibition of serine/threonine protein phosphatase, calcineurin, blocks rec-
tification of AMPA receptor-mediated currents in a slice model of seizures
a) Example extracellular recordings show that activity was not present after 1 hour in
aCSF with CaN inhibited [left] and is sustained in PTZ-aCSF with calcineurin inhibited.
b) Example whole-cell voltage clamp recordings (+50 mV and -50 mV) from pyramidal
neurons incubated in FK506 with control [left] and PTZ-aCSF [right]. c) Normalised I-V
curve is linear in the control group and the PTZ group in the presence of a CaN inhibitor.
Black solid lines are a linear fit to the data in the control group and the PTZ group.
d) Summary of RI; ns: p>0.05, Mann-Whitney U-test
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of regulating GluA2 release from GRIP. GRIP controls release of AMPA receptors to make
them available for insertion into the synaptic membrane and for internalised receptors to be
captured (Braithwaite et al., 2002; Matsuda et al., 2000). The specific subunit combinations
of AMPA receptors regulated by this trafficking pathway has not been looked at.
STEP61 is locally translated in dendrites after mGluR5 activation and is linked to mGluR-
LTD (Zhang et al., 2008), whereas synaptic stimulation of NMDA receptors promotes
STEP61 ubiquitination and degradation after ERK1/2 activation (Xu et al., 2009). In
neuronal cultures with increased activity, there is increased STEP61 activity leading to
reduced phosphorylation of tyrosine residues on GluA2, without affecting their total protein
expression. Activity blockade by TTX reduced STEP61 activity and increased AMPA
receptor expression (Jang et al., 2015). Subunit specificity was not looked at in these ex-
periments. STEP61 is inactive when phosphorylated at Ser
221, and needs dephosphorylating
to be activated (Kamceva et al., 2016).
TC-2153 is STEP61 inhibitor which should leave tyrosine residues phosphorylated at GluA2.
I looked at whether this would increase the incorporation of CP-AMPA receptors into
synapses in the PTZ model. One hour of incubation with TC-2153 did not inhibit epileptiform
activity in PTZ-aCSF, and did not initiate activity in control-aCSF (Fig. 4.4a). Surprisingly,
currents showed inward rectification in both groups (Fig. 4.4b-c), indicating that there
was expression of CP-AMPA receptors in both groups. Unexpectedly there was greater
rectification in the control treatment group than in the PTZ group (Fig. 4.4d; [control]:
0.45 ± 0.03, n=8; [PTZ]: 0.64 ± 0.08, n=9; p=0.026, unpaired t-test). The reason for this
should be investigated further, as it is possible that TC-2153 promotes synaptic CP-AMPA
receptor expression in healthy pyramidal neurons.
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Figure 4.4: Inhibition of the tyrosine phosphatase, STEP61, does not alter rectification
after seizures and increases rectification in the non-seizure treatment group
a) Example extracellular recordings show that activity was not present after 1 hour in
aCSF with tyrosine phosphatase inhibited [left] and is sustained in PTZ-aCSF with tyrosine
phosphatase inhibited. b) Example whole-cell voltage clamp recordings from pyramidal
neurons incubated in TC-2153 (+50mV and -50mV) with control [left] and PTZ-aCSF
[right]. c) Normalised I-V curve is rectified in the control group, and less rectifying in the
PTZ group after incubation in a tyrosine phosphatase inhibitor. Black dotted line is a linear
fit extrapolated from data at negative holding potentials in the control group; black solid
line is fit to the control group at positive holding potentials, purple solid line is fit to the
PTZ group at positive holding potentials. d) Summary of RI. *p<0.05, unpaired t-test.
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4.4 Discussion
In this chapter I investigated the relationship between NMDA receptor activation, subunit
patterns of phosphorylation, and the expression of CP-AMPA receptors following seizure-
like activity. PTZ-induced epileptiform activity was not altered in the presence of NMDA
receptor blockers, but synaptic expression of CP-AMPA receptors was restricted by NMDA
receptor blockade. Further, the calcium-dependent serine/threonine protein phosphatase,
CaN, was also necessary for this expression. Conversely, the tyrosine phosphatase STEP61
limits expression of CP-AMPA receptors, possibly by its action at NMDA receptors. However,
this can not be confirmed by the experiments presented.
Activation of NMDA receptors causes activation of CaN as well as many other intracellular
mediators. Calcium-dependent CaN activation leads to dephosphorylation and activation
of STEP61 at Ser221 (Paul et al., 2003). Phosphatases interact with intracellular signalling
molecules as well as phosphorylating ion channels. The phosphorylation state of residues on
AMPA receptors drives internalisation and lateral movement, for removal from the synapse
(Fig. 4.5). Chen et al. (2013) showed that Ca2+ -induced activation of CaN by NMDA
receptors is required for CP-AMPA receptor expression after nerve injury in the spinal cord
(Chen et al., 2013), which matches my results. FK506 is a non-specific CaN inhibitor which
also acts as an immunosuppressent so it is possible, although very unlikely, that an off-target
action is blocking expression of CP-AMPA receptors.
I found that TC-2153 promoted expression of CP-AMPA receptors. As TC-2153 has actions
at both AMPA receptors and NMDA receptors, reducing STEP61 dephosphorylation of
GluN2B could enhance NMDA receptor activation to promote CP-AMPA receptor expression
(Lee, 2006). Stimulation of NMDA receptors invokes proteolysis of STEP61. Decreased
STEP61, as in the presence of TC-2153, increases phosphorylation of AMPA receptor GluA2
subunits and NMDA receptor subunit Glu2NB. Increased phosphorylation of GluN2B at
T1572 has been shown after febrile seizures (Chen et al., 2016). Phosphorylation of T1336
and T1472 on GluN2B by the Src kinase, Fyn, enhances NMDA receptor-mediated currents
and controls trafficking. T1472 phosphorylation enhances binding of GluN2B with PSD95,
retaining NMDA receptors on synaptic membranes, and increasing LTP (Salter and Kalia,
2004; Nakazawa et al., 2001). Genetic deletion of STEP61 improves cognitive function
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in a mouse model of Alzheimer’s disease, by restoring the number of AMPA receptors
and enhancing LTP (Xu et al., 2014). Alternatively, phosphorylation at T1336 results
in translocation of GluN2B-containing NMDA receptors from synaptic to extrasynaptic
membranes (Bi et al., 2000). STEP61 is degraded by BDNF, which is increased following
SE (Saavedra et al., 2015; Danzer et al., 2004), so this could explain why inhibiting STEP61
has a greater effect in the control group. STEP61 has a neuroprotective role by disrupting
the p38 MAPK pathway (Deb et al., 2013), so it makes sense that inhibiting it will increase
CP-AMPA receptor expression.
NMDA receptor antagonists do not alter epileptiform activity in slice models of seizure,
but they have been shown to improve cell health in vivo (Meldrum, 1993). The AMPA
receptor subunit switch detected after seizures might be induced by the deterioration in cell
health which is evident in slice models of epilepsy. Reducing the excitotoxic influence on
cells may slow the kinetics of intracellular pathways driving the subunit switch. If this is
the case, then there may be CP-AMPA receptor expression after a longer incubation period
than that looked at here.
There are different mechanisms regulating constitutive and activity-induced AMPA receptor.
The pathways I have looked at may target receptor movement after seizures but not alter
constitutive endocytosis. It would be interesting to track the movement of AMPA receptors
in a seizure model by live cell imaging to see which pathways are important for CP-AMPA
receptor movement into the synapse. Auxiliary subunits of AMPA receptors are involved
in receptor trafficking and subunit composition (Bats et al., 2013; Kato et al., 2007; McGee
et al., 2015). It would be interesting to see if the interaction between TARPs and AMPA
receptors is altered following seizures.
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Figure 4.5: Summary of the key findings in this chapter. There is a scale of CP-
AMPA receptor expression, which is increased after seizures. This is dependent of NMDA
receptor activation and calcineurin. Activation of STEP61 promotes expression of CI-AMPA
receptors.
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Chapter 5
The action of decanoic acid and
other MCTs at AMPA receptors
5.1 Summary
In this chapter I looked at the inhibition of AMPA receptors by medium chain triglycerides
(MCTs). Decanoic acid is a MCT and a key component of the MCT ketogenic diet.
It exhibits anti-seizure properties in vitro, and non-competitively blocks isolated AMPA
receptors in Xenopus oocytes and native AMPA receptors in the rodent brain (Chang et al.,
2016).
I first investigated the anti-seizure effect of decanoic acid in acute hippocampal slices. In
comparison to GYKI, another non-competitive AMPA receptor antagonist, decanoic acid
had equivalent anti-seizure properties. This was at concentrations with comparable AMPA
receptor antagonism, suggesting that AMPA receptor antagonism is sufficient to explain
the anti-seizure properties of decanoic acid. Branched chain derivatives of medium chain
triglycerides also inhibit epileptiform activity to a similar extent to decanoic acid, but may
have favourable pharmacokinetics in vivo.
I next looked in further detail at the action of decanoic acid at AMPA receptors. AMPA
receptor kinetics were not affected by decanoic acid. Perampanel and decanoic acid act syn-
ergistically at AMPA receptors to reduce epileptiform activity in a supra-linear way, even
at a sub-therapeutic concentration of perampanel. Finally, I showed that AMPA receptor
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block by decanoic acid was not use-dependent.
These data provide a more thorough understanding of how decanoic acid is acting at AMPA
receptors to have anti-seizure properties, and suggest that this compound could be suitable
as a treatment for epilepsy.
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5.2 Introduction
Research into new treatments for epilepsy is particularly necessary as 30% of epilepsy
patients have continued seizures despite treatment with current AEDs. Further, many
patients on AEDs become refractory to treatment and have unacceptable side-effects on
their present treatments. Alternative treatments such as neurosurgery and dietary in-
tervention are options in epilepsy refractory to pharmacological treatment. The ketogenic
diet is a successful method of seizure control, but compliance is low due to poor tolerability,
associated side effects and metabolic consequences (Cross et al., 2010).
Decanoic acid is a 10 carbon saturated MCT and, along with 8 carbon octanoic acid, is
a key component of the MCT ketogenic diet used clinically for the treatment of refractory
epilepsy. The MCT ketogenic diet is a modification of the high fat, low carbohydrate
classical ketogenic diet, which involves obtaining a high percentage of daily calorific intake
from coconut oil. This version is less strict than the classic diet, but similarly effective.
Decanoic acid crosses the blood-brain barrier and is increased in the brain plasma of those
on the ketogenic diet (Haidukewych et al., 1982). It has been shown that decanoic acid is
able to block PTZ-induced epileptiform activity more efficiently than octanoic acid in vitro
(Chang et al., 2012).
Recently, decanoic acid has been shown to block AMPA receptor-mediated currents in
Xenopus oocytes. In this study, decanoic acid was found to act non-competitively and
in both a voltage-dependent and a dose-dependent way (Chang et al., 2016). Different
AMPA receptor subunit compositions were tested, and decanoic acid was shown to be
effective in both GluA2/3 heteromers and GluA1 homomeric channels but with differing
potency at specific subunit combinations (Chang et al., 2016). Excitatory synapses are
important in the synchronisation of neurons at seizure initiation and the propagation of
seizures, and are therefore a promising target for anti-seizure therapies. In preclinical studies
non-competitive AMPA receptor antagonists, including GYKI, have looked effective however
many have frequent side effects in vivo affecting cognition and attention. Currently, the only
clinically approved drug for use in refractory epilepsy which acts at the AMPA receptor is
perampanel. This is a specific non-competitive AMPA receptor antagonist licensed for the
adjunctive treatment of partial onset and primary generalised tonic-clonic seizures with or
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without secondarily generalised seizures in people aged 12 years and older (Zwart et al., 2014;
Frampton, 2015). However there are still side effects seen after treatment with perampanel
which highlights the continuing need for novel compounds to be tested.
In this chapter I tested the following hypotheses:
 Decanoic acid’s action at AMPA receptors is sufficient to explain its anti-seizure effects
 Branched derivatives of medium chain fatty acids show anti-seizure properties in vitro
 Decanoic acid stops status epilepticus in vivo
 The combination of perampanel and decanoic acid has a synergistic anti-seizure effect.
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5.3 Results
5.3.1 The anti-seizure effect of decanoic acid can be explained by its
action at AMPA receptors
Decanoic acid was compared to another AMPA receptor antagonist using the PTZ seizure
model in hippocampal slices. GYKI is a benzodiazepine which acts as a non-competitive
AMPA receptor antagonist and binds to a different site to the proposed decanoic acid binding
site (Chang et al., 2016). It has a completely different structure to MCTs (Fig. 5.1a).
GYKI was used at 50µM, a concentration that gives the same degree of AMPA receptor
antagonism as 1mM decanoic acid. At lower concentrations, GYKI can potentiate AMPA
receptor-mediated currents (Arai, 2001), however 1mM decanoic acid and 50µM GYKI both
reduce all AMPA receptor-mediated current in hippocampal neurons by approximately 70%
(Chang et al., 2016; Donevan and Rogawski, 1993). PTZ-induced spontaneous bursting
activity was recorded from the stratum radiatum of rodent hippocampal CA1 extracellularly
(Fig. 5.1b). This epileptiform activity was completely blocked by 50µM GYKI (Fig. 5.1b-d;
from 83.1 ± 30.7 events per 5 minutes [baseline] to 0.6 ± 0.6 events [20 minutes in GYKI];
n=4, p=0.036, paired t-test), and returned upon washout. Epileptiform discharges were
also blocked by 1mM decanoic acid (Fig. 5.1b-d; from 73.3 ± 16.7 events per 5 minutes
[baseline] to 0 [20 minutes in decanoic acid]; n=5, p=0.006, paired t-test), and returned
upon washout. Activity returned to 58.1 ± 11.3% of baseline in GYKI washout, and 72.6
± 14.6% with decanoic acid washout (Fig. 5.1b-c).
5.3.2 Modification of epileptiform activity by derivatives of medium chain
triglycerides
Previous studies, which compared different MCTs, showed that 10-carbon decanoic acid has
greater anti-seizure effects in vitro than either longer or shorter straight-chained triglycerides
(Chang et al., 2013). Decanoic acid is present at clinically relevant concentrations in the
brain of those on the ketogenic diet (Haidukewych et al., 1982). Although a concentrated
form of decanoic acid has strong anti-seizure effects in vitro, it may have limited action in
vivo since MCTs accumulate in fatty tissue and undergo rapid metabolism before reaching
the brain. In this section I examined derivatives of medium chain fatty acids, including
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Figure 5.1: The effect of AMPA receptor antagonism on epileptiform activity: GYKI-
52466 compared to decanoic acid
a) The chemical structure of GYKI is completely different to decanoic acid. b) Example
extracellular recording from stratum radiatum of CA1 showing epileptiform activity induced
by application of PTZ, which is stopped upon treatment with AMPA receptor antagonists
[top], (#) expanded below. Example shown includes wash-in of decanoic acid. c) The effect
of the selective AMPA receptor antagonist GYKI-52466 [purple] or decanoic acid [orange]
on the frequency of epileptiform discharges. Bursts were binned into 5 minute intervals and
normalised to the baseline frequency (mean ± SEM). d) Absolute values from (c), showing
epileptiform discharge frequency. Baseline: average over three bins [-10 to 0 minutes];
treatment: average over three bins [30 to 40 minutes]. *p<0.05, **p<0.01, unpaired t-test.
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octanoic acid, which has no anti-epileptic properties itself (Chang et al., 2013).
To test whether modifications to straight-chain fatty acids were effective at increasing its
biological activity, derivatives were tested using the PTZ model in acute hippocampal slices
(Fig. 5.2a). There was a significant reduction in the frequency of PTZ-induced epileptiform
activity 30 minutes after administration of 4-methyl-nonanoic acid, (MNA: 0; p=4.1E-
8, n=5), 4-ethyl-octanoic acid (EOA: 0.06 ±0.05; p=5.1E-8, n=5), trans-4-butylcyclo-
hexane carboxylic acid (BCCA: 0.08 ±0.08; p=4.3E-8, n=5), 4-n-pentylphenyl-ethanoic
acid (PPEA: 0.02 ± 0.01; p=3.9E-8, n=6), and 2-(4-pentlycyclohexyl) ethanoic acid (2PEA:
0.003 ± 0.003; p=4.2E-8, n=5), when compared to DMSO (Fig. 5.2b-c; 0.89 ± 0.18; ANOVA
with Tukey post hoc test). Therefore, the addition of a methyl-branch, an ethyl-branch, a
hexane ring or a phenyl ring structure decreased PTZ-induced activity to a similar extent
as did the same concentration of decanoic acid did (Chang et al., 2015).
5.3.3 Decanoic acid can not block status epilepticus in vivo
Next I looked at the effect of acute administration of decanoic acid in an animal model of
status epilepticus (SE). Self-sustaining status epilepticus (SSSE) was induced by 2 hours of
perforant path stimulation (Fig. 5.3a). There was no difference in seizure severity monitored
behaviourally in animals treated with decanoic acid (ip; 400-600mg/kg, n=3) and DMSO
(volume matched to 0.1ml, n=1). Epileptic spikes tended to get smaller in amplitude,
and less frequent after decanoic acid administration (Fig. 5.3b-d). However, the number of
animals tested was not enough to detect significant differences. Gamma power increased
during SSSE, and was not changed in either vehicle control nor treated animals (Fig. 5.3c).
5.3.4 Decanoic acid has no effect on the kinetics of AMPA receptor
EPSCs
Decanoic acid is predicted to bind AMPA receptors at a novel site (Fig. 1.3; Chang et al.,
2016). As with all fatty acids, decanoic acid favours binding in the lipid bilayer membrane
and interacts with AMPA receptors from here. This suggests that as well as blocking the
ion channel, this compound could have other effects on AMPA receptor kinetics. I began
by measuring eEPSCs after decanoic acid application.
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Figure 5.2: Modified methyl-octanoic acid derivatives have anti-seizure properties in an
acute slice model of epileptiform activity
a) The structure of various fatty acids with modification on the forth or fifth carbon.
b) Summary of the change in frequency of PTZ-induced burst discharges in CA1, following
application of MNA, EOA, BCCA, PPEA, 2PEA; all at 1mM. c) Comparative histogram of
frequency of epileptiform discharges, taken 30 minutes after compound addition into PTZ-
aCSF and normalised to baseline. ***<0.005 compared to DMSO, ANOVA with Tukey
post hoc test for means comparison.
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Figure 5.3: Acute treatment with decanoic acid does not suppress electrically-induced SE.
a) Sample EEG traces recorded prior to, during, and 30 minutes after continuous PPS (2h)
in vivo. b) Sample EEG traces recorded before injection of 600mg/kg decanoic acid (ip),
and after 10 minutes, 30 minutes and 60 minutes. Traces are from the same animal and are
representative of experiments where animals develop SSSE. c) EEG power in the gamma
frequency band (20-70Hz) analysed in all animals that developed SSSE (n=1 control and
n=3 treated). d) Spike frequency in EEG recordings from SSSE animals after 600mg/kg
decanoic acid. Values are mean ± SEM.
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The amplitude of AMPA receptor-mediated currents was decreased upon 300µM decanoic
acid wash-in (to 0.76 ± 0.03 [normalised amplitude], n=5; p=0.0007; paired t-test), and the
single exponential decay constant (τ) was not changed (Fig. 5.4a-b; control: 8.6 ± 2.0ms,
decanoic acid: 9.7 ± 2.6ms; n=5, p=0.74, paired t-test). τ is affected by the duration of
receptor opening and level of desensitisation, so this indicates that decanoic acid does not
change these AMPA receptor kinetics at a concentration that decreases the amplitude of
AMPA receptor-mediated currents.
5.3.5 The action of decanoic acid at AMPA receptors was not use-dependent
Since the binding site on the AMPA receptors is likely to be near the pore region (Chang
et al., 2016), I tested whether the effects of decanoic acid are use-dependent. If decanoic
acid can bind only when the receptor is in its open state, then it will permit use-dependent
inhibition. In this case, only those receptors that are activated (such as during a seizure)
will be inhibited by decanoic acid.
To test this I recorded fEPSPs from two independent pathways (see Fig. 2.3). Stimulation
of one pathway was stopped during application of 300µM decanoic acid, while stimulation
of the other pathway was continued (Fig. 5.5a). After 30 minutes of drug application,
stimulation of the second pathway was switched back on and fEPSPs from both pathways
were compared. There was no difference in the magnitude of fEPSP suppression by decanoic
acid between the two pathways (Fig. 5.5a-b; n=5; P1:0.52 ± 0.11, P2:0.47 ± 0.14 [average
35-40 minutes]; p=0.23, unpaired t-test). Therefore, the effect of decanoic acid was not
use-dependent, similar to the clinically approved AMPA receptor antagonist, perampanel.
5.3.6 Perampanel and decanoic acid act synergistically to reduce epileptiform
discharges
In the clinical treatment of refractory epilepsy patients are commonly given multiple AEDs
at the same time, often targeting different receptors to increase the overall effect. I looked
at the combined action of perampanel and decanoic acid to see if they had a supra-linear
effect on epileptiform discharges when applied together, as has been described for other com-
binations of AEDs (Russmann et al., 2016). Perampanel is also a non-competitive AMPA
receptor antagonist with an IC50 of 60nM at hippocampal CA1 pyramidal neurons, but acts
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at a different binding site to decanoic acid (Barygin, 2016; Chang et al., 2016). If both
perampanel and decanoic acid preferentially bind to and stabilise the desensitised or closed
state, then it would be expected that they would act synergistically (each one potentiating
the action of the other) as the binding of one would promote the binding of the other.
Fitting a dose-response curve with the Hill equation allowed me to estimate the con-
centration of decanoic acid that reduced the frequency of epileptiform discharges by 50%,
in each group. Applied without perampanel, decanoic acid dose-dependently decreased
the frequency of epileptiform discharges (Fig. 5.6a-b; DMSO pre-treatment: 50% reduction
at 314.5 ± 65.7µM; orange; n=8). When decanoic acid was applied with perampanel the
effect on epileptiform discharges was enhanced, and 50% reduction was significantly different
between groups when two different perampanel concentrations were compared to DMSO
(F=4.27, p=0.028; one-way ANOVA).
Following application of a sub-effective concentration of 100nM perampanel ([baseline]
18.9±3.1 events/min to [100nM perampanel] 18.3±3.8 events/min), decanoic acid dose-
dependently reduced the frequency of epileptiform discharges, and this reduction non-
significantly tended to be at a higher rate than pre-treatment with DMSO alone (Fig. 5.6a-
b; 100nM perampanel: 50% reduction= 159.1 ± 30.1µM; purple; n=7; p=0.074, post-hoc
Dunnett’s test). Further, when decanoic acid was washed in after application of a high con-
centration of perampanel (500nM; [baseline] 25.7±6.5 events/min to [500nM perampanel]
20.4±6.8 events/min), it significantly decreased the frequency of epileptiform discharges at
a lower concentration (Fig. 5.6a-b; 500nM perampanel: 50% reduction =125.3 ± 41.7µM;
turquoise; n=8; p=0.023, post-hoc two-sided Dunnett’s test). Perampanel and decanoic acid
acted synergistically to reduce epileptiform discharges.
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5.4 Discussion
Decanoic acid, a key component of the MCT ketogenic diet, has recently been shown to have
acute anti-seizure properties, whilst ketones have no acute effect. In this chapter I looked
at the action of decanoic acid on eEPSCs, and how AMPA receptor antagonism reduces
epileptiform discharges in seizure models. I showed that the rate and extent of epileptiform
discharge inhibition by decanoic acid was similar to that of an AMPA receptor antagonist
with a different binding site. This means that the action of decanoic acid at AMPA receptors
could fully explain its anti-seizure effect.
I also showed that other MCT derivatives have a similar anti-seizure effect in vitro. These
results indicate that modifications to straight-chain molecules could be of interest when
looking for treatments with improved side effects and safety in vivo. The short chain fatty
acid valproic acid is a commonly used AED, but has been correlated with inhibition of
histone deacetylase activity, hepatotoxicity, and sedative properties (Chang et al., 2013;
Bojic et al., 1996). MCTs are promising candidates as different treatments for epilepsy
without those secondary effects. In EC-hippocampal slices the application of PTZ can
induce both ictal and interictal activity. This leads to high variability in spike frequency in
5 minute bins even over the baseline period. All the compounds tested, apart from 2PEA,
had some return of epileptiform discharges upon washout. The washout period showed
considerable variation in spontaneous activity, which in some cases exceeded baseline level
in amplitude and frequency, occasionally becoming ictal, suggesting a rebound effect as has
been described for some other AEDs (Marciani et al., 1985; Fig. 5.2a-b).
I looked at the action of decanoic acid in vivo in the PPS model and found it was unable
to block SE. This is likely due to its pharmacokinetics as decanoic acid has high first-
pass metabolism by the liver. In future experiments, chronic administration of decanoic
acid either through multiple injections or presented in food may increase the concentration
reaching the brain to have greater success at controlling seizures in chronic epilepsy in vivo.
Orally ingested medium chain fatty acids are expected to be rapidly taken up in the liver
(via the portal vein; St-Onge and Jones, 2002), and are quickly metabolised to produce
carbon dioxide, acetate and ketone bodies (Huttenlocher et al., 1971; via co-enzyme A in-
termediates through β-oxidation and the citric acid cycle). In contrast, 4-methyloctanoic
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acid is a branched chain derivative of octanoic acid which decreased spike frequency in the
PPS model and terminated SE in all animals (Chang et al., 2013). Although decanoic acid
does not seem to block SE in vivo, this may be because it does not reach the brain at an
appropriate concentration in acute experiments. It will be worth seeing if the metabolically
favourable compounds tested in vitro in section 5.3.2 are able to block SE. For example,
BCCA blocks epileptiform discharges in vitro and has a central hexane ring which will
reduce its metabolism in vivo compared to straight-chain compounds. It is important to
see if decanoic acid has any benefit to the health of the post-SE brain. NeuN staining
of paraformaldehyde (PFA)-fixed hippocampal slices from these animals could be used to
compare neuron numbers to see if decanoic acid has neuroprotective properties.
Decanoic acid binding to AMPA receptors had a significant effect on the amplitude of
eEPSCs but not on the shape. To measure the postsynaptic effects, isolated from presynaptic
effects, I could measure mEPSCs in Sr2+. If there was a difference here, I would be
interested in seeing whether there was an effect of decanoic acid on deactivation or de-
sensitisation of AMPA receptors. Further, binding of decanoic acid will be affected by
auxiliary AMPA receptor subunits, such as TARPs, as these regulate many AMPA receptor
properties (including trafficking). It is not known whether decanoic acid or other AMPA
receptor antagonists including perampanel interact with TARPs (Rogawski and Hanada,
2013). A novel AMPA receptor antagonist which is dependent on TARP γ-8 has just
been discovered which has anti-seizure efficacy against PTZ-induced convulsions in vivo
(Gardinier et al., 2016; Maher et al., 2016). Decanoic acid has a synergistic anti-seizure
effect with the clinically approved AED perampanel, via action through a different binding
site on the AMPA receptors. This may be clinically relevant as it would predict synergy
between perampanel and the MCT ketogenic diet. Further, it shows that decanoic acid may
boost the actions of current AEDs.
In epilepsy patients the MCT ketogenic diet has diverse positive effects on brain function
such as increased alertness, better cognitive functioning, and improved behaviour (Kinsman
et al., 1992; Pulsifer et al., 2001). Decanoic acid is one of the main constituents in coconut
oil so unlikely to have severe unwanted effects if given clinically. Supplements of decanoic
acid may benefit those who show poor compliance to the stringent regimen necessary for
the MCT ketogenic diet.
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Figure 5.4: Decanoic acid reduces the AMPA receptor-mediated current but has no effect
on eEPSC shape.
a) Example traces of evoked EPSCs before and after application of 300µM decanoic acid
[top]. Scaled responses demonstrate similar kinetics [below]. b) Peak AMPA receptor-
mediated current is decreased, but kinetics were not affected after application of decanoic
acid (n=5). ***p<0.005, ns: non-significant/p>0.05, paired t-test.
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Figure 5.5: Decanoic acid does not act at AMPA receptors in a use-dependent way
a) Example fEPSP responses from independent Schaffer collateral pathways during baseline
[left], with application of 300µM decanoic acid and only pathway 1 on [middle], and when
pathway 2 is reactivated [right]. b) The time course of normalised slopes of AMPA receptor-
mediated fEPSPs evoked by Schaffer collateral stimulation at 0.033Hz (recording electrode
was placed in CA1 st. radiatum). Pathway 1 [purple] is activated throughout. Pathway 2
[orange] is switched off and 300µM decanoic acid washed in at 12 minutes, n=5 slices.
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Figure 5.6: Decanoic acid and perampanel act synergistically to inhibit epileptiform
activity in an acute slice model of epileptiform activity
a) Time course of response to increasing concentrations of decanoic acid. Application of 1µl
DMSO (orange, n=8), 100nM perampanel (purple, n=7) or 500nm perampanel (turquoise,
n=8) at -12 minutes. Grey region is SEM, and top bar shows concentration of decanoic acid.
b) Dose-response curve with a Hill equation fit [left], and concentration of decanoic acid that
reduced the frequency of epileptiform discharges by 50%, in each treatment group [right;
colour represent groups as above]. Frequency of epileptiform discharges is normalised to
baseline in PTZ-aCSF with perampanel [-6 to 0 minutes]. Dashed line shows 0.5 frequency
epileptiform discharges [norm.] used to measure 50% reduction.
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Novel actions of decanoic acid on
neuronal excitability
6.1 Summary
Decanoic acid is one of the main constituents of the MCT ketogenic diet, which successfully
reduces seizures in some patients who do not respond to common AEDs. In the previous
chapter I looked at the anti-seizure action of decanoic acid at AMPA receptors. Previously,
it has been shown that decanoic acid does not affect inhibitory neurotransmission (Chang
et al., 2016). Here I asked whether it reduces the intrinsic excitability of neurons.
I found that decanoic acid increased the rheobase and reduced the number of action potentials
initiated in response to a current injection. This action was not dependent on PI3 kinase,
a previously determined target of medium chain fatty acids (Chang et al., 2014). In TTX,
the voltage response to current injections did not change upon decanoic acid application.
This led me to look in more detail at the action of decanoic acid at VG Na+ channels.
Decanoic acid did not reduce sodium channel-mediated transient currents in CA1 pyramidal
neurons, but did reduce the persistent sodium current, which produces subcellular os-
cillations. Finally I showed that the branched chain derivative, BCCA, reduced the intrinsic
excitability of CA1 pyramidal neurons, which is similar to decanoic acid. This dual action
of decanoic acid at post-synaptic AMPA receptors and presynaptic axons may increase its
anti-seizure potential.
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6.2 Introduction
The previous chapter focused on the anti-seizure effects of decanoic acid, and its specific
action at AMPA receptors. The MCT ketogenic diet is an effective treatment in many
patients who do not achieve seizure freedom from typical AEDs alone, such as the AMPA
receptor blocker perampanel. Here I have tested whether decanoic acid also affects other
neuronal functions.
Other common targets of AEDs are synaptic receptors and VG ion channels (see section 1.2).
Voltage-gated Na+ channels (VGSCs) are closed at resting membrane potential, and depolarise
the neuronal membrane when opened. They are responsible for the depolarising phase of
action potentials. The actions of phenytoin and carbamazepine are attributed to their
voltage- and frequency-dependent inhibition of VGSCs (Mantegazza et al., 2010). Several
hundred VGSC gene mutations lead to inherited epileptic syndromes, many with gain of
function, and hyper excitable effects. Therefore this ion channel is a good target to reduce
neuronal excitability.
Voltage-gated K+ channels (VGKCs) are responsible for the M-current which determines the
threshold and rate of neuronal firing, and which modulates the somatic response to dendritic
inputs. A selectivity filter in the channel blocks Na+ flow. During action potentials, the
delayed rectifier current (IK) is crucial for returning the depolarised cell to a resting state.
Retigabine is the only approved AED to act at K+ channels; This K+ channel opener acts
at KV7, a delayed rectifier responsible for the M-current in the cell soma and AIS.
In this chapter I tested the following hypothesis:
 Decanoic acid and other MCTs do not alter the level of neuronal intrinsic excitability
I started by determining how decanoic acid altered action potentials, the main output of
neurons.
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6.3 Results
6.3.1 Neuronal intrinsic excitability is reduced by decanoic acid
My initial motivation to look at the action of decanoic acid on intrinsic excitability was to
determine if the anti-seizure properties of decanoic acid were exclusively due to inhibiting
AMPA receptors. The intrinsic excitability of a neuron is defined as the relationship between
excitatory current input and action potential frequency output. To test the effect of decanoic
acid on intrinsic excitability, I recorded hippocampal neurons in the current-clamp mode in
the presence of synaptic blockers (50µM d-AP5, 50µM PTX, 10µM NBQX), and looked at
the effect of decanoic acid on action potentials elicited by step current injections. In this
way I eliminated presynaptic effects and the influence of other neurons on the target cell.
Decanoic acid significantly reduced neuronal output in response to progressive step current
injections (Fig. 6.1a-c; reduced in decanoic acid to 0.52 ± 0.17 [normalised area under
the curve]; n=8; p=0.0039, paired t-test). Decanoic acid has poor solubility in water, so
was prepared at a 2000x stock in DMSO. DMSO alone has been shown to reduce action
potentials at a concentration as low as 0.05% (Tamagnini et al., 2014). However, I found
no change in intrinsic excitability after washing in 1/2000 DMSO (in DMSO to 1.02 ± 0.14
[normalised area under the curve]; n=5; p=0.44, paired t-test). Further, decanoic acid
significantly reduced the number of action potentials in comparison to DMSO (comparing
areas under the curve: p=0.012, unpaired t-test). This effect was reversed when decanoic
acid was washed out.
Action potential kinetics can be studied by plotting the derivative of the membrane potential
against the membrane potential (Fig. 6.2a). Figure. 6.2b is a phase plot comparing action
potential kinetics after decanoic acid application. This allowed me to visualise where MCTs
alter action potential kinetics, to help to see which currents are affected by MCTs such
as decanoic acid and BCCA (Trombin et al., 2011). RMP was not changed following ap-
plication of DMSO (Supplementary Table 8.2; RMP [control]: -63.0 ± 3.2mV, [+DMSO]:
-63.0 ± 3.3mV; p=0.98, paired t-test) or decanoic acid (RMP [control]: -62.2 ± 2.0mV,
[+decanoic acid]: -63.4 ± 1.9 mV; p=0.66, paired t-test). There was also no statistically
significant difference when comparing RMP between treatments (p=0.89, unpaired t-test).
I found that voltage threshold (Vthreshold) did not change when decanoic acid was washed
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in (Fig. 6.2c-d: [control]: -46.6 ± 4.9 mV, [+decanoic acid]: -44.9 ± 3.6 mV, p=0.24
paired t-test; [washout]: -43.5 ± 3.7 mV). Further, repolarisation potential (Vrepolarisation)
was not affected by decanoic acid application ([control] -38.4 ± 1.8 mV, [+decanoic acid]
-37.7 ± 2.0 mV, p=0.24 paired t-test; [washout] -36.2 ± 3.2 mV). Finally, maximum voltage
(Vmax) was not affected by decanoic acid wash-in ([control] 32.6 ± 12.4 mV, [+decanoic
acid] 30.5 ± 12.3 mV, p=0.72 paired t-test; washout 38.4 ± 13.2 mV).
6.3.2 Branched derivatives of octanoic acid also reduce neuron intrinsic
excitability
Next, I looked at the effect of the branched MCT derivative, BCCA (see Fig. 5.2a), on
intrinsic excitability. Branched MCTs are as effective as decanoic acid at inhibiting epileptiform
activity in vitro and have increased bioavailability. This fatty acid derivative had a similar
effect on intrinsic excitability to decanoic acid. The number of action potentials significantly
reduced upon BCCA application (Fig. 6.3a-b; in BCCA: 0.29 ± 0.16 [normalised area
under the curve]; n=5, p=0.011, paired t-test) and returned during washout (0.88 ± 0.30
[normalised area under the curve]).
I used a phase plot to see if BCCA altered action potential kinetics. RMP was not
altered by BCCA (Fig. 6.3c-d; [control]: -63.0 ± 3.4mV, [+BCCA]: -62.8 ± 3.7mV, p=0.45
paired t-test; [washout]: -60.7 ± 4.6mV). Voltage threshold (Vthreshold) was significantly
increased in the presence of BCCA, ([control]: -44.0 ± 2.6mV, [+BCCA]: -39.7 ± 3.0mV,
p=0.014 paired t-test; [washout]: -40.7 ± 0.7mV). Further, the repolarisation potential
(Vrepolarisation) also tended to be increased after BCCA application, but this did not reach
statistical significance ([control] -26.3 ± 4.5mV, [+BCCA] -18.5 ± 5.5mV, p=0.054 paired
t-test; [washout] -19.5 ± 4.2mV). Finally, maximum voltage (Vmax) was not affected by
BCCA wash-in ([control] 29.0 ± 2.9mV, [+BCCA] 27.3 ± 1.6mV, p=0.37 paired t-test;
[washout] 33.6 ± 6.5mV).
6.3.3 Decanoic acid does require activation of PI3 kinase to reduce intrinsic
excitability
Valproic acid is a common AED and a short chain fatty acid. One of valproic acid’s
mechanisms of action is at phosphoinositide 3-kinase (PI3 kinase), to counter the seizure-
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Figure 6.1: Decanoic acid reduces neuronal intrinsic excitability
a) Application of 300µM decanoic acid decreases the number of action potentials at each
current step (lower), but the equivalent volume of DMSO alone has no effect (top). Lines
are fitted to the data as a spline function. b) Representative recordings of action potentials
(initiated by current injections at 25pA steps) at baseline, with treatment and during
washout. c) Area under the curve (AUC) was used to quantify changes in intrinsic ex-
citability with decanoic acid compared to DMSO control. *p<0.05, **p<0.01. All recordings
were performed in the presence of synaptic blockers.
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Figure 6.2: Phase plot showing that decanoic acid does not change the kinetics of action
potentials.
a) Comparing the rate of membrane potential change against membrane potential can
reveal differences in action potential kinetics. In recordings not containing action potentials,
the phase plot stays around resting membrane potential (RMP; turquiose). In an action
potential, phase plots reveal RMP (Vrest), action potential threshold (Vthreshold), peak
voltage (Vpeak) and repolarisation potential (Vrepolarisation). b) Corresponding points are
shown in a representative current trace in control conditions [purple] and upon application
of decanoic acid [orange]. Notice the delay to the initial action potential. c) Application
of decanoic acid reduces intrinsic excitability, but does not show gross changes in action
potential kinetics. d) Summary graphs show trend in increase in voltage threshold (not
significant) but no change in RMP or Vrepolarisation. n=6.
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Figure 6.3: BCCA reduces neuronal intrinsic excitability
a) Application of 300µM BCCA acid decreases the number of action potentials at each
current step. Lines are fitted to the data as a spline function. b) Area under the curve
(AUC) was used to quantify changes in intrinsic excitability with BCCA. c) Phase plot
shows no gross changes to action potential kinetics with application of BCCA. d) Threshold
of action potential initiation was significantly altered by BCCA, but RMP, maximum voltage
and repolarisation potential were not affected. *p<0.05. All recordings were performed in
the presence of synaptic blockers.
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induced decrease in phosphatidylinositol-3,4,5-trisphosphate (PIP3; Chang et al., 2014). PI3
kinase phosphorylates PIP2 to produce PIP3, which is important for many cell functions
including neurotransmission, receptor trafficking and membrane repair (Fig. 6.4a). PIP3
is also protective against oxidative stress, which is particularly relevant following seizures.
PI3 kinase regulates VG K+ , Na+ and Ca2+ channels outside of the brain (Ballou et al.,
2015). Further, PI3 kinase inhibition reduces the L-type calcium current (ICaL), the delayed
rectifier potassium currents (IKr), and the peak sodium current; whereas it increases the
persistent sodium current (INaP ; Lu et al., 2013). Seizure-induced depletion of PIP3 would
also interfere in homeostatic synaptic plasticity, which maintains basal synaptic activity
(Wang et al., 2012).
I next used the PI3 kinase inhibitor LY294002 (Vlahos et al., 1994), to determine whether
phosphorylation of PIP2 was required for the reduction in intrinsic excitability produced
by decanoic acid. LY294002 (20µM) included in the recording solution did not change the
effect of decanoic acid on neuronal input-output relationship (Fig. 6.4b-c; with decanoic
acid to 0.29 ± 0.13 [normalised area under the curve]; n=4; p=0.0055, paired t-test). As
above, DMSO in the presence of LY294002 had no effect on this parameter (with DMSO
to 0.91 ± 0.20 [normalised area under the curve]; n=4; p=0.35, paired t-test). There was a
significant difference between the number of action potentials when treated with decanoic
acid compared to DMSO, in the presence of a PI3 kinase inhibitor (area under the curve:
p=0.021, unpaired t-test).
When decanoic acid was compared in control aCSF and in aCSF with LY294022, there
was no statistically significant difference (normalised AUC: p=0.39, unpaired t-test).
6.3.4 Actions of decanoic acid on intrinsic excitability are TTX-sensitive
Next I blocked VGSCs with TTX to distinguish the role of decanoic acid on input resistance
and K+ channels. Neuronal VGSCs comprise one central α-subunit and two auxiliary β-
subunits that modulate α-subunit properties and are implicated in its subcellular targeting.
The α-subunit forms the ion-conducting pore and the channel gate for activation and in-
activation. It consists of four domains, each with six transmembrane segments. Pore loops
between S5 and S6 in each of the four domains form the selectivity filter of the channel,
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Figure 6.4: Decanoic acid continues to reduce intrinsic excitability of neurons with PI3
kinase blocked
a) Schematic diagram showing the role of PI3 kinase in PIP3 production, which has multiple
downstream effects. b) In the presence of LY294002, application of 300µM decanoic acid
decreases the number of action potentials at each current step [right], but the equivalent
volume of DMSO has no effect alone [left]. Lines are fitted to the data as a spline function.
c) Area under the curve (AUC) was used to quantify changes in intrinsic excitability with
treatment by decanoic acid compared to control. *p<0.05, **p<0.01. All recordings were
performed in the presence of synaptic blockers and 20µM LY294002.
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and the four S6 segments form the cytoplasmic end of the pore, which binds various types
of therapeutically important pore-blocking compounds including local anaesthetics, anti-
arrhythmic drugs and AEDs (Mantegazza et al., 2010).
TTX (1µM) was included in the recording solution to block VGSCs and, thus, prevent
action potentials firing. Larger current steps than in the previous experiments (120 pA)
were used here to maximise potential voltage differences in my whole-cell recordings. Small
negative current injections (-40 pA) revealed no difference in neuronal input resistance
upon application of decanoic acid (Fig. 6.5a-c; [baseline]: 123.1 ± 24.2 MW, [decanoic
acid]: 134.6 ± 28.7 MW; n=6, p=0.22, paired t-test; [washout]: 133.5 ± 33.6 MW), or
DMSO ([baseline]: 91.6 ± 9.9 MW, [DMSO]: 92.9 ± 15.2 MW; n=5, p=0.42, paired t-test;
[washout]: 99.6 ± 15.2 MW). Large positive current steps did not reveal any decanoic acid, or
DMSO-induced changes in input resistance either (Fig. 6.5a-c; [baseline]: 112.1 ± 31.6 MW,
[DMSO]: 110.4 ± 29.6 MW; p=0.35, paired t-test; [washout]: 136.0 ± 34.0 MW; [baseline]:
130.7 ± 35.6 MW, [decanoic acid]: 121.4 ± 30.8 MW; p=0.25, paired t-test; [washout]:
118.1 ± 42.6 MW).
These results and those from the phase plot shown above lead me to investigate the action
of decanoic acid at VGSC currents in more detail.
138
Chapter 6. Novel actions of decanoic acid on neuronal excitability
Figure 6.5: Decanoic acid does not affect neuronal input resistance
a) Application of 300µM decanoic acid in the presence of TTX does not alter the voltage
response at each current step [lower], and nor does the equivalent volume of DMSO
[upper]. Lines are fitted to the data as a spline function. b) Representative recordings of
voltage responses to 120pA current steps in baseline, with treatment and during washout.
Grey shaded box in top right trace is representative of the window used for calculation
of resistance. c) Input resistance was determined from the voltage response to current
injections. This was not altered by application of DMSO [left] or decanoic acid [right] after
injection of -40pA [top] or +720pA current [lower]. All recordings were performed in the
presence of synaptic blockers, and TTX.
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6.3.5 Decanoic acid did not change the transient sodium current
VGSCs produce multiple currents, as controlled by different gating modes. The transient
Na+ current (INaT) is a large, rapid activating and fast inactivating current which is TTX-
sensitive and is initiated when the membrane voltage is depolarised above threshold (typically
near -55mV to -50mV; Carter et al., 2012). All known sodium channel α-subunits produce
transient currents, INaT is present in all neurons and is necessary for action potential
generation.
I looked at INaT at a range of voltage steps between -60mV and +20mV (Fig. 6.6a). A
plot of current density against step potential showed no difference in INaT upon decanoic
acid application (Fig. 6.6b; peak current density in [control]: -156.6 ± 76.4 pA/pF, and in
[300µM decanoic acid]: -141.4 ± 43.2 pA/pF; n=5, p=0.59, paired t-test).
I converted the current trace to conductance using Ohm’s law (eq. 2.2), to see if decanoic
acid affected conductance without the influence of driving force. I plotted conductance
against membrane potential and fitted the relationship with a Boltzmann distribution
(eq. 2.4; Fig. 6.6c). Decanoic acid did not change peak conductance (Gmax), voltage at
which sodium current was half maximal (V50), nor the slope factor (k; Table 6.1). The
values of Gmax I measured fit with published values for CA1 pyramidal neurons (e.g. Royeck
et al., 2008).
6.3.6 Decanoic acid reduced the persistent sodium current
Finally, I looked at the effect of decanoic acid on the persistent sodium current (INaP)
which regulates the low threshold of activation and reduces inactivation during sustained
membrane depolarisations (Crill, 1996). The persistent sodium current is much smaller than
INaT, is dependent on the auxiliary β-subunit, and is present in NaV1.2 and NaV1.6 subtypes
(the most numerous type in hippocampal pyramidal neurons; Chatelier et al., 2010). INaP is
particularly important in subthreshold oscillations, spontaneous firing and burst generation
as it is recruited in response to small membrane depolarisations (Magistretti and Alonso,
2002). Therefore, an increase of only a few percent can dramatically alter cell firing and
facilitate hyper-excitability, as in seizure behaviour (Stafstrom, 2007).
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Figure 6.6: Decanoic acid does not change the transient sodium current.
a) Voltage protocol [top] evoked INaT lasting ∼1ms in control aCSF [black] and with decanoic
acid application [orange]. Traces are TTX-subtracted. b) Current density plotted against
step voltage showed no difference in amplitude of INaT after application of decanoic acid.
c) Conductance-voltage relationships were fitted with a Boltzmann function (eq. 2.4) and
showed no difference with decanoic acid application.
Control aCSF +Decanoic acid *p-value
Gmax \ 72.3 ± 3.3 71.8 ± 6.0 0.94
V50 \mV -27.3 ± 2.5 -26.0 ± 3.4 0.77
k 6.4 ± 1.7 9.0 ± 2.9 0.44
Table 6.1: Application of decanoic acid does not alter GNaT kinetics. Decanoic acid did not
change peak conductance (Gmax), half maximal sodium current (V50), nor the slope factor
(k). Values taken from fitting GNaT (eq. 2.2) values to a Boltzmann function (eq. 2.4).
*paired t-test; n=5.
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I patched CA1 hippocampal pyramidal neurons in voltage clamp mode and evoked the INaP
current with a slow voltage ramp from -80mV to 20mV, at a speed of 2mV/s. Recordings
were filtered at 4kHz and acquired at 10kHz as high frequency components were not relevant
to the measured response. The recording solution contained synaptic blockers (50µM d-AP5,
50µM PTX, 10µM NBQX), CdCl2 (VG-Ca
2+ channel blocker) and the internal solution
contained Cs-MSF (to block leak K+ currents). Current traces obtained in TTX were
subtracted to isolate INaP currents. The INaP was present from around -60mV to 0mV; the
current peaked at around -40mV, and reached -183.1 ± 43.8 pA in control aCSF. Upon
application of 300 µM decanoic acid, the peak current amplitude significantly decreased to
-115.7 ± 21.7 pA (maximum negative current minus baseline [grey dashed line]; Fig. 6.7a-b;
n=5, p=0.031, paired t-test). Decanoic acid application decreased currents by 32.7 ± 7.4%.
I next converted I-V traces to a conductance-voltage trace (Fig. 6.7c). Application of
decanoic acid significantly reduced peak conductance (maximum conductance minus baseline
[grey dashed line]; control: 1.9 ± 0.4nS; decanoic acid: 1.2 ± 0.2nS; n=5, p=0.021, paired
t-test).
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Figure 6.7: Decanoic acid reduces the persistent sodium current
a) INaP was evoked by a slow voltage ramp [top]. Current traces obtained in control aCSF
[black], with decanoic acid [orange] and in TTX [grey]. b) Traces recorded in TTX were
subtracted from those in control aCSF and in the presence of decanoic acid. [left] Example
recording showing that INaP is reduced by application of 300µM decanoic acid. [right] Peak
INaP amplitude was reduced by decanoic acid. c) Conductance-voltage trace shows peak
conductance is reduced by decanoic acid. n=5, *p<0.05.
143
Chapter 6. Novel actions of decanoic acid on neuronal excitability
6.4 Discussion
In this chapter I looked at novel actions of decanoic acid and other medium chain fatty
acids on neurons. I found that decanoic acid reduces the intrinsic excitability of neurons
by actions at VGSCs. In the previous chapter, I focused on the action of decanoic acid
as a non-competitive AMPA receptor antagonist. Decanoic acid and other MCTs are also
known to increase mitochondrial citrate synthase and complex I activity, and to act as an
peroxisome proliferator activator receptor-γ (PPAR-γ) agonist (Hughes et al., 2014). None
of these actions would be expected to directly alter neuron intrinsic excitability.
When a square pulse of positive current is directly injected into a neuron it depolarises
the membrane. If this depolarisation is sufficient to bring the membrane to Vthreshold, then
an action potential is initiated by the coordinated opening of VGSCs, followed by VGKCs.
Upon application of decanoic acid or BCCA the same injection of current initiates fewer
action potentials by increasing the rheobase and possibly increasing the voltage threshold.
As these experiments were performed in the presence of synaptic blockers, this effect is
distinct from the inhibition of AMPA receptors by decanoic acid. I used a phase plot to
compare action potential kinetics in control aCSF and following application of BCCA. Phase
plots require a high sampling frequency (at least 50kHz) for accurate comparison, so I could
not interpret experiments with decanoic acid wash in as the sample rate was 20kHz. Further,
phase plots are only useful in recordings which do not have a complete block of spikes upon
BCCA wash-in, which may reduce the measured effect size.
In the presence of the VGSC blocker, TTX, application of decanoic acid has no effect
on neuronal responses to current injections. As action potentials are blocked in TTX, I
could not rule out the possibility that decanoic acid’s effect was masked in TTX. Therefore
I looked in further detail at the effect of decanoic acid on multiple currents produced by
VGSCs. Decanoic acid did not alter INaT in CA1 pyramidal neurons, but did reduce the
amplitude of INaP. The persistent current may provide a small but accelerated depolarising
voltage ramp capable of triggering more efficient opening of other sodium channels.
To minimise the contribution of space-clamp errors to recordings of sodium channel currents,
recordings with obvious space-clamp problems (such as increased delay to onset of an inward
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current or insufficiently blocked K+ currents) were not included in this study. A caesium-
based internal solution improved the voltage clamp and methylsulphonate was used, as
in previous experiments, which is more physiological than commonly used fluoride (Carter
et al., 2012). The input resistance generally decreased with the duration of the recordings, so
the TTX subtraction did not always remove all leak currents; but the persistent current could
always be identified in control aCSF recordings. A very slow (2mV/s) voltage ramp protocol
was used, which produces smaller INaP but was required for reducing escape transient sodium
currents.
Sodium channels vary between three states: closed, open (activated), and inactivated. INaT
has rapid kinetics, reaching its peak in less than one millisecond and declining back to
baseline within a few more milliseconds. This current has an all-or-none threshold behaviour
which makes it suited for action potential initiation. Conversely, INaP is localised on neuronal
dendrites, where it boosts distal synaptic potentials to allow them to reach the soma. It is
also present on the proximal axon, for spike initiation, and peripheral axons. The persistent
current is important in subthreshold membrane oscillations which control spike patterning.
Although the amplitude of persistent currents is typically <1% INaT (and around 3-4% in
my recordings), it is activated 10mV negative to transient currents. Few VG channels are
active here and input resistance is high so a change in voltage spreads further, which allows
postsynaptic potentials in dendrites to get boosted toward threshold for action potential
generation (Crill, 1996). Further, the voltage range in which INaP is activated is traversed
in the interspike interval in an action potential train, so INaP can facilitate repetitive firing.
Increased INaP has been implicated both in acquired (Agrawal et al., 2003; Vreugdenhil
et al., 2004) and possibly in genetically determined epilepsy(Stafstrom, 2007), at a time
point coinciding with the onset of spontaneous recurrent seizures. Several current AEDs
have been found to reduce INaP at clinically appropriate doses, including phenytoin, valproic
acid, topiramate, losigamone, lamotrigine, riluzole, and propofol (Colombo et al., 2013).
VGSC blockers that selectively target INaP could be effective at limiting pathological ex-
citability and neurodegeneration. Decanoic acid shows dual action to reduce the excitability
of neurons in epilepsy. This may explain the benefit of following a ketogenic diet in
pharmaco-resistant epilepsy patients. The two decanoic acid targets may have a synergistic
effect when targeted together. Decanoic acid is an attractive candidate molecule for the
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treatments of epilepsy as it is naturally occurring in food, so these findings can easily be
taken forwards to clinical trials. Finally, the effect of decanoic acid on intrinsic excitability
was equivalent with BCCA treatment. I showed that BCCA inhibits epileptiform discharges
in the previous chapter, and BCCA is also an AMPA receptor antagonist (K. Augustin, un-
published). In Xenopus oocytes, BCCA strongly inhibits GluA2/3 AMPA receptors (IC50:
0.63 ± 0.03mM; n=13) and also inhibits GluA1/2 receptors (IC50: 1.13 ± 0.04mM; n=6).
This supports the use of metabolically favourable MCT derivatives for development as
clinical treatments for seizure control.
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Comparison of experiments in
rodent and human cortical tissue
7.1 Summary
In this chapter I used human brain slices obtained from resective epilepsy surgery to compare
to data presented in previous chapters from rat hippocampal slices. In this physiologically
relevant model I looked at the action of medium chain triglyceride’s on network and single
neuron function. I also examined the properties of AMPA receptors present at the synapse.
Network epileptiform activity was initiated by high potassium with GABAergic inhibition,
and decanoic acid was able to reduce the frequency of epileptiform discharges. Decanoic
acid blocked AMPA receptor-mediated currents in human cortical neurons, as it does in rat
pyramidal neurons. Surprisingly, decanoic acid had no effect on the intrinsic excitability in
human cortical neurons at a concentration which has a significant effect in rat neurons.
The I-V relationship of AMPA receptors in cortical neurons from human surgically resected
tissue was also investigated. These neurons were heterogeneous in their morphology and
in their pathological background. Evoked EPSCs had a linear I-V relationship and were
not sensitive to NASPM. This suggests that the synapses contained only, or mainly, GluA2-
containing AMPA receptors. This chapter provides a platform for the use of resected human
tissue to be used for studies into network changes in epilepsy and the investigation into novel
AEDs.
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7.2 Introduction
The opportunity to compare rat with human neurons provides an important translational
step in the treatment of chronic and pharmacoresistant epilepsy. Slices are prepared from
surgically resected tissue and are viable for up to 36 hours in aCSF (Jones et al., 2016).
The data are obtained from multiple brain regions with heterogeneous medical backgrounds
and the tissue is from apparently normal brain, adjacent to epileptogenic cortex.
Both astrocytes and pyramidal neurons in the human temporal cortex are 2-3 times larger
than those in rodents due to larger dendritic arborisation, and there are at least twice the
number of synapses per pyramidal neuron in humans as there are in mice. There are neuron
classes in human which are not seen in rodents, as well as more diversity in interneuronal
classes. A recent study compared morphologies of human neurons to mouse and macaque
neurons (Mohan et al., 2015). They found the total dendritic length and number of branch
points were higher in human neurons and that there were distinct differences in dendrite
morphologies. Further, processes are much more complex which hints toward differences in
information processing in human neurons (Oberheim et al., 2009).
Neocortical tissue samples were collected from the National Hospital for Neurology and Neu-
rosurgery in ice cold sucrose solution. Different collection solutions were tested including ice
cold aCSF and choline-based aCSF, but sucrose-based aCSF was chosen as it produced con-
sistently high quality slices and matched the protocol used for producing rat slices. The time
from tissue resection to the slicer was < 15 minutes once the protocol and communication
was established. There was delay in the initial preparation of the sample for slicing due to
the additional step of removing the meninges and choosing a slicing angle from the unique
samples. Once the tissue was positioned in the slicing chamber, the same slicing protocol
was followed as for rat slices. The tissue samples obtained were ∼ 1.5cm3 and the slices
produced were larger than horizontal EC-hippocampus rat slices. The benefit of this size
slice is that larger intact networks could help initiate epileptiform activity. The size of slice
made was limited by the size of the recording chamber on the rig, and slices had to be cut
to fit sometimes. (See ”Methods” for more details).
Slices from surgically resected human tissue can remain healthy at least 10-14 hours (Dossi
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et al., 2014). The tissue can be used for multi-electrode recordings, preparation of organotypic
cultures and calcium imaging, as well as extracellular and patch clamp recordings. Op-
portunities to collect human cortex samples were intermittent and infrequent, so the number
of recordings was not enough to draw conclusions about correlations between recordings
based on patient information (see Table 7.1). Individual differences in the age of the
patient, duration of seizures and medication history will increase the variability between
slices. Further, genetic variability is much greater between humans than between laboratory
animals.
A table showing details of single neuron properties has been included in the appendix of
this thesis (Supplementary Table 8.3).
In this chapter I tested the following hypotheses:
 Cortical tissue obtained from resective epilepsy surgery produces slices generates
epileptiform discharges when the network is artificially pushed
 The pharmacology of decanoic acid at human neocortical neurons is similar to that in
rodent hippocampal neurons
 Pyramidal neurons distant from the epileptic foci do not contain CP-AMPA receptors,
but those in the epileptic foci do
149
C
h
a
p
ter
7
.
C
om
p
ariso
n
o
f
ex
p
erim
en
ts
in
ro
d
en
t
an
d
h
u
m
an
cortical
tissu
e
Surgical area Gender Age Onset Seizure frequency Pathology AED
Frontal l. M NA 8yr 1.5/ month cortical scar, prev. intracranial haemorrhage GPN, LAC, CBZ, PHT, CLB
Temporal l. F NA 7yr 28/ week SE (2 times), Type I/II + HS CBZ, ZNS, CLB
Temporal l. M 48yr 31yr 1/month -assc. music non specific neuron loss LTG, PER
Temporal l. F 49yr 16yr 2-7/ day Pleomorphic Xanthoastrocytoma (tumour) LAC, LVT
Temporal l. M 30yr 15yr 10/day Type II HC LTG, LVT
Temporal l. M 25yr NA NA NA NA
Frontal l. M NA 13yr 12.5/ month SE and NAD CBZ, PHT, ZNS
Table 7.1: Patient details of tissue included in this thesis. NA= No data available, HC= Hippocampal sclerosis, CBZ= Carbamazepine,
CLB= Clobazam, GPN= Gabapentin, LAC= Lacosamide, LTG= Lamotrigine, LVT= Levetiracetam, PER = Perampanel, PHT=
Phenytoin, ZNS= Zonisamide
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7.3 Results
7.3.1 Epileptiform discharges are inhibited by decanoic acid in a slice
from human temporal lobe
Cortical tissue obtained from epileptic patients has little spontaneous activity. There are
a few reports of successfully recording interictal activity (Huberfeld et al., 2007; Roopun
et al., 2010), and one of spontaneous ictal activity without modifying aCSF (Cunningham
et al., 2012). It seems that this is only achieved in tissue from within the seizure onset
zone (Simon et al., 2014). Further, pushing the network to a state in which spontaneous
activity would be produced in rodent hippocampal slices also failed to induce epileptiform
activity in human temporal lobe slices. It is not possible to know whether tissue outside the
epileptogenic zone is less excitable than control temporal cortex would be. In rats, 4AP-
induced activity is easier to generate in slices produced from control than from epileptic rats
(Zahn et al., 2008). To promote the induction of epileptiform activity, the most important
factors are slice orientation, perfusion rate, aCSF content and slice health (Husson et al.,
2007). Differences in synaptic architecture or neuronal metabolism may also contribute to
the high threshold for epileptic activity in human brain slices compared to rodent tissue.
The density of neurons in the neocortex compared to hippocampus is lower, which would
also reduce the ability for generation of spontaneous epileptiform activity (Jones et al.,
2016). Inducing epileptiform activity in humans may be easiest to induce 4-5 hours after
slicing (Remy et al., 2003).
Using 450µm slices, epileptiform activity was generated with 12mM K+ and 50µM PTX
(Fig. 7.1a). The initiation of epileptiform activity in this slice required both pro-convulsive
agents and pro-excitable changes in aCSF ion concentrations, however the activity was
sustained and could be measured in both layer 2/3 and layer 5 within the same slice with a
high perfusion rate (Morris et al., 2016). Activity in these two layers was synchronised and
both responded to decanoic acid in the same way. Upon wash in of 300µM decanoic acid,
activity was greatly reduced but did not stop (Fig. 7.1a). I used a concentration comparable
to that observed in humans on the MCT diet. This is lower than that used in the rodent ex-
periments. Activity reduced to 7.6% of control in the human slice (Fig. 7.1b), and returned
when decanoic acid was washed out. Owing to the sporadic collection of human tissue
samples and the difficulty in generating epileptiform activity, this graph contains data from
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a single slice.
7.3.2 Decanoic acid reduces AMPA receptor-mediated currents in human
neurons
Electrophysiological recordings were taken from visually identified pyramidal neurons in
the neocortex of humans from tissue resected for epilepsy surgery (350µm slices; details
on the patients are in Table 7.1). These neurons were more sparsely distributed than rat
hippocampal cell layers, without clear cell body regions and fibre tracts. There was a greater
density of unmyelineted axons in the human tissue. This may be a species difference related
to the greater number of long range connections across the human brain, or just due to the
age of the tissue from humans compared to the P21 rats used. During seal formation human
cortical neurons took longer to reach gigaohm (GW) resistance but upon reaching whole cell
configuration cells were stable which allowed long recordings.
To record evoked EPSCs, the stimulating electrode was placed closer to the neuron being
recorded from than in rat slices (∼500µm away). This is because there were no pronounced
fibre tracts in the human neocortical tissue, compared to the hippocampus. Evoked responses
were recorded in the presence of 50µM d-AP5 and 50µM PTX to block NMDA receptor
and GABAA receptor currents respectively (Fig. 7.2a), so that isolated AMPA receptor-
mediated currents were recorded. Cells were patched using a caesium-methylsulphanate
internal solution with 50µM QX-314, and the cell was held at -60mV for these recordings.
Upon application of 600µM decanoic acid the amplitude of currents was reduced (Fig. 7.2b-c;
n=3, [control]:-244.0 ± 44.5pA; [+decanoic acid]: -95.1 ± 16.9pA; p=0.009, paired t-test).
This concentration was chosen to maximise the effect seen on AMPA receptor-mediated
currents (Chang et al., 2016), as the collection of human tissue was infrequent. The time
course of decanoic acid action in humans is similar to rat hippocampal slices, at a comparable
slice thickness (Fig. 7.2c; Chang et al., 2016). A higher concentration of decanoic acid was
used to show a significant difference with a small numbers of neurons.
There is high homology between rodent and human AMPA receptors (Traynelis et al.,
1993); therefore it is unsurprising that decanoic acid has the same effect in human cells on
AMPA receptor-mediated currents, as has been shown previously in rats. This is important,
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Figure 7.1: Epileptiform discharges are blocked by decanoic acid in one slice from human
temporal lobe.
a) Application of 300µM decanoic acid decreases the number of epileptiform events. Repre-
sentative extracellular recordings of epileptiform activity initiated by raising K+ to 12mM
and adding 50µM PTX. Recordings from layer 2/3 [upper] and layer V [lower] of the cortex
are synchronised. b) Summary of number of events binned into 5 minute blocks. Grey area
indicates presence of decanoic acid. Dashed line indicates baseline frequency. Event count
is normalised to baseline (n=1); recording performed by Dr Gareth Morris.
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as it shows decanoic acid will target AMPA receptor-mediated currents in human neurons,
giving further support for its potential therapeutic benefit.
7.3.3 Decanoic acid does not reduce the intrinsic excitability of human
neurons
Cells identified visually as cortical pyramidal neurons were patched with a K-gluconate
internal solution. Current steps (50pA) were injected into neurons in the presence of
ionotropic glutamate and GABA receptor antagonists (50µM PTX, 10µM NBQX, 50µM
d-AP5) and voltage responses were recorded. Action potentials were very similar in shape
and timing to those recorded from rat neurons (Fig. 7.3a-b). They were first initiated at
-50mV to -40mV, and had a rheobase of 120pA to 200pA (see Supplementary Table 8.3 for
all measured parameters).
300µM decanoic acid reduces the intrinsic excitability of rat hippocampal neurons via action
on the persistent sodium channel current, as shown in Chapter 6. In this experiment,
300µM decanoic acid was applied to cortical human neurons and did not affect the intrinsic
excitability, assessed by measuring the number of action potentials (Fig. 7.3c-d, n=2; area
under the curve: [control]: 1589 ± 330 a.u., [decanoic acid]: 1567 ± 292 a.u.). Unfortunately,
no washout of decanoic acid was achieved in these experiments.
7.3.4 No detection of CP-AMPA receptors at synapses on human cortical
pyramidal neurons
Here, I investigated the presence of CP-AMPA receptors at the synapses onto pyramidal
neurons in the neocortex. The resected tissue used in these experiments was taken from
various sites during surgeries. Therefore some samples will likely have been obtained closer
to the seizure foci than others, although no samples were obtained from within the seizure
onset area.
In my experiments neurons were patched with a Cs-methylsulphanate internal solution
containing QX-314 and spermine. Neurons were voltage clamped (-80mV to +60mV) in the
presence of 50µM PTX and 50µM d-AP5, as in Chapter 3 for experiments using rodent slices.
Fig. 7.4a shows an example trace of the eEPSCs recorded and average I-V relationship. The
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Figure 7.2: Decanoic acid decreases AMPA receptor-mediated currents in neurons from
surgically excised human cortex.
a) Representative evoked AMPA receptor-mediated currents recorded from a pyramidal-like
neuron in a cortical slice from a human. Control [top], and after application of 600µM
decanoic acid [lower]. Current traces are each averaged over 5 evoked EPSCs with the cell
held at -60mV. b) Summary of eEPSC amplitude change from wash in of 600µM decanoic
acid in human cortical neurons. Grey circles are individual cells, black squares are the
average. **p<0.01 (paired t-test). c) Normalised peak current amplitude obtained before
and during application of 600µM decanoic acid, showing time course of amplitude decrease.
Black squares are mean; grey cloud shows ± SEM (n=3 cells).
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Figure 7.3: Decanoic acid does not affect the intrinsic excitability of human neurons
a) Representative recordings of action potentials initiated by 50pA current steps with 300µM
decanoic acid treatment. b) Single action potential recorded from a human cortical neuron
[enlarged from orange box in (a)]. c) The number of action potentials evoked by current
injections were compared upon wash in of decanoic acid, to quantify changes in intrinsic
excitability. Lines are fitted to the data as a spline function. d) Summary for (c): Area
under the curve was not changed after decanoic acid wash-in. All recordings were performed
in the presence of synaptic blockers, n=2.
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I-V relationship was linear and averaged rectification index was 0.81 ± 0.19 (n=6), which
indicated that the activated synapses predominantly contained CI-AMPA receptors. Upon
application of the specific CP-AMPA receptor blocker NASPM (70µM) the peak current and
rectification index did not change (Fig. 7.4b; [control]: 0.79, [+ NASPM]: 0.65; n=1). This
further shows that there were no CP-AMPA receptors present at the synapses investigated.
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Figure 7.4: No CP-AMPA receptors were present in human cortical neurons outside the
seizure onset zone, as the I-V relationship is linear.
a) I-V plot from human neocortical pyramidal neurons averaged (RI =0.81 ± 0.19). [Inset]
Representative eEPSCs at each step potential. b) I-V plots comparing a neuron with
application of the CP-AMPA receptor blocker, NASPM [left] and summary of rectification
index with wash in of NASPM [right], n=1.
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7.4 Discussion
In this chapter I used slices prepared from surgically resected cortical tissue in refractory
epilepsy. Due to the limited tissue available, results from this chapter are preliminary. Nev-
ertheless I was able to show that I could elicit epileptiform activity from human neocortex,
and patch clamp neurons in ex vivo human tissue. This could offer an important step in
translating results from rodent tissue to humans. I showed that decanoic acid is able to block
induced epileptiform activity in a slice, and it reduces AMPA receptor-mediated currents.
Tissue collected in surgery was from patients who were previously taking multiple AEDs
without successful seizure control. Although the tissue used is from outside the seizure onset
zone, the beneficial action of decanoic acid here raises the possibility that decanoic acid will
work in cases when pharmacoresistant to typical AED.
Surprisingly, decanoic acid did not change intrinsic excitability in this preparation, as it
does in rat hippocampal neurons. One explanation of these findings is that there is less
persistent sodium current in human neocortical neurons compared to rat CA1 pyramidal
cells. Mutations affecting the persistent sodium are a cause of human genetic epilepsy
(Stafstrom, 2007), and the persistent sodium currents has been measured in layer V pyramidal
neurons in the human neocortex (Aracri et al., 2006). The persistent sodium current
contributes a smaller component compared to the fast component in humans (1.3%) compared
to rat (1.6% in mature rat and 2% in immature rat neocortex; Cummins et al., 1994). It
could be interesting to compare the action of decanoic acid on intrinsic excitability in rodent
hippocampal pyramidal neurons to its action at rodent cortical pyramidal neurons. Also,
the number of sodium channels needed for action potential initiation could be different in
human neurons, and a higher concentration of decanoic acid is needed to block these. A dose-
response experiment would allow me to find out if this is the reason for the species difference.
Input resistance was 134.0 ± 22.7MΩ and membrane capacitance was 19.0 ± 3.7pF, which is
comparable to cortical neurons (Supplementary Table 8.3). Another key difference between
the slices prepared from rats and those from humans is that rats are anaesthetised under
isofluorane for minutes before dissection, whereas human surgical patients may have been
under anaesthesia for hours. General anaesthetics act at sodium channels, so the effect of
decanoic acid at sodium channels may be altered by the actions of general anaesthetics.
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I also looked at the I-V relationship in neurons from human slices outside of the seizure
foci. These neurons did not have rectifying AMPA receptor-mediated currents, and were
not affected by the CP-AMPA receptor blocker, NASPM. This suggests that the activated
synapses did not contain CP-AMPA receptors. Importantly, the tissue obtained was not
from the seizure foci, as this tissue was required by the clinical pathology team. The
distance from foci varied between specimens, and this could be a confounding factor.
As these recordings were taken from outside the seizure zone, it would be interesting to
see whether there is CP-AMPA receptor expression at synapses within the trigger zone.
Histopathological studies comparing a number of clinical factors with neuronal architecture
found no significant correlation between total dendrite length nor number of branch points
when compared to the number of seizures, disease severity, or age of the patient (Mohan
et al., 2015). However, there may be a more subtle change to neuron morphology, or a
change which only affects certain neuronal types which would not be noticed by this study.
Previous studies using fixed tissue from the brains of patients with refractory TLE have
compared the expression of AMPA receptor subunits and found reduced protein GluA2
levels in hippocampal areas with the most pronounced cell loss, but increased GluA2 levels
within the dentate gyrus (Blumcke et al., 1996b).
Non-invasive whole brain recordings (EEG, fMRI, PET) are taken as part of the pre-surgery
assessment. There could be an interesting correlation between excitability measured here
and recordings taken from slices of tissue from these brains. Perhaps this may predict
which slices would exhibit spontaneous epileptiform activity, and even which would have
CP-AMPA receptor expression.
Given the limited quantity of tissue obtained it is difficult to draw definitive conclusions
from the data. However, the action of decanoic acid on epileptiform activity from phar-
macoresistant cases seem clear, which provides more evidence for the ability of decanoic
acid to control seizures. To summarise, this chapter provides proof of principle for the use
of resected human tissue to be used for studies into network changes in epilepsy and the
investigation into novel AEDs.
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General Discussion
The principal focus of this thesis was to investigate the effect of excessive network activity
on AMPA receptor expression and also the inhibition of epileptiform discharges by medium
chain fatty acids and their derivatives, which are non-competitive AMPA receptor an-
tagonists. AMPA receptors drive the spread of seizure activity through networks and are
increasingly being looked at as an important target for seizure control.
In Chapters 3-4, I used in vitro seizure models and demonstrated that there is CP-AMPA
receptor expression at CA1 pyramidal neuron synapses following excessive activity, and
this is dependent on both NMDA receptors and calcineurin activation. In Chapter 5, I
compared medium chain fatty acids, including decanoic acid, with other AMPA receptor
antagonists at inhibiting epileptiform activity. I found that the action of decanoic acid
at AMPA receptors does not affect receptor kinetics, and was not use-dependent. I also
showed that decanoic acid acts synergistically with perampanel at inhibiting epileptiform
discharges. In Chapter 6, I looked into other actions of decanoic acid, and showed that it
reduces intrinsic excitability via decreasing the persistent sodium current. Finally, I tested
some of these findings in experiments using human surgically resected tissue in Chapter 7,
and provided preliminary evidence for the use of this in mechanistic and pharmacological
studies for epilepsy treatment.
I will first discuss how data recorded in this thesis relate to previously published data
and then I will discuss the physiological impact of my findings. I will address each of my
hypotheses in turn.
161
Chapter 8. General Discussion
8.1 Excessive network activity causes a shift towards GluA2-
lacking AMPA receptor expression at CA1 pyramidal
neurons
There is an elevation of [Ca2+]i to around three times that at control levels, following
excessive network activity (such as during SE; measured using 45CaCl2 autoradiography
and Fura 2AM Ca2+ imaging), which is sustained until after SE is over (Pal et al., 1999;
Friedman et al., 2008). Ca2+ entry via VGCCs, NMDA receptors and AMPA receptors can
trigger cascades causing apoptosis in cells without sufficient calcium buffering proteins, such
as CA1 pyramidal neurons. CP-AMPA receptor expression provides an additional means
for Ca2+ entry into the neuron during excessive network activation.
The experiments presented in Chapter 3 show evidence for increased expression of CP-
AMPA receptors. Incubation of hippocampal slices in 0-Mg2+ or PTZ-aCSF produced
rectifying AMPA receptor-mediated currents. Rectification was used as a measure of the
proportion of CP-AMPA receptors at the synapse, since CP-AMPA receptors are subject to
voltage-dependent inhibition by polyamines. I further confirmed my findings by pharmacology
and used variance analysis to determine if there is an increase in conductance as would be
predicted by CP-AMPA receptor expression.
My results are in line with previous immunohistochemical and electrophysiological findings.
In fixed tissue from the brains of patients with TLE, there is reduced GluA2 in hippocampal
areas with the most pronounced cell loss, but increased GluA2 levels within the dentate
gyrus (Blumcke et al., 1996b). In rats, transient CP-AMPA receptor expression has been
shown up to one month after kindling by PTZ (Ekonomou et al., 2001), and has been
shown in slices from SE models (Rajasekaran et al., 2012; Friedman et al., 2008). A recent
study found increased CP-AMPA receptor expression following hypoxia-induced seizures
in the immature brain, caused by reduced GluA2 expression at the synapse. This results
in impaired LTD, which requires GluA2-containing AMPA receptors (Lippman-Bell et al.,
2016).
CP-AMPA receptor expression at pyramidal cells may also alter classical NMDA receptor-
162
Chapter 8. General Discussion
dependent LTP. This process relies on Ca2+ entry through the NMDA receptor for co-
incidence detection, and therefore Ca2+ entry through CP-AMPA receptors when the cell
has not been previously depolarised could disrupt the specificity of coincidence detection
in synapse strengthening. A critical question is whether plasticity can be induced with
NMDA receptors blocked, due to calcium entry through synaptic CP-AMPA receptors on
pyramidal neurons in these seizure models. CP-AMPA receptors are important for inducing
other forms of plasticity, with high temporal precision and favouring strengthening at hy-
perpolarising potentials in interneurons (Lamsa et al., 2007).
My experiments were carried out using in vitro models of epileptiform discharges in hippocampal
slices. This was a compromise which allowed simple pharmacological manipulation and was
less labour intensive compared to ex vivo preparation from animals with induced epilepsy.
Using slices allowed me to look at an identified set of synaptic connections in the well-
categorised hippocampal network, which could not be achieved in cultures. The experiments
looked at a single time point to compare slice models of seizures, so only acute effects were
looked at. It would be useful to track the duration of this increase in CP-AMPA receptor
expression, as an acute switch may induce apoptosis of damaged cells whereas a chromic
switch may promote epileptogenic network generation. A recent study showed there is
CP-AMPA receptor expression in rat ex vivo slices after systemic pilocarpine-induced SE
(Malkin et al., 2016). The group showed that expression was transient, with the greatest
CP-AMPA receptor expression three days after SE, and baseline expression returned after
seven days. It may be that expression is only during the latent period, before development
of TLE (Malkin et al., 2016).
8.2 The shift toward CP-AMPA receptor expression is blocked
in the presence of NMDA receptor inhibitors
Under physiological conditions, CP-AMPA receptors are only transiently expressed in response
to synaptic activity (Plant et al., 2006; Hou et al., 2008) so expression and trafficking
must be tightly regulated. To answer the question of how CP-AMPA receptors become
functionally expressed at the synapse, I started by asking whether the process is NMDA
receptor-dependent. NMDA receptor activation is a necessary step in the initiation of
numerous cellular processes, including LTP and apoptosis. Activation signals an increase
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in network activity, since the membrane must be already depolarised from previous activity
for glutamate binding to allow the channel to open. NMDA receptor activation further
depolarises the membrane and increases [Ca2+]i to trigger intracellular messenger cascades
(Nowak et al., 1984).
I found that NMDA receptor activation was required for synaptic CP-AMPA receptor
expression, as AMPA receptor-mediated currents were not rectifying if d-AP5 was included
in the PTZ-induction medium (Chapter 4). It is likely that Ca2+ entry through NMDA
receptors triggers a cascade favouring synaptic insertion of GluA2-lacking AMPA receptors.
Based on this result, I looked at which protein phosphatases could be involved in CP-AMPA
receptor expression by dephosphorylating AMPA receptor subunits and found that CP-
AMPA receptor expression was calcineurin (CaN) dependent, but not STEP61 dependent.
CaN is a direct transducer of NMDA receptor signalling, as it is Ca2+ activated; it is
therefore also activated by CP-AMPA receptors (Sanchez et al., 2005). CaN is found in
a complex with kinases (PKA and PKC) and is assembled by AKAP79/150, which is
targeted to the C-termini of AMPA receptors and NMDA receptors. This puts it in an
ideal location to respond to NMDA receptor-mediated Ca2+ influx and regulate AMPA
receptor trafficking. F-actin filaments are organised in a CaN-dependent way to traffic
AMPA receptors to the PSD (Halpain et al., 1998). Further, CaN interacts directly with
the TARP γ-8, which modulates AMPA receptor trafficking and kinetics (Itakura et al.,
2014).
CaN and PKA mediate the transient expression of CP-AMPA receptors following LTD
(Sanderson et al., 2012, 2016). PKA was required for insertion, whereas CaN removed
CP-AMPA receptors from the synaptic membrane. Expression of these proteins acutely
increases after hippocampal sclerosis in P10 rats (Rakhade et al., 2008; Sanchez et al.,
2005). The direction of CaN-mediated trafficking may be dependent on the pattern of Ca2+
influx by NMDA receptors, by restricting which phosphorylation sites CaN acts at. It may
also be age-dependent, as expression of CP-AMPA receptors at pyramidal neuron synapses
following LTP initiation has been described to be. The control of bidirectional plasticity
by CaN allows dynamic regulation, as is seen in oligodendrocyte precursor cells (Zonouzi
et al., 2011). It has recently been shown that phosphorylation of Elk-1 by ERK can have
opposing effects depending on the site of phosphorylation (Mylona et al., 2016), which hints
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at the complexity of interactions between protein regulators. This shows that multisite
modification events do not act unidirectionally and phosphatases may not always produce
the reverse effect to kinases.
AMPA receptor antagonists (such as NBQX) also block the enhanced Ca2+ response and
NASPM sensitivity after hypoxia (Lippman-Bell et al., 2016). AMPA receptors mediate the
bulk of excitatory synaptic transmission for the maintenance and spread of seizure-activity
through the network, including the paroxysmal depolarisation shift (the basis of the EEG
spike) and the electrographic seizure discharge (Rogawski, 2016). It appears that activation
of AMPA receptors is required for CP-AMPA receptor expression. In the presence of NBQX
there was no difference in CP-AMPA receptor-mediated Ca2+ responses in hippocampal CA1
neurons in epileptic compared to control non-epileptic animals. Further, NBQX blocked the
post-seizure decrease in synaptic GluA2 expression (Lippman-Bell et al., 2016). However,
this study was in immature brains, so the results could be specific for that particular de-
velopmental stage. NBQX does not have anti-epileptogenic effects in adults, but it is not
known whether it inhibits the switch to CP-AMPA receptor expression in adults too (Twele
et al., 2015).
The reason for expression of CP-AMPA receptors following seizures is not understood.
NMDA receptors are extensively activated in epilepsy. Increased Ca2+ entry through
NMDA receptors could trigger further [Ca2+]i elevation due to calcium-induced Ca
2+ release
(CICR; Alford et al., 1993). If Ca2+ entry also allows synaptic expression of CP-AMPA
receptors, then the different kinetics of Ca2+ -entry through AMPA receptors may induce
non-overlapping intracellular processes. Many SE models report increased Ca2+ -dynamics
in CA1 pyramidal neurons with similar patterns in cell death, thus studies can not resolve
whether changes in Ca2+ permeability are a product of excitotoxicity pathways, or of epilep-
togenesis pathways. I next looked at whether inhibition of CP-AMPA receptors alters
epileptiform activity.
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8.3 Specific CP-AMPA receptor inhibitors block epileptiform
activity in a similar way to general AMPA receptor inhibitors
The most potent and clinically well-tolerated AMPA receptor inhibitors act via a non-
competitive mechanism, but many potential new AEDs produce adverse side effects. Non-
competitive inhibitors stabilise the inactive receptor, preventing conformation changes leading
to the ion channel opening (Yelshanskaya et al., 2016). Perampanel is a non-competitive
AMPA receptor blocker, which is an approved AED but has CNS-related side effects of
dizziness, somnolence, fatigue and irritability (Frampton, 2015). I asked whether specifically
inhibiting CP-AMPA receptors, which have less widespread expression, would block epileptiform
discharges.
Nascent CP-AMPA receptors are expressed at synapses following excessive network activity.
If this is in addition to CI-AMPA receptors, then specifically blocking nascent CP-AMPA
receptors could be beneficial. Previous studies have shown that selective CP-AMPA receptor
block decreases excessive Ca2+ activity (Rajasekaran et al., 2012; Lippman-Bell et al., 2016),
whereas NMDA receptor or L-type Ca2+ channel inhibition did not prevents seizure-induced
increases in Ca2+ responses in hippocampal slices. In contrast to these findings, I found
that NASPM did not reduce epileptiform discharges in the PTZ slice model of seizures.
Although NASPM did not alter the frequency of epileptiform discharges, there could be
a benefit to long term NASPM administration for cell viability, if excessive Ca2+ entry
through CP-AMPA receptors contributes to cell death.
8.4 AMPA receptor inhibition by decanoic acid can explain
the success of the ketogenic diet
The ketogenic diet is successfully used for seizure control in refractory epilepsy, particularly
in children (Cross et al., 2010). In patients, a long-term ketogenic diet postpones epilepsy
disease progression and in a mouse model it prolongs life expectancy. Those on the MCT
ketogenic diet have appreciable levels of MCTs in the circulation and the brain (Sills et al.,
1986).
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Decanoic acid is a key component of the MCT ketogenic diet, which inhibits epileptiform
activity and acts as a non-competitive AMPA receptor antagonist. Similarly to other
anti-seizure compounds, (such as GYKI and perampanel), decanoic acid acts as a non-
competitive AMPA receptor antagonist. Receptor block by competitive antagonists can be
removed if there is excessive glutamate at the synaptic (such as during a seizure), whereas the
action of non-competitive antagonists is independent of the concentration of glutamate. This
block could have effects on physiological synapse functioning, which I investigated further in
Chapter 5. The hypothesised location of decanoic acid binding on AMPA receptors, based
on modelling, suggested that it may influence the kinetics of AMPA receptor-mediated
currents (Chang et al., 2016). However, I found that it does not affect AMPA receptor
current kinetics. If the eEPSC tail current duration was reduced by decanoic acid, this
would shorten the time window for LTP induction which is a key neuronal process for
learning and memory.
Decanoic acid does not inhibit AMPA receptors in a use-dependent way. Use-dependent
inhibition occurs when the binding site of the compound is inside the receptor pore, so it can
only access here when the receptor is activated and channel open. Use-dependent inhibitors
would preferentially inhibit overactive synapses in a seizure, however they may also be less
effective at synapses which have a high AMPA receptor turn over rate. Perampanel does
not block AMPA receptors in a use-dependent way, whereas polyamines use-dependently
block certain subtype configurations of AMPA receptor.
Synergistic relationships between AEDs and AMPA receptor antagonists are often noted
(Citraro et al., 2014). I found that perampanel enhanced decanoic acid’s anti-seizure effects
in the PTZ slice model. Similarly, GYKI enhances conventional AEDs action against
maximal electric shock (MES)-induced seizures at a sub-therapeutic dose (Yamaguchi et al.,
1993).
8.5 Other neuronal targets of decanoic acid reduce network
excitability
Although decanoic acid acts at AMPA receptors, until now it has been unclear whether it
is specific or, like many AEDs, has multiple targets. I showed that decanoic acid reduced
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neuron intrinsic excitability by actions at VGSCs, including inhibition of INaP.
VGSCs are a common target of AEDs, including those with multiple targets. Sodium
channel blockers have the highest affinity for binding to the inactivated state, which slows
the conformational re-activating process. This produces a voltage- and frequency-dependent
reduction in channel conductance, and limits repetitive neuronal firing (Sills and Brodie,
2001). Phenytoin, carbamazepine and lamotrigine all inhibit INaP more than INaT but none
are specific INaP inhibitors. The polypharmacology of phenytoin includes actions at the
Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, and calcium
channels (Tunnicliff, 1996).
There are other known targets of decanoic acid which indicate it is neuroprotective and
could improve cognition (e.g. in Alzheimer’s patients; Henderson et al., 2009). Decanoic acid
activates PPAR-γ receptors, which decreases inflammation after seizures in the hippocampus
of mice (Jeong et al., 2011). MCTs, including decanoic acid, improve cognition in multiple
memory tests in rats. Decanoic acid decreases many immediate early genes related to
synaptic renovation and protein synthesis following LTP (e.g. activity-regulated cytoskeleton-
associated protein Arc/Arg3.1, the transcription factor jun-B, and early growth response
2 egr2), but increases Akt phosphorylation and expression of proteins involved in synaptic
maintenance (Wang and Mitchell, 2016).
Further, MCTs are metabolised into ketones which also have effects on excitability (Ma et al.,
2007) and neuroprotection (Kim et al., 2015a, 2007); although there is a poor correlation
between serum ketones and seizure control (Likhodii et al., 2000; Thavendiranathan et al.,
2000). The success of the ketogenic diet may be from the multiple targets by decanoic acid
and its metabolites.
8.6 Recordings from human neocortical neurons can be compared
to results obtained in rats
Human tissue obtained during epileptic foci resection surgery gives a unique insight into
pharmacoresistant epilepsy. Decanoic acid reduced epileptiform discharges when induced
in slices of human cortical tissue peripheral to the seizure onset zone. I looked at the
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mechanism of action of decanoic acid at human neurons. I also looked for evidence of CP-
AMPA receptor expression by looking at the I-V relationship at cortical pyramidal neurons.
I showed the potential use of human slices for both pharmacological studies and to look at
the underlying mechanism of seizures.
As this tissue was not from the seizure foci, but from tissue adjacent to the foci, there
were no spontaneously produced epileptic discharges. Further, there would be minimal
receptor and network epileptogenic changes compared to the seizure-onset zone. For future
experiments, it would be useful to fill cells with biocytin during recording to see precisely
which neuron type is being recorded from. Moreover, with more data collected it would
be possible to correlate slice recordings with patient details, such as seizure frequency and
which AEDs were prescribed.
Preliminary results in human tissue give further evidence that decanoic acid will inhibit
seizures in humans as in rodents, which is essential for a compound being developed for
clinical treatment. Decanoic acid inhibited AMPA receptor-mediated currents in human
neurons, but did not reduce intrinsic excitability as shown in rodent neurons in Chapter 6.
The lack of an effect on intrinsic excitability may be due to a lack of persistent sodium
currents in the cells from which I recorded- this needs to be investigated further.
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8.7 Future Directions
Following the first section of this thesis–looking at the expression of CP-AMPA receptors at
CA1 pyramidal neurons after seizures– it is important to work out why this receptor type
becomes expressed at the synapse, and the time period of this expression. Ca2+ imaging
would allow me to see when there is increased Ca2+ influx and how long this lasts. I could
patch neurons at different time points after SE in ex vivo slices, and see when the I-V re-
lationship becomes linear.
CP-AMPA receptors could drive some of the epileptogenic network changes following the
initial insult. There is evidence that CP-AMPA receptors do not lead to cell death (Lippman-
Bell et al., 2016). The mechanism by which CaN activation leads to expression of CP-AMPA
receptors is not known, but the pattern of Ca2+ influx is important for determining whether
there is CP-AMPA receptor expression. Since CaN is required for expression of CP-AMPA
receptors, it would be important to see if reversing the change in AMPA receptors using
clinically available CaN inhibitors has an impact on the outcome of SE.
For the second section of my results, it will be interesting to determine the specific target
of decanoic acid at VGSCs, using HEK cells transfected with both α- and β-subunits of
sodium channels. If decanoic acid is beneficial in patients with refractory epilepsy, then
it may be looked at as a treatment in other neurological conditions. The MCT ketogenic
diet has potential to reduce clinical and cellular symptoms in other neurological disorders
characterised by neuronal cell death (Rho and Stafstrom, 2012), such as Alzheimer’s disease
(Reger et al., 2004; Henderson et al., 2009) and Parkinson disease (Vanitallie et al., 2005).
A ketogenic diet increased serum BHB (ketone) levels and reduced β-amyloid plaques in a
mouse model of Alzheimers disease models, with no changes in behaviour (Van der Auwera
et al., 2005). Finally, the MCT ketogenic diet may be beneficial in ischemia by reducing
oxidative stress, excitotoxicity and apoptosis (Shaafi et al., 2014). Future research into the
use of MCTs for these conditions may provide important advances in therapy for neurological
diseases and cancers. There have been 11 clinical trials of the ketogenic diet in cancer, and
multiple pre-clinical studies showing delayed tumour growth using in vivo models of glioma,
colon cancer, liver cancer, gastric cancer and prostate cancer (Hao et al., 2015; Cay et al.,
1992; Otto et al., 2008). The first trial using MCT oil for two children with advanced
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stage astrocytomas showed a reduction in glucose uptake at the tumour site; and disease
progression was halted in one patient, even after 12 months (Nebeling et al., 1995). This
may be beneficial by a different mechanism to the seizure-inhibiting actions of MCT oil,
such as by reducing the energy supply to cancer cells.
8.8 Conclusions and Perspectives
AMPA receptors are crucial for the spread of seizures. Excessive activity dynamically alters
synaptic expression of AMPA receptors at pyramidal neuron synapses by allowing transient
expression of CP-AMPA receptors after NMDA receptor activation.
Inhibition of CP-AMPA receptors alone is not able to inhibit epileptiform discharges in
a slice model. However, fatty acid molecules based on the MCT ketogenic diet are able to
inhibit seizure-like activity and act as non-competitive AMPA receptor antagonists. These
compounds show polypharmacology, as is common among antiepileptic agents, and also
reduce intrinsic excitability by reducing INaP.
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“Sounded like a load of waﬄe to me.”
“There was some important stuff hidden in the waﬄe.”
- JK Rowling, Harry Potter and the Order of the Phoenix
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control aCSF (n=9) 0-Mg2+ aCSF (n=11) control aCSF (n=10) PTZ-aCSF (n=11)
Bath temperature/ ° C 31.9 ± 0.1 29.1 ± 1.2 31.8 ± 0.1 32.3 ± 0.3
Membrane capacitance/ pF 25.3 ± 3.6 23.7 ± 2.7 26.6 ± 3.2 19.0 ± 1.6
Stimulation intensity/ pA 195 ± 103 180 ± 82 86 ± 36 56 ± 33
Series resistance/ MW 11.5 ± 1.6 13.0 ± 1.2 10.6 ± 0.7 11.2 ± 1.2
Series resistance compensation/ % 66 ± 2 28 ± 8 73 ± 3 61 ± 7
Input resistance/ MW 166 ± 30 145 ± 10 145 ± 33 214 ± 41
Reversal potential/ mV 0.06 ± 1.3 7.3 ± 2.5 0.1 ± 0.8 2.4 ± 1.0
Table 8.1: Supplementary information: Neuronal properties compared between treatment groups in slice models of status epilepticus.
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control aCSF + DMSO washout AB sig.
(p<0.05)
RMP /mV -63.0 ± 3.2 -63.0 ± 3.3 -64.0 ± 4.7 -
Rheobase /norm. 1 0.93 ± 0.16 0.93 ± 0.16 -
Spike amplitude /mV 92.5 ± 5.3 93.6 ± 4.7 91.9 ± 3.7 -
Inter-event interval /ms 30.4 ± 7.4 35.0 ± 10.3 35.3 ± 9.8 -
Rinput /norm. 1 1.07 ± 0.13 1.18 ± 0.29 -
Rise time /ms 0.93 ± 0.08 0.93 ± 0.08 0.91 ± 0.10 -
Half width /norm. 1 1.13 ± 0.15 0.88 ± 0.24 -
Decay time /ms 1 1.12 ± 0.07 0.91 ± 0.25 -
control aCSF + decanoic acid washout AB sig.
(p<0.05)
RMP /mV -62.2 ± 2.0 -63.4 ± 1.9 -62.4 ± 1.5 -
Rheobase /norm. 1 1.9 ± 0.5 1.4 ± 0.2 +
Spike amplitude /mV 96.9 ± 2.5 96.8 ± 1.4 95.0 ± 1.3 -
Inter-event interval /ms 43.6 ± 11.6 48.6 ± 10.9 40.4 ± 10.6 -
Rinput /norm. 1 0.99 ± 0.11 1.02 ± 0.06 -
Rise time /ms 1.01 ± 0.01 1.01 ± 0.01 1.00 ± 0.01 -
Half width /norm. 1 1.43 ± 0.27 1.27 ± 0.16 +
Decay time /ms 1 1.31 ± 0.12 1.31 ± 0.16 -
Table 8.2: Supplementary information: Neuron properties and action potentials compared
in the presence of decanoic acid
Significant change in rheobase and half width with 300µM decanoic acid compared to control.
RMP = resting membrane potential (mV), rheobase = current injection to reach action
potential threshold (pA), Rinput = Input resistance (MΩ)
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Cell no. Raccess (MΩ) Cm (pF) Rinput (MΩ) RMP (mV) AP threshold (mV) Rheobase (pA) Vpeak (mV)
1 8.3 30.2 120
2 8.2 42 122
3 7.75 12.12 200
4 8.2 17.4 166
5 12.4 10.7 166
6 12.8 6.5 71
7 16 13.8 250
8 9.7 19.34 133.9 -72.8
9 9 18.9 40 -74.7 -55 200 32
10 11.9 18.45 71
11 11 200 -67 -40 120 22
12 10.3 125 -83
Table 8.3: Supplementary information: Properties of neurons patched from human surgically resected tissue.
Raccess = access resistance (MΩ), Cm = membrane capacitance (pF) gives an indication of cell size, Rinput = input resistance (MΩ), RMP
= resting membrane potential (mV), rheobase = current injection to reach action potential voltage threshold (pA)
176
References
Abraham, W. C. and Bear, M. F. (1996). Metaplasticity: the plasticity of synaptic plasticity.
Trends in Neurosciences, 19(4):126–130.
Abrahamsson, T., Cathala, L., Matsui, K., Shigemoto, R., and Digregorio, D. A. (2012).
Thin dendrites of cerebellar interneurons confer sublinear synaptic integration and a
gradient of short-term plasticity. Neuron, 73(6):1159–1172.
Adotevi, N. K. and Leitch, B. (2016). Alterations in AMPA receptor subunit expression in
cortical inhibitory interneurons in the epileptic stargazer mutant mouse. Neuroscience,
339:124–138.
Agrawal, N., Alonso, A., and Ragsdale, D. S. (2003). Increased persistent sodium currents
in rat entorhinal cortex layer v neurons in a poststatus epilepticus model of temporal lobe
epilepsy. Epilepsia, 44(12):1601–1604.
Ahmadian, G., Ju, W., Liu, L., Wyszynski, M., Lee, S. H., Dunah, A. W., Taghibiglou,
C., Wang, Y., Lu, J., Wong, T. P., Sheng, M., and Wang, Y. T. (2004). Tyrosine
phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis
and LTD. The EMBO Journal, 23(5):1040–1050.
Alford, S., Frenguelli, B. G., Schofield, J. G., and Collingridge, G. L. (1993). Char-
acterization of Ca2+ signals induced in hippocampal CA1 neurones by the synaptic
activation of NMDA receptors. The Journal of Physiology, 469:693–716.
Ambros-Ingerson, J., Xiao, P., Larson, J., and Lynch, G. (1993). Waveform analysis suggests
that LTP alters the kinetics of synaptic receptor channels. Brain Research, 620(2):237–
244.
Andersen, P. (2007). The Hippocampus Book. Oxford Neuroscience Series. Oxford University
Press, USA.
177
References
Anggono, V. and Huganir, R. L. (2012). Regulation of AMPA receptor trafficking and
synaptic plasticity. Current Opinion in Neurobiology, 22(3):461–469.
Aracri, P., Colombo, E., Mantegazza, M., Scalmani, P., Curia, G., Avanzini, G., and
Franceschetti, S. (2006). Layer-specific properties of the persistent sodium current in
sensorimotor cortex. Journal of Neurophysiology, 95(6):3460–3468.
Arai, A. C. (2001). GYKI 52466 has positive modulatory effects on AMPA receptors. Brain
Research, 892(2):396–400.
Araki, Y., Lin, D.-T., and Huganir, R. L. (2010). Plasma membrane insertion of the
AMPA receptor GluA2 subunit is regulated by NSF binding and Q/R editing of the ion
pore. Proceedings of the National Academy of Sciences of the United States of America,
107(24):11080–11085.
Asrar, S., Zhou, Z., Ren, W., and Jia, Z. (2009). Ca(2+) permeable AMPA receptor induced
long-term potentiation requires PI3/MAP kinases but not Ca/CaM-dependent kinase II.
PLOS One, 4(2):243–339.
Ballou, L. M., Lin, R. Z., and Cohen, I. S. (2015). Control of cardiac repolarization by
phosphoinositide 3-kinase signaling to ion channels. Circulation Research, 116(1):127–
137.
Banke, T. G., Bowie, D., Lee, H., Huganir, R. L., Schousboe, A., and Traynelis, S. F.
(2000). Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase.
The Journal of Neuroscience, 20(1):89–102.
Bar-Yehuda, D. and Korngreen, A. (2008). Space-clamp problems when voltage clamping
neurons expressing voltage-gated conductances. Journal of Neurophysiology, 99(3):1127–
1136.
Barad, Z., Shevtsova, O., Arbuthnott, G. W., and Leitch, B. (2012). Selective loss of AMPA
receptors at corticothalamic synapses in the epileptic stargazer mouse. Neuroscience,
217:19–31.
Barygin, O. I. (2016). Inhibition of calcium-permeable and calcium-impermeable AMPA
receptors by perampanel in rat brain neurons. Neuroscience Letters, 633:146–151.
178
References
Basello, D. A. and Scovassi, A. I. (2015). Poly(ADP-ribosylation) and neurodegenerative
disorders. Mitochondrion, 24:56–63.
Bats, C., Farrant, M., and Cull-Candy, S. G. (2013). A role of TARPs in the expression
and plasticity of calcium-permeable AMPARs: Evidence from cerebellar neurons and glia.
Neuropharmacology, 74:76–85.
Beattie, E. C., Carroll, R. C., Yu, X., Morishita, W., Yasuda, H., von Zastrow, M.,
and Malenka, R. C. (2000). Regulation of AMPA receptor endocytosis by a signaling
mechanism shared with LTD. Nature Neuroscience, 3(12):1291–1300.
Behr, J., Lyson, K. J., and Mody, I. (1998). Enhanced propagation of epileptiform activity
through the kindled dentate gyrus. Journal of Neurophysiology, 79(4):1726–1732.
Beique, J.-C., Na, Y., Kuhl, D., Worley, P. F., and Huganir, R. L. (2011). Arc-dependent
synapse-specific homeostatic plasticity. Proceedings of the National Academy of Sciences
of the United States of America, 108(2):816–821.
Bengzon, J., Kokaia, Z., Elmr, E., Nanobashvili, A., Kokaia, M., and Lindvall, O. (1997).
Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic
seizures. Proceedings of the National Academy of Sciences of the United States of America,
94(19):10432–10437.
Benke, T. A., Luthi, A., Isaac, J. T. R., and Collingridge, G. L. (1998). Modulation of
AMPA receptor unitary conductance by synaptic activity. Nature, 393(6687):793–797.
Benke, T. A., luthi, A., Palmer, M. J., Wikstrom, M. A., Anderson, W. W., Isaac, J. T., and
Collingridge, G. L. (2001). Mathematical modelling of non-stationary fluctuation analysis
for studying channel properties of synaptic AMPA receptors. The Journal of Physiology,
537(Pt 2):407–420.
Bi, R., Rong, Y., Bernard, A., Khrestchatisky, M., and Baudry, M. (2000). Src-mediated
tyrosine phosphorylation of NR2 subunits of N-methyl-D-aspartate receptors protects
from calpain-mediated truncation of their C-terminal domains. The Journal of Biological
Chemistry, 275(34):26477–26483.
Bialer, M. and White, H. S. (2010). Key factors in the discovery and development of new
antiepileptic drugs. Nature Reviews. Drug Discovery, 9(1):68–82.
179
References
Binder, D. K. and Steinhuser, C. (2006). Functional changes in astroglial cells in epilepsy.
Glia, 54(5):358–368.
Bischofberger, J., Engel, D., Li, L., Geiger, J. R., and Jonas, P. (2006). Patch-clamp
recording from mossy fiber terminals in hippocampal slices. Nature Protocols, 1(4):2075–
2081.
Blanco-Suarez, E. and Hanley, J. G. (2014). Distinct subunit-specific α-Amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking mechanisms in cultured
cortical and hippocampal neurons in response to oxygen and glucose deprivation. Journal
of Biological Chemistry, 289(8):4644–4651.
Blumcke, I., Beck, H., Nitsch, R., Eickhoff, C., Scheﬄer, B., Celio, M. R., Schramm,
J., Elger, C. E., Wolf, H. K., and Wiestler, O. D. (1996a). Preservation of calretinin-
immunoreactive neurons in the hippocampus of epilepsy patients with Ammon’s horn
sclerosis. Journal of Neuropathology and Experimental Neurology, 55(3):329–341.
Blumcke, I., Beck, H., Scheﬄer, B., Hof, P. R., Morrison, J. H., Wolf, H. K., Schramm, J.,
Elger, C. E., and Wiestler, O. D. (1996b). Altered distribution of the α-amino-3-hydroxy-
5-methyl-4-isoxazole propionate receptor subunit GluR2(4) and the N-methyl-D-aspartate
receptor subunit NMDAR1 in the hippocampus of patients with temporal lobe epilepsy.
Acta Neuropathologica, 92(6):576–587.
Blumcke, I., Schewe, J. C., Normann, S., Brustle, O., Schramm, J., Elger, C. E., and
Wiestler, O. D. (2001). Increase of nestin-immunoreactive neural precursor cells in the
dentate gyrus of pediatric patients with early-onset temporal lobe epilepsy. Hippocampus,
11(3):311–321.
Blumenfeld, H., Lampert, A., Klein, J. P., Mission, J., Chen, M. C., Rivera, M., Dib-Hajj,
S., Brennan, A. R., Hains, B. C., and Waxman, S. G. (2009). Role of hippocampal sodium
channel NaV1.6 in kindling epileptogenesis. Epilepsia, 50(1):44–55.
Bojic, U., Elmazar, M. M., Hauck, R. S., and Nau, H. (1996). Further branching of valproate-
related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect.
Chemical Research in Toxicology, 9(5):866–870.
Bowie, D. (2012). Redefining the classification of AMPA-selective ionotropic glutamate
receptors. The Journal of Physiology, 590(1):49–61.
180
References
Bowie, D., Lange, G. D., and Mayer, M. L. (1998). Activity-dependent modulation of
glutamate receptors by polyamines. The Journal of Neuroscience, 18(20):8175–8185.
Braithwaite, S. P., Xia, H., and Malenka, R. C. (2002). Differential roles for NSF and
GRIP/ABP in AMPA receptor cycling. Proceedings of the National Academy of Sciences
of the United States of America, 99(10):7096–7101.
Bredt, D. S. and Nicoll, R. A. (2003). AMPA receptor trafficking at excitatory synapses.
Neuron, 40(2):361–379.
Briggs, S. W., Walker, J., Asik, K., Lombroso, P., Naegele, J., and Aaron, G. (2011). STEP
regulation of seizure thresholds in the hippocampus. Epilepsia, 52(3):497–506.
Brockie, P. J., Jensen, M., Mellem, J. E., Jensen, E., Yamasaki, T., Wang, R., Maxfield,
D., Thacker, C., Hoerndli, F., Dunn, P. J., Tomita, S., Madsen, D. M., and Maricq,
A. V. (2013). Cornichons control ER export of AMPA receptors to regulate synaptic
excitability. Neuron, 80(1):129–142.
Burbidge, S. A., Dale, T. J., Powell, A. J., Whitaker, W. R. J., Xie, X. M., Romanos,
M. A., and Clare, J. J. (2002). Molecular cloning, distribution and functional analysis of
the NaV1.6 voltage-gated sodium channel from human brain. Brain Research. Molecular
Brain Research, 103(1-2):80–90.
Butler, J. L. and Paulsen, O. (2015). Hippocampal network oscillations- recent insights
from in vitro experiments. Current Opinion in Neurobiology, 31:40–44.
Carnevale, N. and Hines, M. (2006). The NEURON book. Cambridge University Press,
Cambridge, UK.
Carroll, R. C., Beattie, E. C., Xia, H., Luscher, C., Altschuler, Y., Nicoll, R. A., Malenka,
R. C., and von Zastrow, M. (1999). Dynamin-dependent endocytosis of ionotropic
glutamate receptors. Proceedings of the National Academy of Sciences of the United
States of America, 96(24):14112–14117.
Carter, B. C., Giessel, A. J., Sabatini, B. L., and Bean, B. P. (2012). Transient sodium
current at subthreshold voltages: activation by EPSP waveforms. Neuron, 75(6):1081–
1093.
181
References
Carter, D. S., Harrison, A. J., Falenski, K. W., Blair, R. E., and DeLorenzo, R. J. (2008).
Long-term decrease in calbindin-D28k expression in the hippocampus of epileptic rats
following pilocarpine-induced status epilepticus. Epilepsy Research, 79(2-3):213–223.
Cay, O., Radnell, M., Jeppsson, B., Ahrn, B., and Bengmark, S. (1992). Inhibitory effect of
2-deoxy-D-glucose on liver tumor growth in rats. Cancer Research, 52(20):5794–5796.
Chang, P., Augustin, K., Boddum, K., Williams, S., Sun, M., Terschak, J. A., Hardege,
J. D., Chen, P. E., Walker, M. C., and Williams, R. S. B. (2016). Seizure control by
decanoic acid through direct AMPA receptor inhibition. Brain: A Journal of Neurology,
139(Pt 2):431–443.
Chang, P., Orabi, B., Deranieh, R. M., Dham, M., Hoeller, O., Shimshoni, J. A., Yagen,
B., Bialer, M., Greenberg, M. L., Walker, M. C., and Williams, R. S. B. (2012).
The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce
phosphoinositide levels independently of inositol in Dictyostelium. Disease Models &
Mechanisms, 5(1):115–124.
Chang, P., Terbach, N., Plant, N., Chen, P. E., Walker, M. C., and Williams, R. S.
(2013). Seizure control by ketogenic diet-associated medium chain fatty acids. Neu-
ropharmacology, 69(100):105–114.
Chang, P., Walker, M. C., and Williams, R. S. B. (2014). Seizure-induced reduction in
PIP3 levels contributes to seizure-activity and is rescued by valproic acid. Neurobiology
of Disease, 62:296–306.
Chang, P., Zuckermann, A. M. E., Williams, S., Close, A. J., Cano-Jaimez, M., McEvoy,
J. P., Spencer, J., Walker, M. C., and Williams, R. S. B. (2015). Seizure control by
derivatives of medium chain fatty acids associated with the ketogenic diet show novel
branching-point structure for enhanced potency. Journal of Pharmacology and Ex-
perimental Therapeutics, 352(1):43–52.
Chatelier, A., Zhao, J., Bois, P., and Chahine, M. (2010). Biophysical characterisation of
the persistent sodium current of the NaV1.6 neuronal sodium channel: a single-channel
analysis. Pflugers Archiv: European Journal of Physiology, 460(1):77–86.
Chen, B., Feng, B., Tang, Y., You, Y., Wang, Y., Hou, W., Hu, W., and Chen, Z. (2016).
Blocking GluN2b subunits reverses the enhanced seizure susceptibility after prolonged
182
References
febrile seizures with a wide therapeutic time-window. Experimental Neurology, 283(Pt
A):29–38.
Chen, L., El-Husseini, A., Tomita, S., Bredt, D. S., and Nicoll, R. A. (2003). Stargazin dif-
ferentially controls the trafficking of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate
and kainate receptors. Molecular Pharmacology, 64(3):703–706.
Chen, R.-Q., Wang, S.-H., Yao, W., Wang, J.-J., Ji, F., Yan, J.-Z., Ren, S.-Q., Chen,
Z., Liu, S.-Y., and Lu, W. (2011). Role of glycine receptors in glycine-induced LTD in
hippocampal CA1 pyramidal neurons. Neuropsychopharmacology, 36(9):1948–1958.
Chen, S.-R., Zhou, H.-Y., Byun, H. S., and Pan, H.-L. (2013). Nerve injury increases GluA2-
lacking AMPA receptor prevalence in spinal cords: functional significance and signaling
mechanisms. Journal of Pharmacology and Experimental Therapeutics, 347(3):765–772.
Chung, H. J., Xia, J., Scannevin, R. H., Zhang, X., and Huganir, R. L. (2000). Phos-
phorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction
with PDZ domain-containing proteins. The Journal of Neuroscience, 20(19):7258–7267.
Citraro, R., Aiello, R., Franco, V., Sarro, G. D., and Russo, E. (2014). Targeting α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. Expert Opinion
on Therapeutic Targets, 18(3):319–334.
Clayton, E. L., Evans, G. J. O., and Cousin, M. A. (2007). Activity-dependent control of
bulk endocytosis by protein dephosphorylation in central nerve terminals. The Journal
of Physiology, 585(Pt 3):687–691.
Clem, R. L. and Barth, A. (2006). Pathway-specific trafficking of native AMPARs by in
vivo experience. Neuron, 49(5):663–670.
Coan, E. J. and Collingridge, G. L. (1985). Magnesium ions block an N-methyl-D-aspartate
receptor-mediated component of synaptic transmission in rat hippocampus. Neuroscience
Letters, 53(1):21–26.
Collingridge, G. L., Isaac, J. T. R., and Wang, Y. T. (2004). Receptor trafficking and
synaptic plasticity. Nature Reviews Neuroscience, 5(12):952–962.
183
References
Colom, L. V. and Saggau, P. (1994). Spontaneous interictal-like activity originates in
multiple areas of the CA2-CA3 region of hippocampal slices. Journal of Neurophysiology,
71(4):1574–1585.
Colombo, E., Franceschetti, S., Avanzini, G., and Mantegazza, M. (2013). Phenytoin
inhibits the persistent sodium current in neocortical neurons by modifying its inactivation
properties. PLOS One, 8(1):e55329.
Condorelli, D. F., Belluardo, N., Mud, G., Dell’Albani, P., Jiang, X., and Giuffrida-Stella,
A. M. (1994). Changes in gene expression of AMPA-selective glutamate receptor subunits
induced by status epilepticus in rat brain. Neurochemistry International, 25(4):367–376.
Constals, A., Penn, A. C., Compans, B., Toulm, E., Phillipat, A., Marais, S., Retailleau, N.,
Hafner, A.-S., Coussen, F., Hosy, E., and Choquet, D. (2015). Glutamate-induced AMPA
receptor desensitization increases their mobility and modulates short-term plasticity
through unbinding from Stargazin. Neuron, 85(4):787–803.
Coombs, I. D., Soto, D., Zonouzi, M., Renzi, M., Shelley, C., Farrant, M., and Cull-Candy,
S. G. (2012). Cornichons modify channel properties of recombinant and glial AMPA
receptors. The Journal of Neuroscience, 32(29):9796–9804.
Cossart, R., Bernard, C., and Ben-Ari, Y. (2005). Multiple facets of GABAergic neurons
and synapses: multiple fates of GABA signalling in epilepsies. Trends in Neurosciences,
28(2):108–115.
Crill, W. E. (1996). Persistent sodium current in mammalian central neurons. Annual
Review of Physiology, 58:349–362.
Cross, J. H., Mclellan, A., Neal, E. G., Philip, S., Williams, E., and Williams, R. E. (2010).
The ketogenic diet in childhood epilepsy: where are we now? Archives of Disease in
Childhood, 95(7):550–553.
Cuadra, A. E., Kuo, S.-H., Kawasaki, Y., Bredt, D. S., and Chetkovich, D. M. (2004).
AMPA receptor synaptic targeting regulated by stargazin interactions with the Golgi-
resident PDZ protein nPIST. The Journal of Neuroscience, 24(34):7491–7502.
Cui, J., Zhang, M., Zhang, Y.-Q., and Xu, Z.-H. (2007). JNK pathway: diseases and
therapeutic potential. Acta Pharmacologica Sinica, 28(5):601–608.
184
References
Cull-Candy, S., Kelly, L., and Farrant, M. (2006). Regulation of Ca2+-permeable AMPA
receptors: synaptic plasticity and beyond. Current Opinion in Neurobiology, 16(3):288–
297.
Cummins, T. R., Xia, Y., and Haddad, G. G. (1994). Functional properties of rat and human
neocortical voltage-sensitive sodium currents. Journal of Neurophysiology, 71(3):1052–
1064.
Cunningham, M. O., Roopun, A., Schofield, I. S., Whittaker, R. G., Duncan, R., Russell,
A., Jenkins, A., Nicholson, C., Whittington, M. A., and Traub, R. D. (2012). Glissandi:
transient fast electrocorticographic oscillations of steadily increasing frequency, explained
by temporally increasing gap junction conductance. Epilepsia, 53(7):1205–1214.
Curia, G., Aracri, P., Colombo, E., Scalmani, P., Mantegazza, M., Avanzini, G., and
Franceschetti, S. (2007). Phosphorylation of sodium channels mediated by protein kinase-
C modulates inhibition by topiramate of tetrodotoxin-sensitive transient sodium current.
British Journal of Pharmacology, 150(6):792–797.
Danzer, S. C., He, X., and McNamara, J. O. (2004). Ontogeny of seizure-induced increases in
BDNF immunoreactivity and TrkB receptor activation in rat hippocampus. Hippocampus,
14(3):345–355.
de Curtis, M., Jefferys, J. G. R., and Avoli, M. (2012). Interictal epileptiform discharges in
partial epilepsy: complex neurobiological mechanisms based on experimental and clinical
evidence. In Noebels, J. L., Avoli, M., Rogawski, M. A., Olsen, R. W., and Delgado-
Escueta, A. V., editors, Jasper’s Basic Mechanisms of the Epilepsies. National Center for
Biotechnology Information (US), Bethesda (MD), 4th edition.
Deb, I., Manhas, N., Poddar, R., Rajagopal, S., Allan, A. M., Lombroso, P. J., Rosenberg,
G. A., Candelario-Jalil, E., and Paul, S. (2013). Neuroprotective role of a brain-enriched
tyrosine phosphatase, STEP, in focal cerebral ischemia. The Journal of Neuroscience,
33(45):17814–17826.
DeFelipe, J., Alonso-Nanclares, L., and Arellano, J. I. (2002). Microstructure of the
neocortex: Comparative aspects. Journal of Neurocytology, 31(3-5):299–316.
Delgado, J. Y., Coba, M., Anderson, C. N. G., Thompson, K. R., Gray, E. E., Heusner,
C. L., Martin, K. C., Grant, S. G. N., and ODell, T. J. (2007). NMDA receptor activation
185
References
dephosphorylates AMPA receptor glutamate receptor 1 subunits at Threonine 840. The
Journal of Neuroscience, 27(48):13210–13221.
Derkach, V., Barria, A., and Soderling, T. R. (1999). Ca2+/calmodulin-kinase II
enhances channel conductance of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type
glutamate receptors. Proceedings of the National Academy of Sciences of the United States
of America, 96(6):3269–3274.
Derkach, V. A., Oh, M. C., Guire, E. S., and Soderling, T. R. (2007). Regulatory mechanisms
of AMPA receptors in synaptic plasticity. Nature Reviews Neuroscience, 8(2):101–113.
Di Maio, R., Mastroberardino, P. G., Hu, X., Montero, L., and Greenamyre, J. T. (2011).
Pilocapine alters NMDA receptor expression and function in hippocampal neurons:
NADPH oxidase and ERK1/2 mechanisms. Neurobiology of Disease, 42(3):482–495.
Dias, R. B., Rombo, D. M., Ribeiro, J. A., and Sebastio, A. M. (2013). Ischemia-induced
synaptic plasticity drives sustained expression of calcium-permeable AMPA receptors in
the hippocampus. Neuropharmacology, 65:114–122.
Dineley, K. E., Votyakova, T. V., and Reynolds, I. J. (2003). Zinc inhibition of cellular
energy production: implications for mitochondria and neurodegeneration. Journal of
Neurochemistry, 85(3):563–570.
Doczi, J., Banczerowski-Pelyhe, I., Barna, B., and Vilagi, I. (1999). Effect of a glutamate
receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed
in rat cortical slices. Brain Research Bulletin, 49(6):435–440.
Dogini, D. B., Avansini, S., Schwambach Vieira, A., and Lopes-Cendes, I. (2013). MicroRNA
regulation and dysregulation in epilepsy. Frontiers in Cellular Neuroscience, 7:172.
Donevan, S. D. and Rogawski, M. A. (1993). GYKI 52466, a 2,3-benzodiazepine, is a
highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron,
10(1):51–59.
Dossi, E., Blauwblomme, T., Nabbout, R., Huberfeld, G., and Rouach, N. (2014). Multi-
electrode array recordings of human epileptic postoperative cortical tissue. Journal of
Visualized Experiments : JoVE, (92).
186
References
Dutta, R., Chomyk, A. M., Chang, A., Ribaudo, M. V., Deckard, S. A., Doud, M. K.,
Edberg, D. D., Bai, B., Li, M., Baranzini, S. E., Fox, R. J., Staugaitis, S. M., Macklin,
W. B., and Trapp, B. D. (2013). Hippocampal demyelination and memory dysfunction are
associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA
receptors. Annals of Neurology, 73(5):637–645.
Eckel, R., Szulc, B., Walker, M. C., and Kittler, J. T. (2014). Activation of calcineurin
underlies altered trafficking of α2 subunit containing GABAA receptors during prolonged
epileptiform activity. Neuropharmacology, 88:82–90.
Ehlers, M. D. (2000). Reinsertion or degradation of AMPA receptors determined by activity-
dependent endocytic sorting. Neuron, 28(2):511–525.
Einevoll, G. T., Kayser, C., Logothetis, N. K., and Panzeri, S. (2013). Modelling and
analysis of local field potentials for studying the function of cortical circuits. Nature
Reviews. Neuroscience, 14(11):770–785.
Ekonomou, A., Smith, A. L., and Angelatou, F. (2001). Changes in AMPA receptor
binding and subunit messenger RNA expression in hippocampus and cortex in the
pentylenetetrazole-induced ’kindling’ model of epilepsy. Brain Research. Molecular Brain
Research, 95(1-2):27–35.
Fox, C., Russell, K., Titterness, A., Yu, T., and Christie, B. (2007). Tyrosine phos-
phorylation of the GluR2 subunit is required for long-term depression of synaptic efficacy
in young animals in vivo. Hippocampus, 17(8):600–605.
Frampton, J. E. (2015). Perampanel: A review in drug-resistant epilepsy. Drugs,
75(14):1657–1668.
Francis, J., Jugloff, D. G., Mingo, N. S., Wallace, M. C., Jones, O. T., Burnham, W. M.,
and Eubanks, J. H. (1997). Kainic acid-induced generalized seizures alter the regional
hippocampal expression of the rat KV4.2 potassium channel gene. Neuroscience Letters,
232(2):91–94.
Frerking, M., Malenka, R. C., and Nicoll, R. A. (1998). Synaptic activation of kainate
receptors on hippocampal interneurons. Nature Neuroscience, 1(6):479–486.
187
References
Freund, T. and Buzsaki, G. (1996). Interneurons of the hippocampus. Hippocampus,
6(4):347–470.
Friedman, L. K. (2006). Calcium: a role for neuroprotection and sustained adaptation.
Molecular Interventions, 6(6):315–329.
Friedman, L. K., Pellegrini-Giampietro, D. E., Sperber, E. F., Bennett, M. V., Mosh, S. L.,
and Zukin, R. S. (1994). Kainate-induced status epilepticus alters glutamate and GABAA
receptor gene expression in adult rat hippocampus: an in situ hybridization study. The
Journal of Neuroscience, 14(5 Pt 1):2697–2707.
Friedman, L. K., Saghyan, A., Peinado, A., and Keesey, R. (2008). Age- and region-
dependent patterns of Ca2+ accumulations following status epilepticus. International
Journal of Developmental Neuroscience: The Official Journal of the International Society
for Developmental Neuroscience, 26(7):779–790.
Fritsch, G. (1870). Ueber Die Elektrische Erregbarkeit Des Grosshirns, volume 37. Arch
Anat Physiol Wissen.
Gan, Q., Salussolia, C. L., and Wollmuth, L. P. (2014). Assembly of AMPA receptors:
mechanisms and regulation. The Journal of Physiology, 593(Pt 1):39–48.
Gano, L. B., Patel, M., and Rho, J. M. (2014). Ketogenic diets, mitochondria, and neu-
rological diseases. Journal of Lipid Research, 55(11):2211–2228.
Gardinier, K. M., Gernert, D. L., Porter, W. J., Reel, J. K., Ornstein, P. L., Spinazze, P.,
Stevens, F. C., Hahn, P., Hollinshead, S. P., Mayhugh, D., Schkeryantz, J., Khilevich, A.,
De Frutos, O., Gleason, S. D., Kato, A. S., Luffer-Atlas, D., Desai, P. V., Swanson,
S., Burris, K. D., Ding, C., Heinz, B. A., Need, A. B., Barth, V. N., Stephenson,
G. A., Diseroad, B. A., Woods, T. A., Yu, H., Bredt, D., and Witkin, J. M. (2016).
Discovery of the first α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor antagonist dependent upon transmembrane AMPA receptor regulatory protein
(TARP) γ-8. Journal of Medicinal Chemistry, 59(10):4753–4768.
Gardner, S. M., Takamiya, K., Xia, J., Suh, J.-G., Johnson, R., Yu, S., and Huganir, R. L.
(2005). Calcium-permeable AMPA receptor plasticity is mediated by subunit-specific
interactions with PICK1 and NSF. Neuron, 45(6):903–915.
188
References
Geiger, J. R., Melcher, T., Koh, D. S., Sakmann, B., Seeburg, P. H., Jonas, P., and Monyer,
H. (1995). Relative abundance of subunit mRNAs determines gating and Ca2+ per-
meability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron,
15(1):193–204.
Gerace, E., Masi, A., Resta, F., Felici, R., Landucci, E., Mello, T., Pellegrini-Giampietro,
D. E., Mannaioni, G., and Moroni, F. (2014). PARP-1 activation causes neuronal death
in the hippocampal CA1 region by increasing the expression of Ca2+-permeable AMPA
receptors. Neurobiology of Disease, 70:43–52.
Goldfarb, M. (2011). Voltage-gated sodium channel-associated proteins and alternative
mechanisms of inactivation and block. Cellular and Molecular Life Sciences, 69(7):1067–
1076.
Gorter, J. A., Petrozzino, J. J., Aronica, E. M., Rosenbaum, D. M., Opitz, T., Bennett,
M. V., Connor, J. A., and Zukin, R. S. (1997). Global ischemia induces downregulation of
Glur2 mRNA and increases AMPA receptor-mediated Ca2+ influx in hippocampal CA1
neurons of gerbil. The Journal of Neuroscience, 17(16):6179–6188.
Gray, E. E., Fink, A. E., Sariana, J., Vissel, B., and O’Dell, T. J. (2007). Long-term
potentiation in the hippocampal CA1 region does not require insertion and activation of
GluR2-lacking AMPA receptors. Journal of Neurophysiology, 98(4):2488–2492.
Greco, T., Glenn, T. C., Hovda, D. A., and Prins, M. L. (2015). Ketogenic diet decreases
oxidative stress and improves mitochondrial respiratory complex activity. Journal of
Cerebral Blood Flow and Metabolism, 36(9):1603–1613.
Grooms, S. Y., Opitz, T., Bennett, M. V. L., and Zukin, R. S. (2000). Status epilepticus
decreases glutamate receptor 2 mRNA and protein expression in hippocampal pyramidal
cells before neuronal death. Proceedings of the National Academy of Sciences of the United
States of America, 97(7):3631–3636.
Guire, E. S., Oh, M. C., Soderling, T. R., and Derkach, V. A. (2008). Recruitment of
calcium-permeable AMPA receptors during synaptic potentiation is regulated by CaM-
Kinase I. The Journal of Neuroscience, 28(23):6000–6009.
Haidukewych, D., Forsythe, W. I., and Sills, M. (1982). Monitoring octanoic and decanoic
189
References
acids in plasma from children with intractable epilepsy treated with medium-chain
triglyceride diet. Clinical Chemistry, 28(4 Pt 1):642–645.
Hainmuller, T., Krieglstein, K., Kulik, A., and Bartos, M. (2014). Joint CP-AMPA and
group I mGlu receptor activation is required for synaptic plasticity in dentate gyrus fast-
spiking interneurons. Proceedings of the National Academy of Sciences of the United
States of America, 111(36):13211–13216.
Hajos, N. and Paulsen, O. (2009). Network mechanisms of gamma oscillations in the CA3
region of the hippocampus. Neural Networks: The Official Journal of the International
Neural Network Society, 22(8):1113–1119.
Halpain, S., Hipolito, A., and Saffer, L. (1998). Regulation of F-actin stability in dendritic
spines by glutamate receptors and calcineurin. The Journal of Neuroscience, 18(23):9835–
9844.
Hamill, O., Huguenard, J., and Prince, D. (1991). Patch-clamp studies of voltage-gated
currents in identified neurons of the rat cerebral cortex. Cerebral Cortex, 1(1):48–61.
Hanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A.,
Hatakeyama, S., Ohgoh, M., Ueno, M., and Nishizawa, Y. (2011). Perampanel: a novel,
orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in
rodent models of epilepsy. Epilepsia, 52(7):1331–1340.
Hanley, J. G. (2008). PICK1: a multi-talented modulator of AMPA receptor trafficking.
Pharmacology & Therapeutics, 118(1):152–160.
Hanley, J. G., Khatri, L., Hanson, P. I., and Ziff, E. B. (2002). NSF ATPase and α-/β-
SNAPs disassemble the AMPA receptor-PICK1 complex. Neuron, 34(1):53–67.
Hao, G.-W., Chen, Y.-S., He, D.-M., Wang, H.-Y., Wu, G.-H., and Zhang, B. (2015).
Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or
without omega-3 fatty acids and medium-chain triglycerides. Asian Pacific Journal of
Cancer Prevention, 16(5):2061–2068.
Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs oppose
synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neu-
roscience, 5(5):405–414.
190
References
Hartveit, E. and Veruki, M. L. (2006). Studying properties of neurotransmitter receptors by
non-stationary noise analysis of spontaneous synaptic currents. The Journal of Physiology,
574(3):751–785.
Hayashi, T. and Huganir, R. L. (2004). Tyrosine phosphorylation and regulation of the
AMPA receptor by Src family tyrosine kinases. The Journal of Neuroscience, 24(27):6152–
6160.
Hayashi, Y., Shi, S. H., Esteban, J. A., Piccini, A., Poncer, J. C., and Malinow, R. (2000).
Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and
PDZ domain interaction. Science (New York, N.Y.), 287(5461):2262–2267.
He, K., Song, L., Cummings, L. W., Goldman, J., Huganir, R. L., and Lee, H.-K. (2009).
Stabilization of Ca2+-permeable AMPA receptors at perisynaptic sites by GluR1-S845
phosphorylation. Proceedings of the National Academy of Sciences of the United States
of America, 106(47):20033–20038.
Henderson, S. T., Vogel, J. L., Barr, L. J., Garvin, F., Jones, J. J., and Costantini, L. C.
(2009). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a
randomized, double-blind, placebo-controlled, multicenter trial. Nutrition & Metabolism,
6:31.
Herguedas, B., Garca-Nafra, J., Cais, O., Fernndez-Leiro, R., Krieger, J., Ho, H., and
Greger, I. H. (2016). Structure and organization of heteromeric AMPA-type glutamate
receptors. Science (New York, N.Y.), 352(6285).
Ho, M. T.-W., Pelkey, K. A., Topolnik, L., Petralia, R. S., Takamiya, K., Xia, J., Huganir,
R. L., Lacaille, J.-C., and McBain, C. J. (2007). Developmental expression of Ca2+-
permeable AMPA receptors underlies depolarization-induced long-term depression at
mossy fiber CA3 pyramid synapses. The Journal of Neuroscience, 27(43):11651–11662.
Hodgkin, A. L. and Huxley, A. F. (1952). A quantitative description of membrane current
and its application to conduction and excitation in nerve. The Journal of Physiology,
117(4):500–544.
Hou, Q., Zhang, D., Jarzylo, L., Huganir, R. L., and Man, H.-Y. (2008). Homeostatic
regulation of AMPA receptor expression at single hippocampal synapses. Proceedings of
the National Academy of Sciences of the United States of America, 105(2):775–780.
191
References
Houser, C. R. (1990). Granule cell dispersion in the dentate gyrus of humans with temporal
lobe epilepsy. Brain Research, 535(2):195–204.
Howard, M. A., Elias, G. M., Elias, L. A. B., Swat, W., and Nicoll, R. A. (2010). The role
of SAP97 in synaptic glutamate receptor dynamics. Proceedings of the National Academy
of Sciences of the United States of America, 107(8):3805–3810.
Hu, Y., Jiang, L., Chen, H., and Zhang, X. (2012). Expression of AMPA receptor subunits
in hippocampus after status convulsion. Child’s Nervous System, 28(6):911–918.
Huang, R. Q., Bell-Horner, C. L., Dibas, M. I., Covey, D. F., Drewe, J. A., and Dillon, G. H.
(2001). Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid
type A (GABAA) receptors: mechanism and site of action. The Journal of Pharmacology
and Experimental Therapeutics, 298(3):986–995.
Huberfeld, G., Menendez de la Prida, L., Pallud, J., Cohen, I., Le Van Quyen, M., Adam,
C., Clemenceau, S., Baulac, M., and Miles, R. (2011). Glutamatergic pre-ictal discharges
emerge at the transition to seizure in human epilepsy. Nature Neuroscience, 14(5):627–
634.
Huberfeld, G., Wittner, L., Clemenceau, S., Baulac, M., Kaila, K., Miles, R., and Rivera,
C. (2007). Perturbed chloride homeostasis and GABAergic signaling in human temporal
lobe epilepsy. The Journal of Neuroscience, 27(37):9866–9873.
Hughes, S. D., Kanabus, M., Anderson, G., Hargreaves, I. P., Rutherford, T., Donnell,
M. O., Cross, J. H., Rahman, S., Eaton, S., and Heales, S. J. R. (2014). The ketogenic
diet component decanoic acid increases mitochondrial citrate synthase and complex I
activity in neuronal cells. Journal of Neurochemistry, 129(3):426–433.
Huie, J. R., Stuck, E. D., Lee, K. H., Irvine, K.-A., Beattie, M. S., Bresnahan, J. C.,
Grau, J. W., and Ferguson, A. R. (2015). AMPA receptor phosphorylation and synaptic
colocalization on motor neurons drive maladaptive plasticity below complete spinal cord
injury. eneuro, 2(5).
Hume, R. I., Dingledine, R., and Heinemann, S. F. (1991). Identification of a site in
glutamate receptor subunits that controls calcium permeability. Science (New York,
N.Y.), 253(5023):1028–1031.
192
References
Husson, T. R., Mallik, A. K., Zhang, J. X., and Issa, N. P. (2007). Functional imaging of
primary visual cortex using flavoprotein autofluorescence. The Journal of Neuroscience,
27(32):8665–8675.
Huttenlocher, P. R., Wilbourn, A. J., and Signore, J. M. (1971). Medium-chain triglycerides
as a therapy for intractable childhood epilepsy. Neurology, 21(11):1097–1103.
Itakura, M., Watanabe, I., Sugaya, T., and Takahashi, M. (2014). Direct association of
the unique C-terminal tail of transmembrane AMPA receptor regulatory protein γ-8 with
calcineurin. FEBS Journal, 281(5):1366–1378.
Jackson, A. C., Milstein, A. D., Soto, D., Farrant, M., Cull-Candy, S. G., and Nicoll,
R. A. (2011). Probing TARP modulation of AMPA receptor conductance with polyamine
toxins. The Journal of Neuroscience, 31(20):7511–7520.
Jang, S.-S., Royston, S. E., Lee, G., Wang, S., and Chung, H. J. (2016). Seizure-induced
regulations of Amyloid-β, STEP61, and STEP61 substrates involved in hippocampal
synaptic plasticity. Neural Plasticity, 2016:2123748.
Jang, S.-S., Royston, S. E., Xu, J., Cavaretta, J. P., Vest, M. O., Lee, K. Y., Lee, S., Jeong,
H. G., Lombroso, P. J., and Chung, H. J. (2015). Regulation of STEP61 and tyrosine-
phosphorylation of NMDA and AMPA receptors during homeostatic synaptic plasticity.
Molecular Brain, 8:55.
Jeong, E. A., Jeon, B. T., Shin, H. J., Kim, N., Lee, D. H., Kim, H. J., Kang, S. S., Cho,
G. J., Choi, W. S., and Roh, G. S. (2011). Ketogenic diet-induced peroxisome proliferator-
activated receptor- activation decreases neuroinflammation in the mouse hippocampus
after kainic acid-induced seizures. Experimental Neurology, 232(2):195–202.
Jones, R. S. G., da Silva, A. B., Whittaker, R. G., Woodhall, G. L., and Cunningham, M. O.
(2016). Human brain slices for epilepsy research: Pitfalls, solutions and future challenges.
Journal of Neuroscience Methods, 260:221–232.
Ju, W., Morishita, W., Tsui, J., Gaietta, G., Deerinck, T. J., Adams, S. R., Garner, C. C.,
Tsien, R. Y., Ellisman, M. H., and Malenka, R. C. (2004). Activity-dependent regulation
of dendritic synthesis and trafficking of AMPA receptors. Nature Neuroscience, 7(3):244–
253.
193
References
Kamceva, M., Benedict, J., Nairn, A. C., Lombroso, P. J., Kamceva, M., Benedict, J.,
Nairn, A. C., and Lombroso, P. J. (2016). Role of striatal-enriched tyrosine phosphatase
in neuronal function. Neural Plasticity, Neural Plasticity, 2016, 2016:e8136925.
Kato, A. S., Gill, M. B., Ho, M. T., Yu, H., Tu, Y., Siuda, E. R., Wang, H., Qian, Y.-W.,
Nisenbaum, E. S., Tomita, S., and Bredt, D. S. (2010). Hippocampal AMPA receptor
gating controlled by both TARP and cornichon proteins. Neuron, 68(6):1082–1096.
Kato, A. S., Zhou, W., Milstein, A. D., Knierman, M. D., Siuda, E. R., Dotzlaf, J. E.,
Yu, H., Hale, J. E., Nisenbaum, E. S., Nicoll, R. A., and Bredt, D. S. (2007). New
transmembrane AMPA receptor regulatory protein isoform, γ-7, differentially regulates
AMPA receptors. The Journal of Neuroscience, 27(18):4969–4977.
Khosravani, H., Bladen, C., Parker, D. B., Snutch, T. P., McRory, J. E., and Zamponi, G. W.
(2005). Effects of CaV3.2 channel mutations linked to idiopathic generalized epilepsy.
Annals of Neurology, 57(5):745–749.
Kim, D. Y., Davis, L. M., Sullivan, P. G., Maalouf, M., Simeone, T. A., Brederode, J. v.,
and Rho, J. M. (2007). Ketone bodies are protective against oxidative stress in neocortical
neurons. Journal of Neurochemistry, 101(5):1316–1326.
Kim, D. Y., Simeone, K. A., Simeone, T. A., Pandya, J. D., Wilke, J. C., Ahn, Y., Geddes,
J. W., Sullivan, P. G., and Rho, J. M. (2015a). Ketone bodies mediate antiseizure effects
through mitochondrial permeability transition. Annals of Neurology, 78(1):77–87.
Kim, J.-E., Kim, Y.-J., Kim, J. Y., and Kang, T.-C. (2014). PARP1 activation/expression
modulates regional-specific neuronal and glial responses to seizure in a hemodynamic-
independent manner. Cell Death & Disease, 5(8):e1362.
Kim, S., Titcombe, R. F., Zhang, H., Khatri, L., Girma, H. K., Hofmann, F., Arancio, O.,
and Ziff, E. B. (2015b). Network compensation of cyclic GMP-dependent protein kinase
II knockout in the hippocampus by Ca2+-permeable AMPA receptors. Proceedings of the
National Academy of Sciences of the United States of America.
Kim, S. and Ziff, E. B. (2014). Calcineurin mediates synaptic scaling via synaptic trafficking
of Ca2+-permeable AMPA receptors. PLoS biology, 12(7):e1001900.
194
References
Kinsman, S. L., Vining, E. P., Quaskey, S. A., Mellits, D., and Freeman, J. M. (1992).
Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases.
Epilepsia, 33(6):1132–1136.
Kobayashi, E., Li, L. M., Lopes-Cendes, I., and Cendes, F. (2002). Magnetic resonance
imaging evidence of hippocampal sclerosis in asymptomatic, first-degree relatives of
patients with familial mesial temporal lobe epilepsy. Archives of Neurology, 59(12):1891–
1894.
Kott, S., Sager, C., Tapken, D., Werner, M., and Hollmann, M. (2009). Comparative
analysis of the pharmacology of GluR1 in complex with transmembrane AMPA receptor
regulatory proteins γ-2, γ-3, γ-4, and γ-8. Neuroscience, 158(1):78–88.
Kovac, S., Domijan, A.-M., Walker, M. C., and Abramov, A. Y. (2012). Prolonged seizure
activity impairs mitochondrial bioenergetics and induces cell death. Journal of Cell
Science, 125(Pt 7):1796–1806.
Kovac, S., Domijan, A.-M., Walker, M. C., and Abramov, A. Y. (2014). Seizure activity
results in calcium- and mitochondria-independent ROS production via NADPH and
xanthine oxidase activation. Cell Death & Disease, 5:e1442.
Krestel, H. E., Shimshek, D. R., Jensen, V., Nevian, T., Kim, J., Geng, Y., Bast, T.,
Depaulis, A., Schonig, K., Schwenk, F., Bujard, H., Hvalby, i., Sprengel, R., and Seeburg,
P. H. (2004). A genetic switch for epilepsy in adult mice. The Journal of Neuroscience,
24(46):10568–10578.
Kumar, S. S., Bacci, A., Kharazia, V., and Huguenard, J. R. (2002). A developmental
switch of AMPA receptor subunits in neocortical pyramidal neurons. The Journal of
Neuroscience, 22(8):3005–3015.
Kurz, J. E., Sheets, D., Parsons, J. T., Rana, A., Delorenzo, R. J., and Churn, S. B. (2001).
A significant increase in both basal and maximal calcineurin activity in the rat pilocarpine
model of status epilepticus. Journal of Neurochemistry, 78(2):304–315.
Lamsa, K. P., Heeroma, J. H., Somogyi, P., Rusakov, D. A., and Kullmann, D. M. (2007).
Anti-Hebbian long-term potentiation in the hippocampal feedback inhibitory circuit.
Science (New York, N.Y.), 315(5816):1262–1266.
195
References
Laschet, J., Trottier, S., Leviel, V., Guibert, B., Bansard, J. Y., Chauvel, P., and Bureau,
M. (1999). Heterogeneous distribution of polyamines in temporal lobe epilepsy. Epilepsy
Research, 35(2):161–172.
Lee, H.-K. (2006). AMPA receptor phosphorylation in synaptic plasticity: insights from
knockin mice. In Kittler, J. T. and Moss, S. J., editors, The Dynamic Synapse: Molecular
Methods in Ionotropic Receptor Biology, Frontiers in Neuroscience. CRC Press/Taylor &
Francis, Boca Raton (FL).
Lee, K. H., Won, R., Kim, U. J., Kim, G. M., Chung, M.-A., Sohn, J.-H., and Lee,
B. H. (2010). Neuroprotective effects of FK506 against excitotoxicity in organotypic
hippocampal slice culture. Neuroscience Letters, 474(3):126–130.
Lehmkuhle, M. J., Thomson, K. E., Scheerlinck, P., Pouliot, W., Greger, B., and Dudek,
F. E. (2009). A simple quantitative method for analyzing electrographic status epilepticus
in rats. Journal of Neurophysiology, 101(3):1660–1670.
Lennox, W. G. and Cobb, S. (1928). Epilepsy: From the standpoint of physiology and
treatment. Medicine, 7(2):105–290.
Li, W., Xu, X., and Pozzo-Miller, L. (2016). Excitatory synapses are stronger in the
hippocampus of Rett syndrome mice due to altered synaptic trafficking of AMPA-type
glutamate receptors. Proceedings of the National Academy of Sciences of the United States
of America, page 201517244.
Likhodii, S. S., Musa, K., Mendonca, A., Dell, C., Burnham, W. M., and Cunnane, S. C.
(2000). Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia,
41(11):1400–1410.
Lin, D.-T., Makino, Y., Sharma, K., Hayashi, T., Neve, R., Takamiya, K., and Huganir, R. L.
(2009). Regulation of AMPA receptor extrasynaptic insertion by 4.1n, phosphorylation
and palmitoylation. Nature Neuroscience, 12(7):879–887.
Lippman-Bell, J. J., Zhou, C., Sun, H., Feske, J. S., and Jensen, F. E. (2016). Early-
life seizures alter synaptic calcium-permeable AMPA receptor function and plasticity.
Molecular and Cellular Neurosciences, 76:11–20.
196
References
Liu, S. J. and Zukin, R. S. (2007). Ca2+-permeable AMPA receptors in synaptic plasticity
and neuronal death. Trends in Neurosciences, 30(3):126–134.
Liu, S.-Q. J. and Cull-Candy, S. G. (2000). Synaptic activity at calcium-permeable AMPA
receptors induces a switch in receptor subtype. Nature, 405(6785):454–458.
Liu, Y.-m. C. (2008). Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia, 49
Suppl 8:33–36.
Loddenkemper, T., Talos, D. M., Cleary, R. T., Joseph, A., Snchez Fernndez, I.,
Alexopoulos, A., Kotagal, P., Najm, I., and Jensen, F. E. (2014). Subunit composition
of glutamate and γ-aminobutyric acid receptors in status epilepticus. Epilepsy Research,
108(4):605–615.
Loscher, W. (2011). Critical review of current animal models of seizures and epilepsy used
in the discovery and development of new antiepileptic drugs. Seizure, 20(5):359–368.
Loscher, W., Klitgaard, H., Twyman, R. E., and Schmidt, D. (2013). New avenues for anti-
epileptic drug discovery and development. Nature Reviews. Drug Discovery, 12(10):757–
776.
Loweth, J. A., Scheyer, A. F., Milovanovic, M., LaCrosse, A. L., Flores-Barrera, E., Werner,
C. T., Li, X., Ford, K. A., Le, T., Olive, M. F., Szumlinski, K. K., Tseng, K. Y., and Wolf,
M. E. (2014). Synaptic depression via mGluR1 positive allosteric modulation suppresses
cue-induced cocaine craving. Nature Neuroscience, 17(1):73–80.
Lu, W., Isozaki, K., Roche, K. W., and Nicoll, R. A. (2010). Synaptic targeting of AMPA
receptors is regulated by a CaMKII site in the first intracellular loop of GluA1. Proceedings
of the National Academy of Sciences of the United States of America, 107(51):22266–
22271.
Lu, W. and Roche, K. W. (2012). Posttranslational regulation of AMPA receptor trafficking
and function. Current Opinion in Neurobiology, 22(3):470–479.
Lu, W., Shi, Y., Jackson, A. C., Bjorgan, K., During, M. J., Sprengel, R., Seeburg, P. H.,
and Nicoll, R. A. (2009). Subunit composition of synaptic AMPA receptors revealed by
a single-cell genetic approach. Neuron, 62(2):254–268.
197
References
Lu, Y., Zhong, C., Wang, L., Wei, P., He, W., Huang, K., Zhang, Y., Zhan, Y., Feng, G.,
and Wang, L. (2016). Optogenetic dissection of ictal propagation in the hippocampal-
entorhinal cortex structures. Nature Communications, 7:10962.
Lu, Z., Jiang, Y.-P., Wu, C.-Y. C., Ballou, L. M., Liu, S., Carpenter, E. S., Rosen,
M. R., Cohen, I. S., and Lin, R. Z. (2013). Increased persistent sodium current due to
decreased PI3k signaling contributes to QT prolongation in the diabetic heart. Diabetes,
62(12):4257–4265.
Lutas, A. and Yellen, G. (2013). The ketogenic diet: metabolic influences on brain ex-
citability and epilepsy. Trends in Neurosciences, 36(1):32–40.
Ma, W., Berg, J., and Yellen, G. (2007). Ketogenic diet metabolites reduce firing in central
neurons by opening K(ATP) channels. The Journal of Neuroscience, 27(14):3618–3625.
Magiorkinis, E., Diamantis, A., Sidiropoulou, K., Panteliadis, C., Magiorkinis, E.,
Diamantis, A., Sidiropoulou, K., and Panteliadis, C. (2014). Highights in the history
of epilepsy: The last 200 years, highights in the history of epilepsy: The last 200 years.
Epilepsy Research and Treatment, Epilepsy Research and Treatment, 2014, 2014:e582039.
Magistretti, J. and Alonso, A. (2002). Fine gating properties of channels responsible for
persistent sodium current generation in entorhinal cortex neurons. The Journal of General
Physiology, 120(6):855–873.
Maher, M. P., Wu, N., Ravula, S., Ameriks, M. K., Savall, B. M., Liu, C., Lord, B., Wyatt,
R. M., Matta, J. A., Dugovic, C., Yun, S., Donck, L. V., Steckler, T., Wickenden, A. D.,
Carruthers, N. I., and Lovenberg, T. W. (2016). Discovery and characterization of AMPA
receptor modulators selective for TARP γ-8. Journal of Pharmacology and Experimental
Therapeutics, 357(2):394–414.
Malkin, S. L., Amakhin, D. V., Veniaminova, E. A., Kim, K. K., Zubareva, O. E.,
Magazanik, L. G., and Zaitsev, A. V. (2016). Changes of AMPA receptor properties
in the neocortex and hippocampus following pilocarpine-induced status epilepticus in
rats. Neuroscience, 327:146–155.
Mangan, P. S. and Kapur, J. (2004). Factors underlying bursting behavior in a network of
cultured hippocampal neurons exposed to zero magnesium. Journal of Neurophysiology,
91(2):946–957.
198
References
Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., and Avoli, M. (2010). Voltage-
gated sodium channels as therapeutic targets in epilepsy and other neurological disorders.
The Lancet. Neurology, 9(4):413–424.
Marban, E., Yamagishi, T., and Tomaselli, G. F. (1998). Structure and function of voltage-
gated sodium channels. The Journal of Physiology, 508(Pt 3):647–657.
Marciani, M. G., Gotman, J., Andermann, F., and Olivier, A. (1985). Patterns of seizure
activation after withdrawal of antiepileptic medication. Neurology, 35(11):1537–1543.
Matsuda, S., Launey, T., Mikawa, S., and Hirai, H. (2000). Disruption of AMPA receptor
GluR2 clusters following long-term depression induction in cerebellar Purkinje neurons.
The EMBO Journal, 19(12):2765–2774.
Mattison, H., Bagal, A., Mohammadi, M., Pulimood, N., Reich, C., Alger, B., Kao, J., and
Thompson, S. (2014). Evidence of calcium-permeable AMPA receptors in dendritic spines
of CA1 pyramidal neurons. Journal of Neurophysiology, 112(2):263–275.
McGee, T. P., Bats, C., Farrant, M., and Cull-Candy, S. G. (2015). Auxiliary subunit
GSG1l acts to suppress calcium-permeable AMPA receptor function. The Journal of
Neuroscience, 35(49):16171–16179.
Meldrum, B. S. (1993). Excitotoxicity and selective neuronal loss in epilepsy. Brain
Pathology (Zurich, Switzerland), 3(4):405–412.
Meldrum, B. S. and Rogawski, M. A. (2007). Molecular targets for antiepileptic drug
development. Neurotherapeutics: The Journal of the American Society for Experimental
NeuroTherapeutics, 4(1):18–61.
Menuz, K., Stroud, R. M., Nicoll, R. A., and Hays, F. A. (2007). TARP auxiliary subunits
switch AMPA receptor antagonists into partial agonists. Science, 318(5851):815–817.
Mohan, H., Verhoog, M. B., Doreswamy, K. K., Eyal, G., Aardse, R., Lodder, B. N.,
Goriounova, N. A., Asamoah, B., Brakspear, A. B. C. B., Groot, C., Sluis, S. v. d., Testa-
Silva, G., Obermayer, J., Boudewijns, Z. S. R. M., Narayanan, R. T., Baayen, J. C., Segev,
I., Mansvelder, H. D., and Kock, C. P. J. d. (2015). Dendritic and axonal architecture of
individual pyramidal neurons across layers of adult human neocortex. Cerebral Cortex,
25(12):4839–4853.
199
References
Morace, R., DI Gennaro, G., Quarato, P., D’Aniello, A., Mascia, A., Grammaldo, L.,
DE Risi, M., Sparano, A., DE Angelis, M., DI Cola, F., Solari, D., and Esposito, V.
(2016). Deep brain stimulation for intractable epilepsy. Journal of Neurosurgical Sciences,
60(2).
Morita, D., Rah, J., and Isaac, J. (2014). Incorporation of inwardly rectifying AMPA
receptors at silent synapses during hippocampal long-term potentiation. Philosophical
Transactions of the Royal Society B: Biological Sciences, 369(1633):20130156.
Morris, G., Jiruska, P., Jefferys, J. G. R., and Powell, A. D. (2016). A New Approach
of Modified Submerged Patch Clamp Recording Reveals Interneuronal Dynamics during
Epileptiform Oscillations. Frontiers in Neuroscience, 10:519.
Mosbacher, J., Schoepfer, R., Monyer, H., Burnashev, N., Seeburg, P. H., and Ruppersberg,
J. P. (1994). A molecular determinant for submillisecond desensitization in glutamate
receptors. Science (New York, N.Y.), 266(5187):1059–1062.
Mylona, A., Theillet, F.-X., Foster, C., Cheng, T. M., Miralles, F., Bates, P. A., Selenko,
P., and Treisman, R. (2016). Opposing effects of Elk-1 multisite phosphorylation shape
its response to ERK activation. Science, 354(6309):233–237.
Nakazawa, T., Komai, S., Tezuka, T., Hisatsune, C., Umemori, H., Semba, K., Mishina,
M., Manabe, T., and Yamamoto, T. (2001). Characterization of Fyn-mediated tyrosine
phosphorylation sites on glur2 (NR2b) subunit of the N-methyl-D-aspartate receptor. The
Journal of Biological Chemistry, 276(1):693–699.
Nebeling, L. C., Miraldi, F., Shurin, S. B., and Lerner, E. (1995). Effects of a ketogenic
diet on tumor metabolism and nutritional status in pediatric oncology patients: two case
reports. Journal of the American College of Nutrition, 14(2):202–208.
Neuman, R., Cherubini, E., and Ben-Ari, Y. (1988). Epileptiform bursts elicited in CA3
hippocampal neurons by a variety of convulsants are not blocked by N-methyl-D-aspartate
antagonists. Brain Research, 459(2):265–274.
Nishimura, T., Imai, H., Minabe, Y., Sawa, A., and Kato, N. (2006). Beneficial effects of
FK506 for experimental temporal lobe epilepsy. Neuroscience Research, 56(4):386–390.
200
References
Noh, K.-M., Hwang, J.-Y., Follenzi, A., Athanasiadou, R., Miyawaki, T., Greally, J. M.,
Bennett, M. V. L., and Zukin, R. S. (2012). Repressor element-1 silencing transcription
factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal
death. Proceedings of the National Academy of Sciences of the United States of America,
109(16):962–971.
Noh, K.-M., Yokota, H., Mashiko, T., Castillo, P. E., Zukin, R. S., and Bennett, M. V. L.
(2005). Blockade of calcium-permeable AMPA receptors protects hippocampal neurons
against global ischemia-induced death. Proceedings of the National Academy of Sciences
of the United States of America, 102(34):12230–12235.
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., and Prochiantz, A. (1984). Magnesium
gates glutamate-activated channels in mouse central neurones. Nature, 307(5950):462–
465.
Oberheim, N. A., Takano, T., Han, X., He, W., Lin, J. H. C., Wang, F., Xu, Q., Wyatt, J. D.,
Pilcher, W., Ojemann, J. G., Ransom, B. R., Goldman, S. A., and Nedergaard, M. (2009).
Uniquely hominid features of adult human astrocytes. The Journal of Neuroscience,
29(10):3276–3287.
O’Brien, J. E. and Meisler, M. H. (2013). Sodium channel SCN8a (NaV1.6): properties and
de novo mutations in epileptic encephalopathy and intellectual disability. Behavioral and
Psychiatric Genetics, 4:213.
Ogoshi, F., Yin, H. Z., Kuppumbatti, Y., Song, B., Amindari, S., and Weiss, J. H. (2005).
Tumor necrosis-factor-alpha (TNF-α) induces rapid insertion of Ca2+-permeable α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/kainate (Ca-A/K) channels
in a subset of hippocampal pyramidal neurons. Experimental Neurology, 193(2):384–393.
Oh, M. C., Derkach, V. A., Guire, E. S., and Soderling, T. R. (2006). Extrasynaptic
membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA
receptors for long-term potentiation. The Journal of Biological Chemistry, 281(2):752–
758.
Opazo, P., Labrecque, S., Tigaret, C. M., Frouin, A., Wiseman, P. W., De Koninck, P.,
and Choquet, D. (2010). CaMKII triggers the diffusional trapping of surface AMPARs
through phosphorylation of stargazin. Neuron, 67(2):239–252.
201
References
Ota, Y., Zanetti, A. T., Hallock, R. M., Ota, Y., Zanetti, A. T., and Hallock, R. M. (2013).
The role of astrocytes in the regulation of synaptic plasticity and memory formation, the
role of astrocytes in the regulation of synaptic plasticity and memory formation. Neural
Plasticity, Neural Plasticity, 2013, 2013:e185463.
Otto, C., Kaemmerer, U., Illert, B., Muehling, B., Pfetzer, N., Wittig, R., Voelker, H. U.,
Thiede, A., and Coy, J. F. (2008). Growth of human gastric cancer cells in nude mice
is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain
triglycerides. BMC Cancer, 8:122.
Pal, S., Sombati, S., Limbrick Jr., D. D., and DeLorenzo, R. J. (1999). In vitro status
epilepticus causes sustained elevation of intracellular calcium levels in hippocampal
neurons. Brain Research, 851(12):20–31.
Pandey, S. P., Rai, R., Gaur, P., and Prasad, S. (2015). Development- and age-related
alterations in the expression of AMPA receptor subunit GluR2 and its trafficking proteins
in the hippocampus of male mouse brain. Biogerontology, 16(3):317–328.
Parent, J. M., Janumpalli, S., McNamara, J. O., and Lowenstein, D. H. (1998). Increased
dentate granule cell neurogenesis following amygdala kindling in the adult rat. Neu-
roscience Letters, 247(1):9–12.
Park, P., Sanderson, T. M., Amici, M., Choi, S.-L., Bortolotto, Z. A., Zhuo, M., Kaang,
B.-K., and Collingridge, G. L. (2016). Calcium-permeable AMPA receptors mediate the
induction of the protein kinase A-dependent component of long-term potentiation in the
hippocampus. The Journal of Neuroscience, 36(2):622–631.
Park, Y. Y., Johnston, D., and Gray, R. (2013). Slowly inactivating component of Na+
current in peri-somatic region of hippocampal CA1 pyramidal neurons. Journal of Neu-
rophysiology, 109(5):1378–1390.
Passafaro, M., Pich, V., and Sheng, M. (2001). Subunit-specific temporal and spatial
patterns of AMPA receptor exocytosis in hippocampal neurons. Nature Neuroscience,
4(9):917–926.
Paul, S., Nairn, A. C., Wang, P., and Lombroso, P. J. (2003). NMDA-mediated activation
of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nature Neu-
roscience, 6(1):34–42.
202
References
Paxinos, G., Watson, C., Pennisi, M., and Topple, A. (1985). Bregma, lambda and the
interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight.
Journal of Neuroscience Methods, 13(2):139–143.
Payandeh, J., Scheuer, T., Zheng, N., and Catterall, W. A. (2011). The crystal structure of
a voltage-gated sodium channel. Nature, 475(7356):353–358.
Payne, N. E., Cross, J. H., Sander, J. W., and Sisodiya, S. M. (2011). The ketogenic and
related diets in adolescents and adultsA review. Epilepsia, 52(11):1941–1948.
Pedersen, S., Kvist, T., Rathje, M., Bruner-Osborne, H., Andreassen, T., and Madsen, K.
(2016). Novel combination of calcium and pH biosensors reveals pyruvate as an inhibitor
of ionotropic glutamate receptors. In FENS abstract book.
Peng, P. L., Zhong, X., Tu, W., Soundarapandian, M. M., Molner, P., Zhu, D., Lau, L., Liu,
S., Liu, F., and Lu, Y. (2006). ADAR2-dependent RNA editing of AMPA receptor subunit
GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron, 49(5):719–733.
Plant, K., Pelkey, K. A., Bortolotto, Z. A., Morita, D., Terashima, A., McBain, C. J.,
Collingridge, G. L., and Isaac, J. T. R. (2006). Transient incorporation of native
GluR2-lacking AMPA receptors during hippocampal long-term potentiation. Nature Neu-
roscience, 9(5):602–604.
Poon, M. M. and Chen, L. (2008). Retinoic acid-gated sequence-specific translational control
by RARα. Proceedings of the National Academy of Sciences of the United States of
America, 105(51):20303–20308.
Psarropoulou, C. and Avoli, M. (1992). CPP, an NMDA-receptor antagonist, blocks 4-
aminopyridine-induced spreading depression episodes but not epileptiform activity in
immature rat hippocampal slices. Neuroscience Letters, 135(1):139–143.
Pulsifer, M. B., Gordon, J. M., Brandt, J., Vining, E. P., and Freeman, J. M. (2001). Effects
of ketogenic diet on development and behaviour: preliminary report of a prospective study.
Developmental Medicine and Child Neurology, 43(5):301–306.
Qiao, X., Werkman, T. R., Gorter, J. A., Wadman, W. J., and van Vliet, E. A. (2013).
Expression of sodium channel α subunits 1.1, 1.2 and 1.6 in rat hippocampus after kainic
acid-induced epilepsy. Epilepsy Research, 106(12):17–28.
203
References
Quirk, J. C., Siuda, E. R., and Nisenbaum, E. S. (2004). Molecular determinants responsible
for differences in desensitization kinetics of AMPA receptor splice variants. The Journal
of Neuroscience, 24(50):11416–11420.
Racine, R. J. (1972). Modification of seizure activity by electrical stimulation. I. After-
discharge threshold. Electroencephalography and Clinical Neurophysiology, 32(3):269–279.
Ragsdale, D. S. and Avoli, M. (1998). Sodium channels as molecular targets for antiepileptic
drugs. Brain Research Reviews, 26(1):16–28.
Raimondo, J. V., Burman, R. J., Katz, A. A., and Akerman, C. J. (2015). Ion dynamics
during seizures. Frontiers in Cellular Neuroscience, 9:419.
Rajasekaran, K., Todorovic, M., and Kapur, J. (2012). Calcium-permeable AMPA receptors
are expressed in a rodent model of status epilepticus. Annals of Neurology, 72(1):91–102.
Rakhade, S. N., Fitzgerald, E. F., Klein, P. M., Zhou, C., Sun, H., Huganir, R. L.,
and Jensen, F. E. (2012). Glutamate receptor 1 phosphorylation at Serine 831 and
845 modulates seizure susceptibility and hippocampal hyperexcitability after early life
seizures. Journal of Neuroscience, 32(49):17800–17812.
Rakhade, S. N., Zhou, C., Aujla, P. K., Fishman, R., Sucher, N. J., and Jensen, F. E.
(2008). Early alterations of AMPA receptors mediate synaptic potentiation induced by
neonatal seizures. The Journal of Neuroscience, 28(32):7979–7990.
Reger, M. A., Henderson, S. T., Hale, C., Cholerton, B., Baker, L. D., Watson, G. S., Hyde,
K., Chapman, D., and Craft, S. (2004). Effects of β-hydroxybutyrate on cognition in
memory-impaired adults. Neurobiology of Aging, 25(3):311–314.
Remy, S., Gabriel, S., Urban, B. W., Dietrich, D., Lehmann, T. N., Elger, C. E., Heinemann,
U., and Beck, H. (2003). A novel mechanism underlying drug resistance in chronic epilepsy.
Annals of Neurology, 53(4):469–479.
Rho, J. M. and Stafstrom, C. E. (2012). The ketogenic diet as a treatment paradigm for
diverse neurological disorders. Neuropharmacology, 3:59.
Rogawski, M. A. (2013). AMPA receptors as a molecular target in epilepsy therapy. Acta
Neurologica Scandinavica, 127:9–18.
204
References
Rogawski, M. A. (2016). A fatty acid in the MCT ketogenic diet for epilepsy treatment
blocks AMPA receptors. Brain, 139(2):306–309.
Rogawski, M. A. and Hanada, T. (2013). Preclinical pharmacology of perampanel, a
selective non-competitive AMPA receptor antagonist. Acta neurologica Scandinavica.
Supplementum, (197):19–24.
Roopun, A. K., Simonotto, J. D., Pierce, M. L., Jenkins, A., Nicholson, C., Schofield, I. S.,
Whittaker, R. G., Kaiser, M., Whittington, M. A., Traub, R. D., and Cunningham, M. O.
(2010). A nonsynaptic mechanism underlying interictal discharges in human epileptic
neocortex. Proceedings of the National Academy of Sciences of the United States of
America, 107(1):338–343.
Rouach, N., Byrd, K., Petralia, R. S., Elias, G. M., Adesnik, H., Tomita, S., Karimzadegan,
S., Kealey, C., Bredt, D. S., and Nicoll, R. A. (2005). TARP γ-8 controls hippocampal
AMPA receptor number, distribution and synaptic plasticity. Nature Neuroscience,
8(11):1525–1533.
Royeck, M., Horstmann, M.-T., Remy, S., Reitze, M., Yaari, Y., and Beck, H. (2008). Role of
axonal NaV1.6 sodium channels in action potential initiation of CA1 pyramidal neurons.
Journal of Neurophysiology, 100(4):2361–2380.
Rozov, A. and Burnashev, N. (1999). Polyamine-dependent facilitation of postsynaptic
AMPA receptors counteracts paired-pulse depression. Nature, 401(6753):594–598.
Rozov, A., Sprengel, R., and Seeburg, P. H. (2012). GluA2-lacking AMPA receptors in
hippocampal CA1 cell synapses: evidence from gene-targeted mice. Frontiers in Molecular
Neuroscience, 5:22.
Russmann, V., Salvamoser, J. D., Rettenbeck, M. L., Komori, T., and Potschka, H. (2016).
Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal
lobe epilepsy. Epilepsia, 57(4):638–647.
Russo, I., Bonini, D., Via, L. L., Barlati, S., and Barbon, A. (2013). AMPA receptor
properties are modulated in the early stages following pilocarpine-induced status
epilepticus. Neuromolecular Medicine, 15(2):324–338.
205
References
Saavedra, A., Puigdellvol, M., Tyebji, S., Kurup, P., Xu, J., Gins, S., Alberch, J., Lombroso,
P. J., and Prez-Navarro, E. (2015). BDNF induces striatal-enriched protein tyrosine
phosphatase 61 degradation through the proteasome. Molecular Neurobiology, 53(6):4261–
4273.
Salter, M. W. and Kalia, L. V. (2004). Src kinases: a hub for NMDA receptor regulation.
Nature Reviews. Neuroscience, 5(4):317–328.
Sanchez, R. M., Dai, W., Levada, R. E., Lippman, J. J., and Jensen, F. E. (2005).
AMPA/kainate receptor-mediated downregulation of GABAergic synaptic transmission
by calcineurin after seizures in the developing rat brain. The Journal of Neuroscience,
25(13):3442–3451.
Sanchez, R. M., Koh, S., Rio, C., Wang, C., Lamperti, E. D., Sharma, D., Corfas, G., and
Jensen, F. E. (2001). Decreased glutamate receptor 2 expression and enhanced epilep-
togenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. The
Journal of Neuroscience, 21(20):8154–8163.
Sanderson, J. L., Gorski, J. A., and DellAcqua, M. L. (2016). NMDA receptor-dependent
LTD requires transient synaptic incorporation of Ca2+-permeable AMPARs mediated by
AKAP150-anchored PKA and calcineurin. Neuron, 89(5):1000–1015.
Sanderson, J. L., Gorski, J. A., Gibson, E. S., Lam, P., Freund, R. K., Chick, W. S., and
Dell’Acqua, M. L. (2012). AKAP150-anchored calcineurin regulates synaptic plasticity
by limiting synaptic incorporation of Ca2+-permeable AMPA receptors. The Journal of
Neuroscience, 32(43):15036–15052.
Schubert, M., Siegmund, H., Pape, H.-C., and Albrecht, D. (2005). Kindling-induced
changes in plasticity of the rat amygdala and hippocampus. Learning & Memory (Cold
Spring Harbor, N.Y.), 12(5):520–526.
Schwenk, J., Baehrens, D., Haupt, A., Bildl, W., Boudkkazi, S., Roeper, J., Fakler, B., and
Schulte, U. (2014). Regional diversity and developmental dynamics of the AMPA-receptor
proteome in the mammalian brain. Neuron, 84(1):41–54.
Schwenk, J., Harmel, N., Zolles, G., Bildl, W., Kulik, A., Heimrich, B., Chisaka, O.,
Jonas, P., Schulte, U., Fakler, B., and Klocker, N. (2009). Functional proteomics identify
206
References
cornichon proteins as auxiliary subunits of AMPA receptors. Science (New York, N.Y.),
323(5919):1313–1319.
Sepkuty, J. P., Cohen, A. S., Eccles, C., Rafiq, A., Behar, K., Ganel, R., Coulter, D. A., and
Rothstein, J. D. (2002). A neuronal glutamate transporter contributes to neurotransmitter
GABA synthesis and epilepsy. The Journal of Neuroscience, 22(15):6372–6379.
Setou, M., Seog, D.-H., Tanaka, Y., Kanai, Y., Takei, Y., Kawagishi, M., and Hirokawa, N.
(2002). Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites.
Nature, 417(6884):83–87.
Shaafi, S., Mahmoudi, J., Pashapour, A., Farhoudi, M., Sadigh-Eteghad, S., and Akbari, H.
(2014). Ketogenic diet provides neuroprotective effects against ischemic stroke neuronal
damages. Advanced Pharmaceutical Bulletin, 4(Suppl 2):479–481.
Shah, M. M., Anderson, A. E., Leung, V., Lin, X., and Johnston, D. (2004). Seizure-
induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. Neuron,
44(3):495–508.
Shelley, C., Farrant, M., and Cull-Candy, S. G. (2012). TARP-associated AMPA receptors
display an increased maximum channel conductance and multiple kinetically distinct open
states. The Journal of Physiology, 590(Pt 22):5723–5738.
Shepherd, J. D., Rumbaugh, G., Wu, J., Chowdhury, S., Plath, N., Kuhl, D., Huganir,
R. L., and Worley, P. F. (2006). Arc/Arg3.1 mediates homeostatic synaptic scaling of
AMPA receptors. Neuron, 52(3):475–484.
Sills, G. J. and Brodie, M. J. (2001). Update on the mechanisms of action of antiepileptic
drugs. Epileptic Disorders: International Epilepsy Journal with Videotape, 3(4):165–172.
Sills, M. A., Forsythe, W. I., and Haidukewych, D. (1986). Role of octanoic and decanoic
acids in the control of seizures. Archives of Disease in Childhood, 61(12):1173–1177.
Simon, A., Traub, R. D., Vladimirov, N., Jenkins, A., Nicholson, C., Whittaker, R. G.,
Schofield, I., Clowry, G. J., Cunningham, M. O., and Whittington, M. A. (2014). Gap
junction networks can generate both ripple-like and fast ripple-like oscillations. The
European Journal of Neuroscience, 39(1):46–60.
207
References
Sisodiya, S. M. (2003). Mechanisms of antiepileptic drug resistance. Current Opinion in
Neurology, 16(2):197–201.
Sloviter, R. S., Dean, E., Sollas, A. L., and Goodman, J. H. (1996). Apoptosis and
necrosis induced in different hippocampal neuron populations by repetitive perforant path
stimulation in the rat. Journal of Comparative Neurology, 366(3):516–533.
Smith, T. C., Wang, L. Y., and Howe, J. R. (2000). Heterogeneous conductance levels of
native AMPA receptors. The Journal of Neuroscience, 20(6):2073–2085.
Sobolevsky, A. I., Rosconi, M. P., and Gouaux, E. (2009). X-ray structure, symmetry and
mechanism of an AMPA-subtype glutamate receptor. Nature, 462(7274):745–756.
Sommer, B., Kohler, M., Sprengel, R., and Seeburg, P. H. (1991). RNA editing in brain
controls a determinant of ion flow in glutamate-gated channels. Cell, 67(1):11–19.
Song, I. and Huganir, R. L. (2002). Regulation of AMPA receptors during synaptic plasticity.
Trends in Neurosciences, 25(11):578–588.
Song, I., Kamboj, S., Xia, J., Dong, H., Liao, D., and Huganir, R. L. (1998). Interaction of
the N-ethylmaleimide-sensitive factor with AMPA receptors. Neuron, 21(2):393–400.
Soto, D., Coombs, I. D., Gratacs-Batlle, E., Farrant, M., and Cull-Candy, S. G. (2014).
Molecular mechanisms contributing to TARP regulation of channel conductance and
polyamine block of calcium-permeable AMPA receptors. The Journal of Neuroscience,
34(35):11673–11683.
Soto, D., Coombs, I. D., Kelly, L., Farrant, M., and Cull-Candy, S. G. (2007). Stargazin
attenuates intracellular polyamine block of calcium-permeable AMPA receptors. Nature
Neuroscience, 10(10):1260–1267.
Spiers, H. J. (2012). Hippocampal formation. The Encyclopedia of Human Behaviour,
2:297–304.
Spruston, N. (2008). Pyramidal neurons: dendritic structure and synaptic integration.
Nature Reviews. Neuroscience, 9(3):206–221.
St-Onge, M.-P. and Jones, P. J. H. (2002). Physiological effects of medium-chain
triglycerides: potential agents in the prevention of obesity. The Journal of Nutrition,
132(3):329–332.
208
References
Stafstrom, C. E. (2007). Persistent sodium current and its role in epilepsy. Epilepsy
Currents, 7(1):15–22.
Sterratt, D. C., Groen, M. R., Meredith, R. M., and van Ooyen, A. (2012). Spine calcium
transients induced by synaptically-evoked action potentials can predict synapse location
and establish synaptic democracy. PLoS computational biology, 8(6):e1002545.
Steward, O., Wallace, C. S., Lyford, G. L., and Worley, P. F. (1998). Synaptic activation
causes the mRNA for the IEG Arc to localize selectively near activated postsynaptic sites
on dendrites. Neuron, 21(4):741–751.
Stringer, J. L. and Colbert, C. M. (1994). Analysis of field potentials evoked in CA1 by
angular bundle stimulation in the rat. Brain Research, 641(2):289–294.
Studniarczyk, D., Coombs, I., Cull-Candy, S. G., and Farrant, M. (2013). TARP γ-7
selectively enhances synaptic expression of calcium-permeable AMPARs. Nature Neu-
roscience, 16(9):1266–1274.
Sullivan, P. G., Rippy, N. A., Dorenbos, K., Concepcion, R. C., Agarwal, A. K., and Rho,
J. M. (2004). The ketogenic diet increases mitochondrial uncoupling protein levels and
activity. Annals of Neurology, 55(4):576–580.
Sun, W., Mao, W., Meng, X., Wang, D., Qiao, L., Tao, W., Li, L., Jia, X., Han, C., Fu, M.,
Tong, X., Wu, X., and Wang, Y. (2012). Low-frequency repetitive transcranial magnetic
stimulation for the treatment of refractory partial epilepsy: a controlled clinical study.
Epilepsia, 53(10):1782–1789.
Swanson, G. T., Kamboj, S. K., and Cull-Candy, S. G. (1997). Single-channel properties
of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit
composition. The Journal of Neuroscience, 17(1):58–69.
Tada, H., Koide, M., Ara, W., Shibata, Y., Funabashi, T., Suyama, K., Goto, T., and
Takahashi, T. (2015). Estrous cycle-dependent phasic changes in the stoichiometry of
hippocampal synaptic AMPA receptors in rats. PLOS One, 10(6):e0131359.
Talos, D. M., Kwiatkowski, D. J., Cordero, K., Black, P. M., and Jensen, F. E. (2008).
Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex
cortical tubers. Annals of Neurology, 63(4):454–465.
209
References
Tamagnini, F., Scullion, S., Brown, J. T., and Randall, A. D. (2014). Low concentrations
of the solvent dimethyl sulphoxide alter intrinsic excitability properties of cortical and
hippocampal pyramidal cells. PLOS One, 9(3):e92557.
Teber, I., Kohling, R., Speckmann, E.-J., Barnekow, A., and Kremerskothen, J. (2004).
Muscarinic acetylcholine receptor stimulation induces expression of the activity-regulated
cytoskeleton-associated gene (ARC). Brain Research. Molecular Brain Research, 121(1-
2):131–136.
Terashima, A., Cotton, L., Dev, K. K., Meyer, G., Zaman, S., Duprat, F., Henley, J. M.,
Collingridge, G. L., and Isaac, J. T. R. (2004). Regulation of synaptic strength and AMPA
receptor subunit composition by PICK1. The Journal of Neuroscience, 24(23):5381–5390.
Terashima, A., Pelkey, K. A., Rah, J.-C., Suh, Y. H., Roche, K. W., Collingridge, G. L.,
McBain, C. J., and Isaac, J. T. R. (2008). An essential role for PICK1 in NMDA receptor-
dependent bidirectional synaptic plasticity. Neuron, 57(6):872–882.
Thavendiranathan, P., Mendonca, A., Dell, C., Likhodii, S. S., Musa, K., Iracleous, C.,
Cunnane, S. C., and Burnham, W. M. (2000). The MCT ketogenic diet: effects on
animal seizure models. Experimental Neurology, 161(2):696–703.
Thiagarajan, T. C., Lindskog, M., and Tsien, R. W. (2005). Adaptation to synaptic
inactivity in hippocampal neurons. Neuron, 47(5):725–737.
Tigerholm, J., Borjesson, S. I., Lundberg, L., Elinder, F., and Fransn, E. (2012). Dampening
of hyperexcitability in CA1 pyramidal neurons by polyunsaturated fatty acids acting on
voltage-gated ion channels. PLOS One, 7(9):e44388.
Tomita, S., Byrd, R. K., Rouach, N., Bellone, C., Venegas, A., O’Brien, J. L., Kim, K. S.,
Olsen, O., Nicoll, R. A., and Bredt, D. S. (2007a). AMPA receptors and stargazin-
like transmembrane AMPA receptor-regulatory proteins mediate hippocampal kainate
neurotoxicity. Proceedings of the National Academy of Sciences of the United States of
America, 104(47):18784–18788.
Tomita, S., Shenoy, A., Fukata, Y., Nicoll, R. A., and Bredt, D. S. (2007b). Stargazin
interacts functionally with the AMPA receptor glutamate-binding module. Neu-
ropharmacology, 52(1):87–91.
210
References
Traynelis, S. F., Silver, R. A., and Cull-Candy, S. G. (1993). Estimated conductance of
glutamate receptor channels activated during EPSCs at the cerebellar mossy fiber-granule
cell synapse. Neuron, 11(2):279–289.
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K.,
Hansen, K. B., Yuan, H., Myers, S. J., and Dingledine, R. (2010). Glutamate receptor ion
channels: Structure, regulation, and function. Pharmacological Reviews, 62(3):405–496.
Trombin, F., Gnatkovsky, V., and Curtis, M. d. (2011). Changes in action potential features
during focal seizure discharges in the entorhinal cortex of the in vitro isolated guinea pig
brain. Journal of Neurophysiology, 106(3):1411–1423.
Tunnicliff, G. (1996). Basis of the antiseizure action of phenytoin. General Pharmacology,
27(7):1091–1097.
Turrigiano, G. G., Leslie, K. R., Desai, N. S., Rutherford, L. C., and Nelson, S. B.
(1998). Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature,
391(6670):892–896.
Twele, F., Bankstahl, M., Klein, S., Romermann, K., and Loscher, W. (2015). The
AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects
in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neu-
ropharmacology, 95:234–242.
Uebachs, M., Opitz, T., Royeck, M., Dickhof, G., Horstmann, M.-T., Isom, L. L., and Beck,
H. (2010). Efficacy loss of the anticonvulsant carbamazepine in mice lacking sodium
channel β subunits via paradoxical effects on persistent sodium currents. The Journal of
Neuroscience, 30(25):8489–8501.
Uysal, H., Cevik, I. U., Soylemezoglu, F., Elibol, B., Ozdemir, Y. G., Evrenkaya, T., Saygi,
S., and Dalkara, T. (2003). Is the cell death in mesial temporal sclerosis apoptotic?
Epilepsia, 44(6):778–784.
Van der Auwera, I., Wera, S., Van Leuven, F., and Henderson, S. T. (2005). A ketogenic
diet reduces amyloid β 40 and 42 in a mouse model of Alzheimer’s disease. Nutrition &
Metabolism, 2:28.
211
References
Vanitallie, T. B., Nonas, C., Di Rocco, A., Boyar, K., Hyams, K., and Heymsfield, S. B.
(2005). Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility
study. Neurology, 64(4):728–730.
Vieira, M., Fernandes, J., Burgeiro, A., Thomas, G. M., Huganir, R. L., Duarte, C. B.,
Carvalho, A. L., and Santos, A. E. (2010). Excitotoxicity through Ca2+-permeable AMPA
receptors requires Ca2+-dependent JNK activation. Neurobiology of Disease, 40(3):645–
655.
Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994). A specific
inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-
4-one (LY294002). Journal of Biological Chemistry, 269(7):5241–5248.
Vreugdenhil, M., Hoogland, G., van Veelen, C. W. M., and Wadman, W. J. (2004).
Persistent sodium current in subicular neurons isolated from patients with temporal lobe
epilepsy. The European Journal of Neuroscience, 19(10):2769–2778.
Vyazovskiy, V. V., Cirelli, C., Pfister-Genskow, M., Faraguna, U., and Tononi, G. (2008).
Molecular and electrophysiological evidence for net synaptic potentiation in wake and
depression in sleep. Nature Neuroscience, 11(2):200–208.
Wagenaar, D. A., Pine, J., and Potter, S. M. (2006). Searching for plasticity in dissociated
cortical cultures on multi-electrode arrays. Journal of Negative Results in BioMedicine,
5:16.
Walker, M. C., White, H. S., and Sander, J. W. a. S. (2002). Disease modification in partial
epilepsy. Brain: A Journal of Neurology, 125(Pt 9):1937–1950.
Wang, D. and Mitchell, E. S. (2016). Cognition and synaptic-plasticity related changes in
aged rats supplemented with 8- and 10-carbon medium chain triglycerides. PLOS One,
11(8):e0160159.
Wang, G., Gilbert, J., and Man, H.-Y. (2012). AMPA receptor trafficking in homeostatic
synaptic plasticity: functional molecules and signaling cascades. Neural Plasticity,
2012:e825364.
Wang, H.-X. and Gao, W.-J. (2010). Development of calcium-permeable AMPA receptors
212
References
and their correlation with NMDA receptors in fast-spiking interneurons of rat prefrontal
cortex. The Journal of Physiology, 588(Pt 15):2823–2838.
Wang, J. H. and Kelly, P. T. (1996). Regulation of synaptic facilitation by postsynaptic
Ca2+/CaM pathways in hippocampal CA1 neurons. Journal of Neurophysiology,
76(1):276–286.
Wenthold, R., Petralia, R., Blahos, I., and Niedzielski, A. (1996). Evidence for multiple
AMPA receptor complexes in hippocampal CA1/CA2 neurons. Journal of Neuroscience,
16(6):1982–1989.
Wieser, H. (2004). Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia,
45(6):695–714.
Williams, S., Hamil, N., Abramov, A. Y., Walker, M. C., and Kovac, S. (2015). Status
epilepticus results in persistent overproduction of reactive oxygen species, inhibition of
which is neuroprotective. Neuroscience, 303:160–165.
Wiltgen, B. J., Royle, G. A., Gray, E. E., Abdipranoto, A., Thangthaeng, N., Jacobs, N.,
Saab, F., Tonegawa, S., Heinemann, S. F., O’Dell, T. J., Fanselow, M. S., and Vissel, B.
(2010). A role for calcium-permeable AMPA receptors in synaptic plasticity and learning.
PLOS One, 5(9):e12818.
Wlaz, P., Socaa, K., Nieoczym, D., arnowski, T., Zarnowska, I., Czuczwar, S. J., and Gasior,
M. (2015). Acute anticonvulsant effects of capric acid in seizure tests in mice. Progress
in Neuro-Psychopharmacology & Biological Psychiatry, 57:110–116.
Xie, X., Liaw, J. S., Baudry, M., and Berger, T. W. (1997). Novel expression mechanism for
synaptic potentiation: alignment of presynaptic release site and postsynaptic receptor.
Proceedings of the National Academy of Sciences of the United States of America,
94(13):6983–6988.
Xu, J., Chatterjee, M., Baguley, T. D., Brouillette, J., Kurup, P., Ghosh, D., Kanyo, J.,
Zhang, Y., Seyb, K., Ononenyi, C., Foscue, E., Anderson, G. M., Gresack, J., Cuny,
G. D., Glicksman, M. A., Greengard, P., Lam, T. T., Tautz, L., Nairn, A. C., Ellman,
J. A., and Lombroso, P. J. (2014). Inhibitor of the tyrosine phosphatase STEP reverses
cognitive deficits in a mouse model of Alzheimer’s disease. PLoS Biol, 12(8):e1001923.
213
References
Xu, J., Kurup, P., Zhang, Y., Goebel-Goody, S. M., Wu, P. H., Hawasli, A. H., Baum,
M. L., Bibb, J. A., and Lombroso, P. J. (2009). Extrasynaptic NMDA receptors couple
preferentially to excitotoxicity via calpain-mediated cleavage of STEP. The Journal of
Neuroscience, 29(29):9330–9343.
Yamaguchi, S., Donevan, S. D., and Rogawski, M. A. (1993). Anticonvulsant activity
of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal
electroshock and chemoconvulsant seizure models. Epilepsy Research, 15(3):179–184.
Yang, G., Xiong, W., Kojic, L., and Cynader, M. S. (2009). Subunit-selective palmi-
toylation regulates the intracellular trafficking of AMPA receptor. European Journal
of Neuroscience, 30(1):35–46.
Yang, J., Peng, C., and Wu, B. (2003). [Advance in signal analysis of auditory evoked
potential]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi = Journal of Biomedical En-
gineering = Shengwu Yixue Gongchengxue Zazhi, 20(3):563–566.
Yarov-Yarovoy, V., DeCaen, P. G., Westenbroek, R. E., Pan, C.-Y., Scheuer, T., Baker, D.,
and Catterall, W. A. (2012). Structural basis for gating charge movement in the voltage
sensor of a sodium channel. Proceedings of the National Academy of Sciences of the United
States of America, 109(2):E93–E102.
Yelshanskaya, M. V., Singh, A. K., Sampson, J. M., Narangoda, C., Kurnikova, M., and
Sobolevsky, A. I. (2016). Structural bases of noncompetitive inhibition of AMPA-subtype
ionotropic glutamate receptors by antiepileptic drugs. Neuron, 91(6).
Ying, Z., Babb, T. L., Comair, Y. G., Bushey, M., and Touhalisky, K. (1998). Increased
densities of AMPA GluR1 subunit proteins and presynaptic mossy fiber sprouting in the
fascia dentata of human hippocampal epilepsy. Brain Research, 798(1-2):239–246.
Yue, C., Remy, S., Su, H., Beck, H., and Yaari, Y. (2005). Proximal persistent Na+ channels
drive spike afterdepolarizations and associated bursting in adult CA1 pyramidal cells. The
Journal of Neuroscience, 25(42):9704–9720.
Zahn, R. K., Tolner, E. A., Derst, C., Gruber, C., Veh, R. W., and Heinemann, U. (2008).
Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of
kainate-treated chronic epileptic rats. Neurobiology of Disease, 29(2):186–200.
214
References
Zamanillo, D., Sprengel, R., Hvalby, i., Jensen, V., Burnashev, N., Rozov, A., Kaiser,
K. M. M., Koster, H. J., Borchardt, T., Worley, P., Lubke, J., Frotscher, M., Kelly,
P. H., Sommer, B., Andersen, P., Seeburg, P. H., and Sakmann, B. (1999). Importance of
AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science,
284(5421):1805–1811.
Zhang, L. and Luo, X.-P. (2011). Plasticity and metaplasticity of lateral perforant path
in hippocampal dentate gyrus in a rat model of febrile seizure. Sheng li xue bao: [Acta
physiologica Sinica], 63(2):124–130.
Zhang, Y., Venkitaramani, D. V., Gladding, C. M., Zhang, Y., Kurup, P., Molnar, E.,
Collingridge, G. L., and Lombroso, P. J. (2008). The tyrosine phosphatase STEP mediates
AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. The
Journal of Neuroscience, 28(42):10561–10566.
Zimmer, T., Haufe, V., and Blechschmidt, S. (2014). Voltage-gated sodium channels in the
mammalian heart. Global Cardiology Science & Practice, 2014(4):449–463.
Zonouzi, M., Renzi, M., Farrant, M., and Cull-Candy, S. G. (2011). Bidirectional plasticity
of calcium-permeable AMPA receptors in oligodendrocyte lineage cells. Nature Neu-
roscience, 14(11):1430–1438.
Zwart, R., Sher, E., Ping, X., Jin, X., Sims, J. R., Chappell, A. S., Gleason, S. D., Hahn,
P. J., Gardinier, K., Gernert, D. L., Hobbs, J., Smith, J. L., Valli, S. N., and Witkin, J. M.
(2014). Perampanel, an antagonist of α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic
acid receptors, for the treatment of epilepsy: Studies in human epileptic brain and
nonepileptic brain and in rodent models. Journal of Pharmacology and Experimental
Therapeutics, 351(1):124–133.
215
